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Abstract 
Crohn’s disease (CD) is now recognised as a defective host response to bacteria in genetically 
susceptible individuals.  The role of innate immunity and impaired bacterial clearance are 
widely accepted.  In this thesis the role of ADAM-like, Decysin-1 (ADAMDEC1) in 
macrophage-mediated inflammation and gut mucosal immunity is explored.  Using 
transcriptomic analysis of monocyte derived macrophages (MDM) ADAMDEC1 was identified 
as grossly under expressed in a subset of patients with CD.  ADAMDEC1 was found to be 
highly selective to the intestine, peripheral blood monocyte-derived and lamina propria 
macrophages. It was shown to be an inflammatory response gene, upregulated in response 
to bacterial antigens and inflammation. ADAMDEC1 was expressed in prenatal and germ free 
mice, demonstrating exposure to a bacterial antigen is not a prerequisite for expression.  
Adamdec1 knock out mice were used to investigate the role of ADAMDEC1 in vivo. 
Adamdec1-/- mice displayed an increased susceptibility to dextran sodium sulphate (DSS), 
Citrobacter rodentium and Salmonella typhimurium induced colitis. In Adamdec1-/- mice, 
bacterial translocation and systemic infection were increased in bacterial models of colitis.  
These results suggest that individuals with grossly attenuated expression of ADAMDEC1 may 
be at an increased risk of developing intestinal inflammation as a consequence of an impaired 
ability to handle enteric bacterial pathogens.  
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1. Introduction 
 
1.1 The Intestinal Barrier and Gut Homeostasis 
 
1.1.1 The Intestinal Microflora 
The mammalian intestine is densely colonised with a diverse population of microbes, 
collectively termed the ‘gut flora’. Metagenomic sequencing has identified 1000-1150 
prevalent species, with at least 160 species in each individual host [3].  The concentration and 
diversity of bacteria depends on the anatomic location and increases from proximal to distal 
along the gastrointestinal (GI) tract.  It is estimated that over 1011-1012 organisms/ml of faeces 
populate the lower GI tract of an adult human, whereas the concentration in the terminal ileum 
(TI) is in the order of 107-108 and this drops further to less than 103-104 in the proximal bowel 
[4]. During embryological development the intestine is sterile and colonised following birth. In 
humans a relatively stable resident population has developed by 1-2 years of age [5]. 
The commensal bacteria of the gut live in mutualistic symbiosis with their host.  Rather than 
exerting a detrimental affect they are essential to maintain a healthy functioning gut [6]. Not 
only do they offer protection against colonisation by pathogens but they play important roles 
in a wide variety of host systems, including food digestion, metabolism of some vitamins, short 
chain fatty acids and bile salts, fat storage and immunological homeostasis [7].  More recently 
evidence suggests that brain development, behaviour and mood may even be affected by 
alteration in the gut microflora [8].  
 
1.1.2 The Intestinal Mucosal Barrier 
Although the gut flora remains innocuous within the lumen of the intestinal tract, the same 
organisms cause significant harm within the tissue leading to local inflammation and potentially 
overwhelming sepsis.  The intestinal mucosa constitutes a barrier which prevents the luminal 
microbiota from gaining access to the tissues of the bowel wall where they could potentially 
cause harm to the host.  Not only does it act as a physical barrier but it is also an immunological 
defence against microbes and ingested antigens.  It comprises several layers, each of which 
plays an important role in the innate defence of the human gut (Figure 1.1). 
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Intestinal Epithelial Cells and Mucus Layer 
A wall of single layered columnar epithelial cells lines the intestine.  These intestinal epithelial 
cells (IEC) are firmly attached to one another by tight junctions and continuously renewed by 
pluripotent intestinal epithelial stem cells that reside in the bases of the crypts [9]. Enterocytes 
predominate and are interspersed by specialised IEC:  Mucin producing Goblet cells produce 
a thick viscous layer of mucus which protects the luminal surface of the IEC against direct 
contact with the faecal stream and bacterial load.  Organisation of the mucus layer does 
however differ according to location [10]. In the small bowel it consists of a single layer of 
mucus which is not anchored to the ileal epithelium and moves with peristatic waves in a distal 
direction.  Although penetrable to bacteria, it provides a diffusion barrier.  In the large bowel, 
which hosts a significantly greater concentration of bacteria, two mucus layers are found; a 
permeable outer layer, inhabited by commensal bacteria, and an inner mucus layer which is 
attached to the epithelial cells and is generally impermeable to the colonic bacteria.  Paneth 
cells are peppered through the small bowel and along with Goblet cells secrete bactericidal 
proteins such as defensins and lysozyme into the mucus layer. Immunoglobulin A, also 
present in the mucus layer, is delivered by epithelial transcytosis.  Together these anti-
microbial peptides (AMPs) limit bacterial access to the epithelial cells and translocation of 
commensal and pathogenic species across the intestinal barrier.  In addition hormone 
producing Neuroendocrine cells are located at the base of the crypts, they sense luminal 
contents and secrete hormones on their basolateral side which aid digestion and regulate 
hunger and satiety. 
Apart from physically protecting the internal mucosal layer from the faecal stream, IEC play 
an active role in immune-surveillance of intestinal microbiota and luminal contents: M cells 
reside in Peyers Patches predominately in the small intestine and specialise in the uptake and 
sampling of luminal antigens and the initiation of acquired antigen specific immune responses 
[11]. Goblet cells have also been reported to take up and deliver antigens to dendritic cells 
(DCs) and been shown to induce immunological unresponsiveness or ‘tolerance’ to antigens 
that would otherwise provoke an immune response [12]. 
The intestinal epithelial cells express pattern recognition receptors (PRRs); Toll-like receptors 
(TLRs) and intracellular Nod-like receptors (NLRs), which recognise evolutionary conserved 
molecular patterns in damaged tissue and pathogens (damage- and pathogen- associated 
molecular patterns; DAMPs, PAMPs).  Under steady state (non-inflamed) conditions, sensing 
of the microbiota and basal PRR signalling is important for intestinal homeostasis and constant 
renewal of the epithelial barrier.  In addition, PRR stimulation of IEC maintains an immune 
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pressure on the commensal flora; bacterial stimulation of TLRs up-regulates the production of 
a range of immune modulators and broad-spectrum AMPs [13]. 
Scattered among the epithelial cells are intraepithelial lymphocytes (IELs), or Innate Lymphoid 
Cells (ILC).  ILC are a unique T cell population in the intestine which unlike other T cells do 
not require priming and are devoid of the classic T cell antigen receptors.  These are innate 
effector cells. Upon encountering antigens, they immediately release cytokines and kill 
infected target cells [14]. A subset express the transcription factor, retinoic acid related orphan 
receptor γ t (RORγ t) that promotes Interleukin 23 (IL23) receptor (IL23R) expression. 
Classically IL23 controls the expansion and maintenance of T helper 17 (Th17) cells [15].  
However recent evidence has demonstrated that IL23 may also mediate T cell independent 
colitis, through its action on innate IELs, associated with secretion of IL17, interferon-γ (IFNγ) 
and IL22[16].  Depletion of innate IEL has been shown to completely abrogate acute and 
chronic bacterial induced colitis, in T cell knockout mice (Rag-/-), highlighting the importance 
of these cells in the innate immune response to intestinal pathogens [16].  In addition, IL22 
secreted from IEL is thought to play an important role in epithelial homeostasis and induces 
production of mucin and AMP [17].  IL22-deficient mice are highly susceptible to Citrobacter 
rodentium infection, and it is reported that IL22 production by ILC may be more important in 
resistance to this bacterial induced colitis than T cell-derived IL22 [18]  
 
Sub-Epithelial Layer: Stromal Cells and Extracellular Matrix (ECM) 
The epithelial monolayer is supported by the stromal cells and ECM; the collective term for 
the structural proteins: collagen, proteoglycan, fibronectin, elastin, and laminin.  This sub- 
epithelial mesenchymal compartment provides not only much of the structural framework of 
the intestine but is essential for wound healing, cell migration and fibrosis.  Furthermore, its 
dynamic role in mucosal immunity through the regulation of cell signalling, response to 
cytokines and interaction with the haematopoietic immune cells is becoming increasingly 
recognised [19].  Stromal cells share the ability to sense pathogens by expression of PRR 
receptors along with intestinal immune and epithelial cells suggesting these cells play a role 
in governing host protection after bacterial translocation across the epithelium [20].  ECM turn-
over is regulated by the matrix metalloproteases (MMPs), which in turn influence the immune 
homeostasis though their actions on chemokines, cytokines and growth factors [21]. 
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Resident Immune Cells 
A basal level of resident immune cells populate the lamina propria (LP) during the steady state, 
predominately mononuclear phagocytes, lymphocytes (T and B cells), ILC and a small 
population of neutrophils.  Mast cells and a limited number of eosinophils are also present. 
Resident Mononuclear Phagocyte 
The intestinal mononuclear phagocytes (iMNPs) are essential for both the induction of active 
immunity and the maintenance of intestinal homeostasis.  Historically, this compartment has 
been subdivided into distinct cell types: DCs and macrophages, although it is now appreciated 
that this is a gross oversimplification. 
The ability to distinguish iMNP subsets unambiguously and dissect the roles that each play in 
tissue homeostasis, gut immunity and pathology has been complicated by the finding that 
many of the markers used to identify them are expressed, at different levels, by multiple cell 
types in the intestine.  This has generated considerable confusion over the exact identification 
of functionally distinct macrophage populations within the gut and has sparked considerable 
interest in recent years.  Multi-coloured fluorescence-activated cell sorting (FACS) analysis 
has been employed to delineate these cell populations by the combination of surface 
expression, including cluster of differentiation [22] (CD), markers (Table 1.1). 
Classically, murine iMNPs are subdivided according to the expression pattern of characteristic 
surface markers CD11b, CD11c, CD103 and CX3CR1.  This heterogeneous population 
consists of CD103＋CD11c+ DCs and CX3CR1 CD11b＋ macrophages.  Although there is 
significant overlap between the surface markers expressed on cells, the iMNPs have now 
been well characterised in the mouse intestine [23]–[26]. 
Albeit less well studied, recent reports have described human counterparts to mouse iMNP 
with conservation of surface marker expression, such as high levels of CD64, MHCII, CD163, 
CD68 and CD103 [27]–[29].  However, unlike murine, human resident intestinal macrophages 
essentially lack expression of the human F4/80 equivalent, EMR1 [30]. CD14 and CD16 are 
the classical markers for human monocytes (Table 1.1). 
Each subset of iMNP perform distinct yet complementary functions. In general terms DCs are 
able to migrate from the intestine to the mesenteric lymph nodes (MLNs) and initiate adaptive 
immune responses by priming naïve T cells.  Resident macrophages reside in the intestinal 
LP and act as innate effector cells in the intestinal LP, where they phagocytose, kill and digest 
bacteria, secrete cytokines, chemokines and proteases and maintain intestinal homeostasis 
[31].  Resident gut macrophages, in comparison to inflammatory MDM, secrete high levels of 
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interleukin 10 (IL10) and reduced levels of pro-inflammatory cytokines and their phenotype is 
predominately phagocytic and bactericidal [29], [32].  It has been proposed that the anti-
inflammatory tendency of resident macrophages contributes to antigenic tolerance to foreign 
material in the gut wall and prevents a continuous state of inflammation which would be 
detrimental to the host. 
Albeit to a lesser extent than DCs, macrophages sample and present antigens and support T 
cell expansion thereby coordinating the adaptive immune response [33].  A subset of 
CX3CR1+ macrophages have been described in the small bowel with transepithelial dendritic 
(TED) like extensions which sample the lumen and play a role in antigen presentation [34], 
[35].  
Resident Lymphocytes 
In addition to the innate immune cells, the intestinal LP harbours T and B cells.  T cells present 
in the intestinal LP are primed in the gut associated lymphoid tissues (GALT) such as Peyer’s 
Patches and in MLNs [36].  As discussed epithelial M cells, CX3CR1+ macrophages and, in 
particular, migratory CD103+ CD11c+ DCs all have the capacity to sample antigens in the gut, 
prime T cells and induce appropriate T cell responses.  This process results in the up 
regulation of gut homing markers, such as the integrin α4β7, on naive T cells and enables 
primed T cells to enter the intestine tissue in response to specific ligands expressed by the 
tissue [37], [38]. 
CD103+ DCs are also responsible for immune tolerance to the intestinal antigens by promoting 
Forkhead box (Fox) p3+ regulatory T (Treg) cell differentiation through the production of 
retinoic acid and transforming growth factor (TGF)-β.  In the steady state the number and 
activity of effector T cells are tightly regulated by Fox p3+ Treg.  These cells suppress 
inflammatory responses through the production of anti-inflammatory cytokines including IL10 
and TGF-β [39].  Intestinal Fox p3+ Treg cells produce a large amount of IL10 compared with 
those present in other tissues and, as such, are believed to play an important role in the 
maintenance of gut homeostasis [40]. 
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Table 1.1: Table of cell surface markers (CD; cluster of differentiation) molecules.  The 
CD nomenclature was developed and is maintained through the HLDA (Human Leukocyte 
Differentiation Antigens) workshop [41].  The markers used in this thesis are highlighted in 
bold. 
 
 
1.1.3 Acute Inflammatory Response to Breach in Intestinal Barrier 
When the intestinal mucosal barrier is disrupted, or breeched by an invasive pathogen, the 
innate immune cells mount a vigorous response leading to containment and clearance of the 
foreign material and microbes with subsequent resolution of inflammation and wound healing.  
This system has evolved to be highly effective as a breach in the GI wall could expose the 
host to the 100 trillion commensal bacteria resident in the gut lumen and harmful faecal 
contents. 
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The resident professional phagocytes; neutrophils, macrophages and DCs, express a 
multitude of receptors on their surfaces, including PRR, that detect ‘non self’ signals foreign 
to healthy tissue and allow selective phagocytosis of pathogens and cell debris [42].   
The intensity of the immune response is tailored to the insult by sensing of microbial products 
and damaged tissue via the PRRs.  Stimulation of PRRs result in activation of specific 
downstream pathways and a cascade of signalling culminating in up-regulation and secretion 
of immune modulators such as chemokines, cytokines and proteases which act in the local 
vicinity and facilitate the extravasation of leukocytes from the circulation to sites of 
inflammation.  Neutrophils are the first line of defence and arrive on the scene within hours.  
Over the next 24-48 hours, monocytes are recruited from the circulation; initially Ly6clow 
monocytes ‘patrolling’ the local environment enter the inflamed tissue, followed by Ly6chi 
‘inflammatory’ monocytes, in response to inflammation the Ly6chi monocytes egress from the 
bone marrow.  These monocytes differentiate in the tissue into inflammatory macrophages to 
further control the foreign insult and replenish the pool of resident intestinal cells [43]. 
If this innate immune response and clearance of invading pathogens, and debris, is effective 
then resolution of inflammation will occur and wound healing will commence.  Such an 
inflammatory response may be subclinical or manifest in an episode of overt gastroenteritis or 
infective colitis with transient self-limiting symptoms of diarrhoea and vomiting and, in severe 
cases, rectal bleeding requiring antibiotic and supportive therapies until the infection resolves.  
In the majority of cases there will be no long term sequelae.  
In response to infection the host will mount an adaptive immune response.  During the early 
stages of the inflammatory response DCs migrate to the MLN, and lymphatic organs such as 
the spleen, to present antigens to lymphocytes thereby activating an antigen specific CD4+ T 
helper (Th) and  CD8+ T cytotoxic (Tc) cell responses and initiating B cell antibody formation.  
This secondary immune response delivers primed T cells, approximately 5-8 days after the 
onset of inflammation. Antibody formation and the development of ‘memory’ takes 
approximately 2 weeks. 
A characteristic feature of CD4+ Th cells is that, following antigen recognition, they develop a 
specific phenotype which is tailored to deliver the appropriate response against the perceived 
insult.  This phenotype is defined on the basis of the cytokine signatures produced.  Classically, 
Th1 lymphocytes secrete pro-inflammatory cytokines, such as; tumour necrosis factor (TNF), 
IFNγ and IL2, in response to intracellular infections.  Th2 cells mediate immunity against 
helminth parasite infection and secretion IL4, IL5 and IL13. Th17 cells, activated by IL23, IL1β 
and IL6, are characterised by the secretion of IL17 in response to extracellular bacteria and 
fungi [44].  In recent years other Th cells have been described; Th9, Th22 producing IL9 and 
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IL22 cells respectively.  In addition to the T cell role in adaptive immunity, Th cells enhance 
the innate immune response by supporting the recruitment of leukocytes, activating 
macrophages and, in the case of Th17, induce defensins and AMP production [45]. 
 
 
 
Figure 1.1: Schematic diagram of Intestinal barrier.  The host is protected from the 
luminal contents and colonising bacteria by a mucus layer which contains antimicrobial 
peptides, a monolayer of epithelial cells, a supporting stromal layer and the resident LP cells.  
Following an intestinal insult bacteria breakthrough the barrier walls due to loss of the mucus 
layer and destruction of epithelial cells.  As a result an acute inflammatory response ensues, 
with recruitment of leukocytes (initially neutrophils, followed by monocyte derived 
macrophages and T cells), to effectively clear the invading bacteria and foreign material within 
the tissue and restore homeostasis. 
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1.1.4 Malfunction of Intestinal Barrier and Innate Immune Response to Luminal 
Contents 
A fault at any stage in this tightly regulated process could disrupt the delicate balance between 
effector and regulatory immune responses within the intestinal mucosa.  As a consequence 
restoration of gut homeostasis may be hindered and chronic intestinal inflammation leading to 
further tissue destruction could ensue. 
An inadequate acute inflammatory response that fails to clear the invading pathogens will 
predispose to chronic inflammation, systemic inflammation and bacteraemia.  In an attempt to 
prevent a potentially overwhelming sepsis the host may form ‘granulomas’ within the tissue 
walls whereby leukocytes coalesce and surround the pathogen and/or undigested foreign 
material.  In so doing the inflammatory insult will be contained or ‘walled off’.  Although 
beneficial for the host, by minimising risk of bacteraemia, the granulomas themselves 
contribute to pathology as the active cells within the granuloma wall exude an abundance of 
pro-inflammatory cytokines driving an exaggerated local chronic Th1/Th17 inflammation. 
At the other end of the spectrum, an exaggerated immune response to invading pathogens, 
or failure to control or switch off the inflammaory cascade could also predispose to chronic 
inflammation.  Such a dysregulated response may cause extensive tissue damage and allow 
further bacteria to penetrate the tissue, thereby potentiating the intestinal inflammation and 
preventing wound healing. 
Inflammatory bowel disease (IBD), which encompasses both Crohn's disease (CD) and 
ulcerative colitis (UC), is the clinical consequence of mucosal barrier and immune dysfunction 
in the intestine. 
 
 
1.2 IBD 
UC and CD are chronic relapsing-remitting inflammatory disorders of the GI tract.  
 
1.2.1 Epidemiology 
Prevalence and Incidence 
The prevalence and incidence of IBD varies with geographical region with highest rates in the 
Western World.  In Europe the reported prevalence per 100,000 ranges from 4.9-505 in UC 
and 0.6-322 in CD, compared with 4.9-168.3 in UC and 0.88-67.9 in CD in Asia.  The highest 
annual incidence per 100,000 in Europe is 24.3 in UC and 12.7 in CD, in Asia it is 6.3 in UC 
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and 5.0 in CD [46].  Within a defined geographical area, incidence rates are heterogeneous 
with regional variations.  The incidence of both UC and CD tend to be higher in urban [47]–
[49], Caucasian [50] and the Ashkenazi Jewish populations [51]. 
Rising Incidence and Prevalence 
The incidence and prevalence of IBD has changed significantly over the last few decades.  
Not only has a significant increase been seen in high prevalence regions [46], [52]–[54], but 
this trend has also been reported in Asia and the Middle East, indicating that IBD is 
progressively emerging as a global epidemic [46], [55]–[57].  The reason for this dramatic 
change in the epidemiology of IBD is unknown but it does correlate with globalisation and a 
westernisation of lifestyle [49] and diet [58].  In support of this, studies have shown that 
individuals emigrating from low prevalent regions to higher prevalent countries are at 
increased risk of developing IBD, particularly among first and second generation children [59]–
[63]. 
Age of Onset 
The onset of both UC and CD is common between the second and third decade of life.  A 
second peak is seen between 60-79 years of age.  Paediatric onset IBD is also well recognised 
[64] however reported cases of very early onset are likely to reflect an underlying 
immunodeficiency [65].  Late onset disease is associated with a more benign course whereas 
early onset is frequently associated with a more aggressive disease [66]. Male and females 
are equally affected. 
Inheritance of Disease 
A family history of IBD is common in patients with the disease [67].  Twins studies in CD 
demonstrate a moderate concordance rate in monozygotic twins of 20-50% compared to less 
than 7% in dizygotic twins [68]–[70], highlighting a role for genetic and environmental factors 
in the underlying predisposition to CD.  The evidence from twin studies in UC implies a weaker 
inheritable risk than CD.  The concordance rate of UC in monozygotic twins is reported at 
about 16% in monozygotic, and about 4% in dizygotic, twins [68]–[70]. 
 
1.2.2 Clinical and Histological Presentation 
Although UC and CD may be indistinguishable both clinically and histologically, key 
differences are well recognised at a macroscopic, microscopic and molecular level.  While UC 
is confined to the colon and characterised by a continuous superficial mucosal inflammation, 
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starting at the rectum, CD may affect any part of the GI tract, is usually discontinuous, 
transmural and characterised histologically by granulomas, the hall mark of undigested 
material in the tissue. 
Both conditions demonstrate an acute and chronic inflammatory infiltrate at the affected sites.  
Although predominately neutrophilic in the early stages of an acute flare, both mononuclear 
and polypmorphonuclear leukocytes infiltrate the mucosa during inflammation, driven by local 
production of inflammatory mediators.  The inflamed bowel demonstrates increased 
production of many pro-inflammatory cytokines including IL1β, IL6, IL8 and TNFα [71].  The 
chronic state exhibits a classical Th1/Th17 phenotype with raised concentrations of TNFα, IL2, 
IFNγ and IL17, IL23, IL21. In addition UC displays evidence of a Th2 immune response with 
high levels of IL4, IL5 and IL13 [72], [73]. 
Chronicity is associated with persisting inflammation, ulceration and fibrosis.  In UC fibrosis 
results in loss of haustrae, colonic shortening, classic ‘lead pipe’ colon with potential colonic 
dysmotility [74].  Due to the transmural nature of the inflammation in CD, fibrosis is more 
frequently associated with stricturing of the bowel than in UC, and faecal obstruction 
necessitating surgery is not uncommon [75].  Fistulae are also a feature of CD, abnormal 
connections between the affected bowel and other sections of bowel, skin or neighbouring 
organs through which faecal material can pass, leading to abscess formation and abdominal 
sepsis.  
Increased Risk of Colorectal Cancer 
UC and colonic CD are associated with a significantly increased risk of colorectal cancer [76], 
[77]. This risk is increased with the severity [78], extent and duration of colitis [79], family 
history [80], [81], and coexistence of Primary Sclerosing Cholangitis [82]. 
Extra-Intestinal Manifestations 
Both UC and CD patients may experience extra-intestinal manifestations of IBD with the most 
frequently affected organs being the eyes (iritis and uveitis), joints (reactive arthritis; 
spondyoarthropathies; sacroileitis) and the skin (polyarteritis nodosa; pyoderma 
gangrenosum), suggesting that both diseases are systemic and not specific to the gut. 
 
1.2.3 Risk factors for IBD 
Smoking 
34 
Cigarette smoking is a strong environmental risk factor for CD; it confers a five-fold increase 
in susceptibility, a higher incidence of exacerbations and need for surgery.  It is however 
protective for UC and smokers are less likely to require a colectomy [83], [84]. 
Appendectomy 
Appendectomy in childhood has a preventative effect on the development of UC [85] but is 
associated with an increased risk of CD [86]. 
The contrasting response to these two environmental factors highlights that the inflammatory 
bowel disorders are different diseases.  The mechanisms by which they influence the course 
of each disease remain elusive but it is postulated that smoking may modulate disease activity 
by its immunosuppressive effect whereas removal of the appendix, with its abundant lymphoid 
aggregates, might alter the balance between the regulatory and effector T cells.  It is however 
probable that the surgical intervention itself in patients at risk of CD may precipitate future 
Crohn’s lesions at the site of anastomosis. 
 
1.2.4 Current Treatment Options in IBD 
Despite differences in pathology, the currently available treatment options for UC and CD are 
similar and aimed at suppressing the chronic inflammation. Immunosuppression therefore 
forms the basis of current management and includes corticosteroids, 5-aminosalicylates (5-
ASA) and immune modulators; thiopurines, methotrexate and biological agents. Monoclonal 
antibodies that target specific cytokines, in particular TNFα [87]–[90]  and more recently other 
components of the inflammatory response, such as adhesion molecules (e.g., α4β7 integrin 
[91], [92]) which regulate endothelial-lymphocyte interactions and thereby leukocyte 
recruitment to the gut, have been shown to be clinically effective in patients with CD and UC. 
Despite medical therapy, the life time risk of surgery remains 70-80% in CD and 30-40% in 
UC [93] and although an improvement in elective colectomy has been reported in UC, the rate 
of emergency colectomy remains unchanged [55].  Whilst a colectomy in UC offers a ‘surgical 
cure’, CD patients are at high risk of recurrence at the anastomosis site.  A recent meta-
analysis found postoperative endoscopic recurrence rates at three years to be as high as 85-
100% [94]. 
A number of less conventional medications have been trialled in both UC and CD including 
leucocytophoresis [95], granulocyte-macrophage colony stimulating factor (GM-CSF) [96]–
[98], nicotine patches [99], omega-3 [100], Helminths [101] and aloe vera [102] with varying 
results. The use of pre- and probiotics, discussed in section 1.3.3, have been shown to be 
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beneficial in UC [103], [104]. Elemental or polymeric diets are used in conventional practice 
for CD, particularly in paediatric CD [66], [105] and have been shown to be clinically effective 
[66], [106], [107].  
 
 
1.3 Pathogenesis of CD 
The underlying cause for the chronic intestinal inflammation that characterises both CD and 
UC remains intensely debated.  Numerous hypotheses have been proposed but no single 
theory has been unequivocally proven.  Differences in clinical features and the contrasting 
response to smoking and appendectomy suggest that UC and CD are fundamentally different 
diseases.  Variations in epidemiology, clinical heterogeneity and evidence from twin studies 
support the notion that UC and CD may represent a spectrum of disorders with complex 
multifactorial aetiologies.  This concept is supported by results from Genome Wide Association 
Studies (GWAS) which have to date identified single nucleotide polymorphisms (SNPs) in 162 
genomic regions associated with an increased risk of developing IBD, many of which were 
unique to CD [108], [109].  These studies, however, also found that UC and CD do share a 
significant genetic overlap, with 26 common IBD susceptibility loci identified at to date [110].  
CD-UC relative pairs are a well-recognised phenomenon supporting the findings that some 
genetic factors predispose to IBD as a single entity whereas other genes are specific to CD or 
UC [111], [112][113].  It is therefore highly probable that the final phenotype is likely to be 
determined by the synergistic effect of low penetrance genetic abnormalities and gene-
environment interactions.  A unifying theory, which is now generally accepted, is that IBD is 
the pathological consequence of an aberrant mucosal immune response to enteric bacteria 
penetrating the intestinal epithelial barrier in genetically susceptible individuals influenced by 
environmental factors [114].   
In recent years clinical, immunological and genetic studies have greatly advanced our 
understanding of this complex disease spectrum.  The following section will discuss current 
and historical theories regarding the aetiopathogenesis of CD and, in doing so, will examine 
how modifications at each stage in the intestinal barrier defence (from luminal contents, 
mucosal layer, to the LP immune cells) may contribute to a gut homeostasis and predispose 
to intestinal inflammation seen in CD.   
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1.3.1 Causal Infectious Pathogens in CD 
Early theories focused on discovering a potential infective aetiology for CD.  Dr T.K. Dalziel, 
who described the first case series of CD in the early twentieth century noted the similarity to 
Johne’s disease, a bovine granulomatous ileitis, caused by Mycobacterium avium subspecies 
paratuberculosis (MAP) [115].  In the 1980s, MAP was isolated from CD tissue [116] and was 
reported to be more prevalent in CD patients in a number of studies [117].  However, the rates 
of detection in CD were found to be highly variable, ranging from 0-100%, and often similar to 
healthy controls (HCs) [117]. Furthermore, clinicopathological differences exist between 
Johne’s disease and CD, the latter is not cured by antibiotics as one would expect from an 
infective cause [118] and the efficacy of anti TNF therapy in CD, which can trigger reactivation 
of mycobacterial infections as a side effect, is not compatible with the theory that MAP infection 
is the underlying cause.  
More recently, the role of adherent invasive Escherichia coli (AIEC) in CD has attracted 
attention.  AIEC is able to bind and invade the mucosal epithelium.  It has been reported as 
significantly increased in the intestinal mucosa [119], [120], LP macrophages [121], in MDM 
[122] and granulomas [123] in CD.  AIEC has been shown to survive and replicate in CD MDM 
and initiate inflammation by the induction of pro-inflammatory cytokines [124].  These bacteria 
are also reported to encourage granuloma formation [125]. These findings implicate AIEC in 
the pathogenesis of CD.  
Over the years a host of other bacteria [126]–[128] and viral [129], [130] pathogens have also 
been implicated in CD but to date a causal role for a single infectious agent has not been 
proven [131], [132].  
 
1.3.2 Role of Faecal Stream in CD 
Although it now appears unlikely that CD is caused by a single enteric pathogen there is 
unequivocal evidence that the faecal contents are critical for CD pathogenesis.  A series of 
clinical experiments in patients with active CD clearly demonstrated that diversion of the faecal 
stream, by creation of a proximal ileostomy, lead to a rapid resolution of intestinal inflammation 
[133], [134].  Reintroduction of faecal contents either by re-anastomosis or by experimentally 
infusing the bowel with ileostomy effluent resulted in relapse of disease activity [135]  Further 
support that faecal antigens may drive CD activity comes from the observation that 
introduction of a simple amino acid ‘elemental’ diet improves inflammation in CD. 
The majority of CD lesions occur at sites where the faecal stream contains the highest 
bacterial load; in the colon and terminal ileum (TI), compared with other regions of the small 
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bowel which contain significantly lower concentration of bacteria.  Meta-analysis supports the 
use of antibiotics as an effective therapy in CD [136]. The benefit of oral antibiotics in 
preventing postoperative recurrence of CD is also well documented [137], [138]. Collectively, 
these observations suggest that the bacterial load maybe important in disease pathogenesis.  
Findings from animal models also support a role for enteric bacteria in the induction of colitis.  
Many genetically susceptible models do not develop colitis when raised in a germ-free or 
Helicobacter-free environment. In fact, disease in most models can be attenuated or 
completely abolished with antibiotic treatment [139], [140]. However, the direct applicability of 
these animal models to human CD is debatable. 
 
1.3.3 Dysbiosis 
A discussion regarding the pathogenesis of CD and the intestinal bacteria must consider the 
epidemiological observations that CD is more prevalent in regions with a ‘westernised’ life 
style and diet.  One possible explanation could be the differences in the intestinal flora. In rural 
Sub-Saharan Africa, for example, where CD is rare, the gut flora contains lower concentrations 
of obligate anaerobic gram negative rods such as Bacteroides species, and higher 
concentrations of Lactobacillus and Bifidobacteria than is found in individuals from urban UK 
[141]. 
Meta-genomic studies of gut microflora, in healthy individuals, have revealed the existence of 
distinct enterotypes (Firmicutes, Bacteroides, Prevotella or Ruminococcus), which are 
predominantly driven by dietary intake [142], [143]. Bacteroides species are associated with a 
‘western’, protein & animal fat rich, diet while the Prevotella enterotype was associated with a 
high fibre, carbohydrate rich diet [144]. In addition to diet the intestinal bacterial composition 
is also dependent on other environmental factors, e.g., smoking [145], antibiotics use [146], 
mode of delivery at birth (vaginal verses caesarean) [147] and breast feeding [148], variables 
which have all been associated with CD [149]. 
Differences in the bacterial composition of the bowel have been extensively documented in 
IBD.  This alteration in the gut microbiome has been termed ‘dysbiosis’ [150].  Some changes 
in the gut microbiome are common to both UC and CD but others can be clearly separated 
into CD or UC clusters.  The most frequently reported differences in CD patients are a reduced 
number and diversity of Firmicutes (including Faecalibacterium prausnitzii and Clostridia 
cluster IV species) and an increased number of Bacteroides and Escherichia coli (E.coli) 
[151]–[153].  The decrease in abundance of F. prausnitzii and the diversity of Firmicutes is 
particularly evident in patients with ileal CD [154].  Reduced levels of F. prausnitzii have been 
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suggested as a predictive factor for CD relapse as low faecal levels correlated with time to 
relapse following cessation of anti-TNF therapy [155] and reduced ileal mucosal levels were 
associated with post-operative recurrence [65].  
Dysbiosis may potentially disturb the host-microbial mutualism and the homeostatic balance 
between pro-inflammatory and anti-inflammatory mechanisms in the gut [156].  F. praunitzii, 
for example, has been shown to exhibit anti-inflammatory effects both in vitro and in vivo [65]. 
Whereas Bacteroides species have been reported to impair phagocytosis and microbicidal 
activity of neutrophils [157].  
Whether the observed dysbiosis predisposes to CD or is a consequence of established 
disease and/or medication remains debated. Interestingly a recent study reported that patients 
with CD share aspects of their dysbiosis with unaffected siblings, specifically lower levels of 
the Firmicutes (in particular Clostridia cluster IV species, F. prausnitzii) in faecal samples, 
suggesting these features are not secondary to disease but may predispose to the disease 
[158].  Variation in the level of E.coli and Bacteroides, were not seen in the unaffected siblings 
suggesting these changes only occur once disease is established.  A follow up study of 
mucosal microbiota, using next generation sequencing, confirmed attenuated levels of F. 
prausnitzii and reduced diversity in CD [159].  Other studies, however, have not observed 
sharing of dysbiosis between unaffected relatives and patients [160] and CD twin studies 
suggested bacterial composition is influenced by disease status rather than the genetic 
background of the host [161], [162]. 
 
Faecal Transplantation/ Probiotics 
If intestinal dysbiosis is critical for the onset and/or maintenance of CD then manipulation of 
the microbiota should modify disease activity.  Therapeutic approaches to change the 
intestinal microbiota include faecal transplantation and probiotics.  A systematic review of 
randomised control trials of probiotics in IBD concluded that probiotics were effective at 
maintaining remission in pouchitis and UC, and could be used as an effective adjunct to 
conventional therapy to induce remission in UC.  However, no significant difference in outcome 
was seen in CD [103].  Similarly, the small number of studies employing faecal transplantation 
have been promising for UC but not CD [163].  Manipulation of the bacterial flora in CD with 
either method has failed to demonstrate a significant improvement in CD suggesting that the 
observed alterations in intestinal commensal composition may not be of primary pathogenic 
significance in the pathogenesis of CD. 
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It remains debatable whether specific abnormalities of the faecal stream such as an infectious 
pathogen or altered microbiota composition are causally related to CD.  Evidence from animal 
studies, with human-relevant susceptibility mutations, suggests that CD is unlikely to be 
caused by diminished commensal diversity alone, but requires a susceptible genotype [164].  
What is undisputable is that the presence of faeces within the lumen is a prerequisite for 
disease activity and it is highly likely that the bacterial load plays an important role in the 
pathogenesis.  
 
1.3.4 Alterations in Mucus Layer 
Defects in the mucus barrier have been implicated in CD, albeit they are more strongly 
associated with UC [110].  Abnormal expression of mucins have been reported in CD [165], 
[166] and decreased expression of MUCIN 1 (MUC1) is seen in the inflamed TI of patients 
with CD [167].  GWAS have linked MUC1, MUC19, and PTGER4 to CD [109] and 
polymorphisms in MUC3A have also been identified in CD [168], [169].  Further support for 
the role of mucins in IBD arises from the Muc2 knock out mice, which develops a spontaneous 
colitis [170]. 
Reduced α-defensins in ileal, and β-defensins in colonic, disease and defective antimicrobial 
peptide production from paneth cells have been reported in CD [171]. CD patients, 
homozygous for the autophagy-related 16 like-1 (ATG16L1) CD risk allele, have been shown 
to have reduced numbers of paneth cell granules which are dysmorphic in shape and 
functionally impaired [172]. 
 
1.3.5 Increased Intestinal Permeability 
Increased intestinal permeability has been demonstrated in CD patients [173] and a number 
of studies have reported increased intestinal permeability in their first degree relatives [173]–
[175] and spouses [176].  These results suggest that the abnormal permeability observed in 
CD maybe secondary to a combination of causes, with both genetic and environmental 
influences, such as smoking and non-steroidal anti-inflammatory drugs (NSAIDs).  Disruption 
of  intercellular tight junctions proteins within the epithelial layer has been reported in the 
mucosa of patients with inactive CD [177], [178] and dysregulated expression of Claudins are 
seen during inflammation [179].  Discontinuous tight junctions may permit the invasion of 
bacterial antigens which could initiate and/or perpetuate altered immune function in CD. 
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1.3.6 Bile Salt Composition 
Bile salts have long been considered to play a role in the pathogenesis of CD.  Primary bile 
acids are produced by the liver, secreted as conjugated salts into the duodenum to facilitate 
the absorption of fats and reabsorbed into the circulation via an active, sodium dependent 
process in the terminal ileum, the site of which corresponds with the most common location of 
lesions for CD. A proportion of primary bile salts are deconjugated, converted into secondary 
bile salts by the action of bacteria present in the large bowel [180], and absorbed by passive 
diffusion in the colon.  
A number of in vitro, in vivo and biopsy studies have shown that bile can disrupt the intestinal 
mucosa and increase permeability [181]–[184], by loosening tight junctions [184] or inducing 
apoptosis of gut epithelial cells [185]. As such, it has been proposed that bile salts may 
contribute to intestinal barrier dysfunction, and allow ingress of antigenic material into the 
bowel wall which could act as the trigger for the development of small bowel CD. Cyclo-
oxygenase 2 (COX2-/-) deficient mice fed a high fat diet containing cholic acid (a primary bile 
salt) developed ileocaecal lesions remarkably similar to those observed in CD [186].  This 
suggests that in a model of impaired acute inflammation, dietary bile salts may be sufficient to 
cause damage to the intestinal mucosa.  Furthermore, dietary supplements of deoxycholate 
(a secondary bile salt) were shown to induce colitis in another mouse model [187] and 
exacerbate chemical induced dextran sodium sulphate (DSS) colitis in wild type C57Bl/6J mice.  
Ursodeoxycholic acid has been shown to ameliorate experimental colonic inflammation [188], 
[189].  The damaging effect of bile acids in CD could be enhanced by abnormalities in 
membrane lipid composition [190] and changes induced in the intestinal microbiota [191]. 
Antibiotics which alter both the microbiota have been shown to change the bile acid 
composition in mice [192].  Whether differences in bacterial flora seen in CD patients are 
associated with alteration in bile acid composition is yet to be ascertained. 
 
1.3.7 Defective Adaptive Immunity 
The prevailing opinion, and medical school teaching, in the nineties and well into the turn of 
the twenty-first century was that CD was an autoimmune disease, due to abnormalities in T 
cell function and an overly aggressive immune response [71].  This theory was based on the 
characteristic histological appearance of established CD lesions in which Th1 lymphocytes 
predominate [193] and the effective response of immunosuppressive drugs [71].  CD does not 
however meet standard criteria for classification of an autoimmune disorder [132] and although 
auto-reactive T cells and antibodies have been reported [194], [195] their pathogenic 
relevance has not been proven.  Furthermore, the observation that intestinal luminal contents 
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are required for the development of Crohn’s lesions supports a concept that CD is due to an 
abnormal response to faecal, and not ‘self’, antigens.  
 
1.3.8 GWAS: Candidate Genes 
Over the last decade, the scientific community has made a concerted effort to identify the 
genetic defects in IBD.  An international IBD genetics consortium (IIBDGC) has developed 
which has enabled large datasets from across the world to be studied collectively.  New 
technologies such as GWAS and transcriptomal profiling have been employed and have 
provided an insight into some of the genetic variants and alterations in gene expression 
associated with an increased risk of developing IBD [108]–[110], [196]–[198].  In particular, 
GWAS has highlighted the importance of genes associated with the innate immune function 
in the pathogenesis of CD [199] and mucosal barrier function in UC [110]. 
NOD2 
The first genetic variants significantly associated with CD were discovered in the gene 
encoding nucleotide-binding oligomerization domain 2 (NOD2), located on Chromosome 
16q12 [200], [201].  Despite reports of over 100 loci, the three loss of function SNPs identified 
in NOD2 confer the greatest risk of developing CD in the Caucasian population [108].  
Individuals heterozygous for one of the variants have a two-four fold risk of developing whilst 
individuals homozygous or compound heterozygotes have a 20-40 fold risk [202].  NOD2 is 
however noticeably absent in the genetics of Asian CD patients [202], [203] highlighting that 
the genetic basis for CD differs according to ethnic background. 
NOD2 is an intracellular, cytosolic, pattern recognition receptor, which senses the ubiquitous 
bacterial peptidoglycan muramyl dipeptide (MDP), via its leucine rich repeat (LRR) domain. It 
is expressed on peripheral blood leucocytes [201], intestinal macrophages [204], IEC [204]and 
Paneth cells [205]. It is up-regulated during inflammation and in response to the pro-
inflammatory cytokines TNF and IFNγ [206], [207].  
Stimulation of the NOD2 receptor with MDP results in oligomerisation at the central nucleotide-
binding domain (NBD) and interaction of its multiple caspase-recruitment domains (CARD) 
with downstream adaptors such as receptor-interacting protein-2 (RIP2).  This activates 
nuclear factor- κβ (NF-κβ), mitogen-activated protein kinases (MAPK), resulting in activation 
of pro-inflammatory cytokines [208], [209]. CD patients who are homozygote or compound 
heterozygote for the CD associated NOD2 polymorphisms (L1007fs, R702W and G908R) are 
associated with an impaired pro-inflammatory cytokine secretion in response to MDP 
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stimulation [209]–[211]. Paradoxically NOD2 has also been demonstrated to suppress the 
TLR2 pro-inflammatory signalling [212].  
The cytoplasmic position of NOD2 suggests that it may not be the primary sensor for the 
majority of extracellularly located enteric bacteria.  A few bacteria such as Salmonella 
typhimurium (S. typhimurium) and Listeria monocytogenes invade the host and cytoplasm 
where they are recognised by NOD2, but the majority of enteric bacteria are extracellular.  It 
is possible that NOD2 initially regulates inflammation by dampening the inflammatory 
response induced by the extracellular bacteria sensor TLR2, but once bacterial antigens 
invade the host cytoplasm it acts as a ‘back-up sensor’ enhancing the pro-inflammatory 
response in an effort to effectively clear the pathogens. 
In addition to its role in cytokine secretion, NOD2 has been implicated in Paneth cell defensin 
production [205].  Patients with ileal CD, in particular those with the L1007fs mutation of NOD2, 
are reported to have decreased antimicrobial α-defensin expression [213], [214].  NOD2 
mutations are associated with an increased risk of small bowel, stricturing disease [202]. 
Autophagy Genes: ATG16L1, IRGM and PTPN2 
Through its interactions, NOD2 has also been linked to autophagy.  Autophagy is an 
intracellular degradation system that delivers cytoplasmic contents to lysosomal 
compartments for proteolytic degradation.  It occurs ubiquitously in all eukaryotic cells and is 
essential for survival.  It is activated as an adaptive catabolic response to metabolic stressors 
including nutrient deprivation and hypoxia [215] and allows clearance and recycling of cellular 
components. Autophagy is also important in the innate host defence as it facilitates digestion 
of intracellular pathogens [216]–[219]. Defective autophagy is associated with an increased 
susceptibility to bacterial infection [20], [220]–[222].   
Autophagy involves the formation of a double membrane vesicle, the autophagosome. Fusion 
of the autophagosome with a lysosome results in an autolysosome and lysosomal degradation 
of the contents. Multiple ATG proteins are required for this process. A component, ATG16L1 
forms a complex with ATG5-ATG12 and is responsible for the membrane localisation and 
formation of the autophagosome [223]. NOD2 has been shown to colocalise with the 
autophagy protein ATG16L1 on the cytosolic side of the plasma membrane and initiate the 
autophagocytic process [224]. The CD associated frameshift mutation of NOD2 (L1007fs) 
encodes a shortened protein which does not localise to the membrane [225], [226]. Cells 
homozygous for this mutation failed to recruit ATG16L1 to the plasma membrane with the 
consequence of impaired clearance of invading bacteria by autophagosomes [224].  
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GWAS has also identified CD associated SNPs in ATG16L1, and in two other autophagy 
related genes; IRGM and PTPN2 [227] further strengthening a role for impaired autophagy 
function in CD. Human intestinal cells with the CD associated ATG16L1 variant (T300A) were 
found to have impaired autophagy of internalised Salmonella within autophagosomes [228]. 
NOD2 stimulation of peripheral blood mononuclear cells from humans with ATG16L1 T300A 
variant demonstrated reduced autophagy and activation of the inflammasome with increased 
secretion of caspase-1 dependent cytokines IL1β and IL18 [229].  The clearance of AIEC has 
been shown to be dependent on NOD2, ATG16L1 and IRGM-mediated autophagy [216].  In 
addition to a role in the autophagosome formation [230], PTPN2 is an important inhibitor of 
the response to pro-inflammatory cytokines such as IFNγ and IL6 because of its ability to 
dephosphorylate STAT1 and STAT3.  Gene PTPN2 knockout mice develop systemic 
inflammation and increased expression of PRPN2 has been found in the inflamed mucosa of 
patients with CD [231].  
Benefits and Limitations of GWAS 
The discovery of NOD2 and the autophagy genes have highlighted potentially important 
pathways involved in the pathogenesis of CD.  In particular they have underscored the role of 
the innate immune system in this disease.  Animal studies have since demonstrated the 
functional importance of many of these genes in inflammation models, albeit the overall effect 
of the gene variants on the development of Crohn’s remains controversial.  Although the 
identified polymorphisms confer a high risk of CD they are also found in a significant proportion 
of the general population and therefore, alone, are not ‘causal’ genes. 
GWAS has provided robust evidence that no single common causal mutation exists for CD 
reinforcing the principle that CD is a heterogeneous syndrome in which the underlying 
pathological mechanisms may differ between individual patients.  This is supported clinically 
by the variability in patient and disease phenotype and the lack of complete concordance 
between monozygotic twins.  It is, however, the heterogeneous nature of CD which limits the 
contribution of GWAS.  The assumption of ‘common disease, common gene’ underpins GWAS 
analysis.  As such, rare causal genes will potentially be missed in a heterogeneous population.  
In recognition of this short coming, meta-analysis of the GWAS data has been performed and 
a number of pooled next-generation sequencing studies were undertaken to look for low-
frequency and rare protein altering variants [198], [232].  Despite this it is currently estimated 
that the known genetic associations still only account for approximately 20% of the genetic 
risk for IBD [109], [110]. Of the SNPs that have been identified as significantly associated with 
CD by GWAS, many do not clearly identify loss of function mutations or candidate genes. In 
fact, the majority of the common risk variants identified by GWAS to date have not been in 
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protein-coding regions, and so may affect risk via regulation of gene expression [233]. Finally, 
one of the major criticisms of GWAS has been the concern that the genetic data does not add 
up to a unifying or plausible immunological scenario for the pathogenesis of CD [234]. 
 
1.3.9 Defective Innate Immune Response 
In 1970s, A.W. Segal proposed that CD may result from an initial weak inflammatory response 
to faecal material in the intestinal tissue [235].  He observed that CD shares similarities with 
chronic granulomatous disease (CGD), a primary deficiency of neutrophil function [236].  
Indeed chronic granulomatous bowel inflammation and perianal disease are recognised 
features of a number of congenital monogenic innate immune-deficiencies which impair 
neutrophil chemotaxis (Leukocyte adhesion deficiency) [237], lysosomal vesicle trafficking 
(Chediak-Higashi [238] and Hermansky-Pudlak syndromes [239]) or the respiratory burst and 
digestion of bacteria in the neutrophil phagolysosome (CGD and Glycogen storage disease-
1b [240].  Although neutrophil function is normal in CD, recruitment of neutrophils to skin 
abrasion windows was impaired.  Based on these observations, he hypothesised that failure 
to clear the foreign material in the wall of the bowel may lead to the granulomata formation 
and chronic inflammation in CD.  This argument was largely dismissed at the time, principally 
because of the response to emerging immunosuppressive therapies and the predominance of 
theories focusing on CD as a pro-inflammatory disorder.  However following the publication of 
GWAS, this theory has regained popularity, and an increasing body of evidence now exists to 
support a systemic defect of innate immunity and bacterial clearance in CD.  
CD is associated with impaired neutrophil recruitment, evidence from human in vivo studies 
30 years later, a series of in vivo investigations were carried out on human subjects which 
support Segal’s early findings in CD.  Studies demonstrated impaired neutrophil recruitment 
to the tissue and bowel of CD patients, compared with HC and UC patients, following trauma 
using skin abrasion windows and serial endoscopic bowel biopsy techniques, respectively 
[241].  Not only did these studies reinforce the idea that the acute inflammatory response is 
attenuated in CD, but they highlighted that CD was a systemic disorder and not restricted to 
the gut. Independent investigators have replicated these experiments in skin windows and 
verified the results [242]. 
In order to demonstrate the response to bacteria, subcutaneous injection of heat killed 
Escherichia coli (HkEc) was injected into the volar aspect of the arm [243].  Consistent with 
past studies, patients with quiescent CD had an attenuated acute inflammatory response at 
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the wound site and a reduced accumulation of intravenously injected, radio-labelled 
neutrophils. 
CD is associated with impaired cytokine secretion, evidence from human in vitro studies 
The migration of neutrophils to sites of inflammation requires the presence of a chemotactic 
gradient and the up-regulation of adhesion molecules.  Macrophages play an important role 
in orchestrating this response through the secretion of pro-inflammatory cytokines such as 
TNFα.  Following activation with bacterial antigens, including HkEc and specific TLR ligands 
(LPS and Pam3CSK4), macrophages from patients with CD demonstrated reduced secretion 
of a range of cytokines, most notably TNFα,  [243], [244]. This was not due to a failure of cell 
signalling in response to the stimuli, abnormal cytokine gene transcription or the processing 
and translation of the messenger ribonucleic acid (mRNA).  Instead, it appeared to be a 
consequence of defective vesicle trafficking resulting in misdirection of the cytokine protein to 
the lysosomal compartment for degradation, rather than secretion.  The underlying molecular 
causes for this are currently under investigation [245] and one potential molecule 
OPTINEURIN (OPTN) has been identified to date [246]. 
CD is associated with delayed bacterial clearance, evidence from vivo studies 
Clearance of HkEc at the sites of injection was also found to be impaired in patients with CD, 
but not in those with UC or HC.  Notably, impaired bacterial clearance was dose dependent, 
and only evident at high bacterial doses [243].  Following an injection of 105 and 106 organisms 
no difference in local inflammatory response or bacterial clearance was observed between HC 
and CD.  However, gross differences became apparent at concentrations of 107-108.  This 
finding supports a role for the bacterial load in CD, and may explain why the intestinal tract, 
with its high bacterial load, is the primary target of CD. 
 
1.3.10 Three Stage Hypothesis of CD 
A three-stage model has been proposed by Professor Segal’s team to explain the 
development of bowel lesions in CD [247].  The first stage involves penetration of the bowel 
wall by luminal contents facilitated by environmental factors (e.g. infection, NSAIDs) or defects 
of the mucosal barrier.  In the second stage, a defective macrophage response, with 
inadequate secretion of pro-inflammatory cytokines (in particular TNFα), fails to trigger a 
robust acute inflammatory response, which results in reduced influx of neutrophils.  As a 
consequence of impaired neutrophil recruitment, the bacteria persist within the tissue and are 
phagocytosed by macrophages.  Further defects in macrophage function, such as impaired 
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bacterial recognition (NOD2 mutations) and autophagocytic mechanisms (ATG16L1, IRGM) 
may exacerbate the failure to clear bacteria.  Finally, in the third stage, persistence of 
undigested bacteria results in granuloma formation, in an attempt to contain the bacteria, and 
a temporally distinct secondary phase of pro-inflammatory cytokine and chemokine secretion 
which drives the recruitment of T lymphocytes to the tissue resulting in a compensatory chronic 
adaptive immune response.  The ensuing chronic inflammation causes local tissue damage 
(including fibrosis, stricturing and fistulisation) and systemic responses which are 
characteristic of established CD.  
 
1.3.11 Potential candidate molecules responsible for the defective macrophage 
response in CD 
In an attempt to identify macrophage defects in CD, which may contribute to impaired bacterial 
clearance, transcriptomic studies of MDM were carried out on patients with quiescent CD 
compared with HCs (discussed further in section 3.1). OPTINEURIN (OPTN) was identified 
as grossly under expressed in a subset of patients with CD [245]. This molecule has 
subsequently been shown to play a role in cytokine secretion, neutrophil recruitment and 
autophagy [246]. A disintegrin and metalloproteinase (ADAM)-like, decysin 1 (ADAMDEC1) 
was also identified, in this study, as significantly under expressed in a subset of patients with 
CD [245]. The role of this molecule is currently unknown. 
 
1.4 ADAMDEC1: Published literature 
Very little published literature is available on ADAMDEC1 (ADAM like decysin 1). First 
identified in 1997 by Chris Mueller and colleagues [248], ADAMDEC1 is the sole member of 
a subsidiary class of the ADAM’s (A Disintegrin And Metalloprotease) family, which in turn is 
part of the Metzincin superfamily, along with MMPs, ADAMTS (ADAMs with a thrombospondin 
motif), astacins and bacterial serralysins. 
These groups share common functional domains (Figure 1.2).  They possess a signal 
sequence at their N-termini which direct the proteins to the secretory pathway.  This is then 
followed by a prodomain and a catalytic metalloprotease domain.  The latter contains a highly 
conserved zinc binding sequence, HEXXHXXGXXH, essential for proteolytic activity.  A latent 
(non-active) state is maintained by a cysteine residue in the prodomain (termed the cysteine 
switch).  This amino acid interacts covalently with a Zinc2+ ion in the active centre of the 
catalytic domain which effectively blocks access of the catalytic site to the substrate [249], 
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[250].  Cleavage of the prodomain by a pro-protein convertase, such as furin [251], [252] or a 
furin independent convertase [253] or autocatalysis [254], results in opening of the cysteine-
Zinc bond, yielding a proteolytic active site which, in many of these zinc dependent 
endopeptidases, has been shown to cleave, activate and degrade a variety of substrates [255], 
[256].  
The main structural difference between the metzincins is the C-terminus domains which 
influence their location and function within cells and tissues.  In general, ADAM proteins 
contain an epidermal growth factor (EGF) - like repeat domain, a cysteine rich domain, and a 
disintegrin like domain.  While the biological function of the EGF domain has not been fully 
elucidated, the cysteine rich and disintegrin domains enable the ADAMs to engage with the 
ECM and ligands on neighbouring cells.  The disintegrin domain mediates cell-cell and cell-
matrix interactions by binding integrins.  The cysteine rich domain enables ADAMs to bind 
several extracellular components, such as proteoglycans [257] and fibronectin [258], 
independently of integrin-disintegrin interactions. 
ADAMs and membrane bound-MMPs are active at the cell surface and are anchored by a 
transmembrane domain and cytoplasmic tail.  In contrast, all other metalloproteases lack this 
domain and are soluble.  Some remain active within the cell such as a splice variant of 
ADAM19 [259], but the majority of MMPs, ADAMTS and snake venom metalloproteases are 
secreted from their native cells and act extracellular [21], [255].  Soluble splice variants for at 
least two ADAMs have also been described which lack the C terminal domains [260], [261]. 
ADAMDEC1 is a unique member of the ADAM family.  Firstly it has a truncated disintegrin 
domain, due to a premature stop codon, and lacks the C terminal domains including the EGF, 
cysteine rich and transmembrane domains and cytoplasmic tail (Figure 3.13).  As such it is 
predicted to be a soluble protein.  The disintegrin site is believed to be defunct as it is missing 
the ‘disintegrin loop’, a 14 amino acid stretch which has been implicated in interactions 
between other ADAM family members and integrins [262], [263].  The second distinguishing 
feature of ADAMDEC1 is that it is the only mammalian ADAM protease in which a histidine 
(H) is replaced by an aspartic acid (D) residue within the zinc binding sequence of the 
metalloprotease domain (H362D).  This substitution is found in some bacterial metzincins 
which are biologically active endopeptidases [259], [264].  Furthermore, despite this alteration 
the metalloprotease site of ADAMDEC1 has recently been reported to be proteolytically active 
in vitro [265]. 
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Figure 1.2: Schematic diagram comparing the domain structures of ADAMDEC1 with 
ADAMs, MMPs and their closest relatives.  ADAM proteins typically contain a prodomain 
(blue), catalytic domain (red) which encompasses the zinc binding site (dark purple), a 
disintegrin domain (green), cysteine rich domain (orange), Epidermal growth factor domain, 
EGF (navy blue) and transmembrane domain, TM (purple) and cytoplasmic tail. (A). In 
contrast, ADAMDEC1 has a truncated disintegrin domain and lacks the transmembrane 
domain and cytoplasmic tail. (B). Snake venom metalloproteases contain the disintegrin 
domain and lack the transmembrane domain and cytoplasmic tail. (C). ADAMTSs are soluble 
proteins which contain thrombospondin motifs (TS) and a spacer region (D). In comparison 
the archetypical MMP contains a hinge region (wiggle line), and hemopexin-like domain 
(green) (C). Whilst the membrane type-MMPs have an addition transmembrane domain (light 
purple) (F) or glycosyl-phosphatidyl inositol (GPI) membrane anchor (orange) (G). 
 
 
In recent years these zinc dependent metalloproteases have become recognised as major 
players in inflammation and tissue repair [255], [266], [267] and a growing interest has 
developed in their potential role in gut homeostasis and bowel inflammation [21], [268], [269].  
To date the vast majority of literature regarding metalloproteases in the GI tract has focused 
on the MMPs.  These molecules classically degrade ECM proteins, such as collagen, 
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proteoglycan, fibronectin, elastin, and laminin [21] and thereby collectively maintain ECM 
turnover, homeostasis, and are central to tissue remodelling.  Less is known regarding the 
ADAMs proteins in maintenance of gut integrity, homeostasis and immunology.  However, one 
ADAM in particular, ADAM17, has gained notoriety as the principal protease involved in 
cleavage and activation of pro-TNFα and as such it has been termed the TNFα convertase 
(TACE) [270].  A family carrying a deletion in ADAM17 have recently been described in which 
the affected individuals suffer from a potentially fatal, inflammatory disease involving the skin 
and bowel [269] which is thought to be secondary to a failure to cleave and activate TNF. A 
number of MMPs and ADAMs are also capable of cleaving TNF, albeit not as effectively as 
ADAM17 [271]–[274].  Many are also reported to cleave, activate, and in some cases degrade, 
other pro-inflammatory cytokines, in particular IL1β [275], [276]).  In addition, metalloproteases 
commonly interact with growth factors and chemokines either by activating or antagonising 
their substrates [21], [256].  By their substrate interactions, it has become increasingly evident 
that these zinc dependent metalloproteases influence the function and migration of 
inflammatory cells, maintain tissue homeostasis, aid wound healing and are pivotal in the 
regulation of the innate and adaptive immune response [277]–[279]. 
 
 
1.5 Outline of Thesis 
 
In this thesis, the expression and role of ADAMDEC1 in health and disease is explored, with 
particular emphasis to its function in the intestinal tract and association with CD. 
The methods employed throughout the research project are described in Chapter 3. When 
investigations have been the result of a collaboration or carried out by a third party it is 
highlighted in this section. 
In Chapter three, the finding of low ADAMDEC1 in a subgroup of patients with CD is verified 
and replicated in a second cohort.  Demographic data is analysed to identify any predisposing 
factors which may contribute to the reduced expression of this gene. Genotyping is performed 
to see whether patients with attenuated expression of ADAMDEC1 share a polymorphism that 
could account for this observation. The expression of ADAMDEC1 in ileocolonic samples from 
patients with CD, UC and healthy controls is examined.  The publically available genomics 
data repository, Genome Expression Omnibus (GEO), is interrogated to compare ADAMDEC1 
expression levels in other datasets. This database is also used to examine the expression of 
ADAMDEC1 at extra-intestinal sites during inflammatory states. 
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In Chapter four, the tissue, cellular and subcellular location of ADAMDEC1 is explored. The 
response to bacterial antigens and vesicle trafficking molecules is assessed. 
In chapters five and six, the role of ADAMDEC1 in vivo is investigated. Using Adamdec1 
knockout mice the response to three different colitis models; dextran sodium sulphate (DSS), 
Citrobacter rodentium and the intracellular pathogen, Salmonella typhimurim, is assessed to 
ascertain whether ADAMDEC1 has a functional role in gut immunity. 
A general discussion of the findings and limitations of the study are discussed finally in Chapter 
seven.  
 
The hypotheses investigated: 
• Significantly reduced expression of ADAMDEC1 in MDM is specific to CD patients 
• ADAMDEC1 plays a role in the inflammatory response to bacteria  
• Absence or reduced levels of ADAMDEC1 will result in bowel inflammation  
• ADAMDEC1 deficiency may predispose to Crohn’s disease, in a subgroup of patients  
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2. Materials and Methods 
 
2.1 Patients and Healthy Controls 
2.1.1 Subject recruitment and selection 
IBD patient selection 
CD and UC patients were recruited from the IBD clinic or endoscopy unit, at University College 
London Hospitals Foundation Trust (UCLH), for the following studies:   
MDM studies: Two independent studies (Primary and Replication studies) were performed on 
peripheral blood MDM, from patients with quiescent CD and healthy volunteers. Subjects were 
recruited for the first study (The Primary Cohort) between 2009-2010, and the expression data 
has been published [245]. Subjects for the ‘Replication Cohort’ were recruited between 2011-
2014. 
Ileocolonic biopsy study: For the bowel biopsy study CD, UC and non-IBD (controls) patients 
undergoing surveillance colonoscopy or routine flexible sigmoidoscopy were recruited. 
All subjects were adults, aged between 18 and 75 years of age. IBD patients were included if 
they had a definite clinical and histological diagnosis of CD, which met internationally accepted 
diagnostic Lennard-Jones criteria [280]. Subjects were excluded if the diagnosis had been 
made less than one year previously, other causes of inflammation had not been excluded, 
only non-specific or indeterminate features were present or if the clinical and histological 
findings were inconsistent. Patients were clinically phenotyped using the Montreal 
Classification [281]. IBD patients were included if they had clinically quiescent disease with a 
Harvey–Bradshaw score [282] of less than 3 in CD and a Partial Mayo activity score [283] of 
less than 2 in UC. For MDM studies endoscopic examination was not performed to exclude 
subclinical GI lesions. In the bowel biopsy study, patients were excluded post endoscopy if 
microscopic inflammation or dysplasia was reported by a specialist UCLH consultant 
histopathologist. In general, subjects were eligible if they were on no medication or a stable 
maintenance dose of 5-ASA for at least three months.  In addition, patients were also included 
if they had been quiescent on a stable dose of thiopurines or monoclonal antibodies against 
TNFα for greater than three months, in the Replication Cohort study. In the ileocolonic biopsy 
study, subjects were included on a stable dose of thiopurine, but not monoclonal antibodies. 
Patients were excluded in all studies if they had taken steroids within 3 months.  
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Healthy control (HC) selection 
MDM studies: healthy control (HC) volunteers were recruited from the staff and student 
population in the Division of Medicine, University College London (UCL), and 
Gastroenterology department at UCLH, and were invited to participate via a departmental 
email.  Blood samples from control subjects, were used in the Primary and Replication studies 
in Chapter 3 and in the studies in Chapter 4.  
Bowel biopsy study: HC were non-IBD patients attending for endoscopic investigation of 
gastrointestinal symptoms with no evidence of macroscopic ileocolonic pathology at the time 
of endoscopy. Individuals were excluded post endoscopy if inflammation or dysplasia was 
reported on histological examination, by a specialist consultant histopathologist, UCLH. 
Surgical specimens: In addition to the MDM and ileocolonic biopsies, small and large bowel 
surgical specimens were obtained from healthy resection margins of patients undergoing 
curative surgery for colorectal adenocarcinoma, in the Department of Surgery, UCLH. These 
specimens were used for immunohistochemical staining and in situ hybridisation. 
In all studies, IBD patients and controls were excluded if they had known hepatitis B or C, 
Human Immunodeficiency Virus (HIV) or were pregnant.  HC were also excluded if they had 
a family history of CD, an autoimmune or other inflammatory condition or if they were taking 
anti-inflammatory or immune-modulating drugs. 
 
2.1.2 Consent and sample collection 
MDM studies: Eligible patients were offered the option to participate in the study at the end of 
their outpatient clinic consultation. If they agreed eligibility was confirmed and consent 
obtained separately by a study recruiter, not their clinician, to minimise patient coercion. 
Subjects were asked to gift 100ml of blood for MDM studies (See section 2.3.1) and an EDTA 
sample for testing gDNA. Routine blood samples were also taken from patients to measure 
full blood count, C-reactive protein ± erythrocyte sedimentation rate, urea and electrolytes, 
liver function tests. Additional blood tests were taken at the clinicians’ request. 
Ileocolonic biopsy studies: Subjects were approached, and consented, prior to their 
endoscopic procedure, by study recruiters, not the endoscopists. Paired endoscopic pinch 
biopsies (Radial Jaw 4 2.8 mm Single-Use Biopsy Forceps; Boston Scientific Corporation, 
Marlborough, MA) were obtained from macroscopically normal mucosa of the terminal ileum, 
ascending colon, descending colon, and rectum (section 3.2.9). Where possible samples were 
taken from all 4 locations in each subject. One biopsy was placed in RNAlater stabilization 
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reagent (Qiagen, Hilden, Germany) and stored at −80°C for messenger RNA (mRNA) 
preparation, and the other was placed in 4% formaldehyde for histological evaluation. Biopsies 
were also taken from the rectum for protein analysis and snap frozen in liquid nitrogen and 
stored at -80°C. Routine blood samples were also taken from patients to measure full blood 
count, C-reactive protein ± erythrocyte sedimentation rate, urea and electrolytes, liver function 
tests. 
Intestinal resection specimens: Patients with colorectal cancer, amenable to curative surgical 
resection, were identified at colorectal multidisciplinary meetings and consented prior to 
surgery by a study recruiter.  
Incentives were not offered for inclusion in any of the studies. Written informed consent was 
obtained from all participants. No subject was included in more than one study. 
 
2.1.3 Patient database 
Patient details and clinical information were recorded in an encrypted, password protected 
database, registered and covered by the Data Protection Act, 1998.  Access to this database, 
and the process of obtaining informed consent from the subjects, was restricted to named 
individuals with up to date certificates in Good Clinical Practice (study recruiters). Clinical 
details included were name, date of birth, hospital number, Montreal classification, 
comorbidities, current and past medication, smoking status, family history.  
 
2.1.4 Ethical Approval for human studies 
Ethical approval was obtained from the Joint UCL/UCLH Committee for the Ethics of Human 
Research (project number 02/0324) and the NHS National Research Ethics Service, London-
Surrey Borders Committee (project number 10/H0806/115). 
 
2.2 Adamdec1-/- and Adamdec1+/+ Mice 
Animal studies were performed in accordance with the United Kingdom Animals (Scientific 
Procedures) Act 1986 and European Directive 2010/63/EU on the protection of animals used 
for scientific purposes.  
Adamdec1 heterozygote (Adamdec1+/-)  mice were generated by targeted mutagenesis of the 
Adamdec1 gene 1227 on Chromosome 8 and insertion of a neomycin resistant cassette into 
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exon 11 (section 5).  The line was reconstituted from frozen embryos from the Deltagen 
repository (http://www.deltagen.com).  Embryonic stem cells were re-derived from 129/OlaHsd 
mice.  The chimeric mice were backcrossed onto C57BL/6 mice (supplied by Charles River) 
for at least 6 generations before three Adamdec1+/- mice were purchased by UCL.  Adamdec1 
heterozygote mice were then cross matched to obtain Adamdec1+/+ (wild type) and Adamdec1-
/- (knock out) mice. 
 
2.2.1 Mice Genotyping 
Mouse genomic deoxyribonucleic acid (gDNA) was extracted from ear clips. The ear clips 
were incubated over night at 55ºC in 95µl of DNA extraction buffer containing 5µl of 4mg/ml 
proteinase K (Quiagen).  The samples were vortexed at 1400rpm at 55ºC for 10 minutes in an 
Eppendorf Thermomixer Comfort (Fisher Scientific) then centrifuged at 28,000g for 10 minutes 
to pellet the hair.  Samples were subsequently transferred to clean new tubes and boiled at 
95 ºC for 5 minutes. 
Genotyping was performed by polymerise chain reaction (PCR) of the isolated genomic DNA 
amplified with Adamdec1 gene specific primers. For Adamdec1+/+ mice: Forward primer: 
AGCTTGAGCGCAAACCCAATGCTTC. Reverse primer: CCTCAGGTACTGATTCATCACA 
CAG, expected size 332bp. For Adamdec1-/- mice: Forward primer: GACGAGTT 
CTTCTGAGGGGATCGATC. Reverse primer: CCTCAGGTACTGATTCATCACACAG, 
expected size 600bp (see table 2.1). For further details on generation of the Adamdec1-/- 
mouse see figure 5.6. 
 
Table 2.1: Primer table for genotyping Adamdec1
+/+
 and Adamdec1
-/- 
mice.  GS - 
Gene specific; NEO – Neomycin cassette; E – Endogenous region of gene; T - Target region 
of gene.  
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The PCR reaction volume was made up of 12.5µl HotStar Taq Mastermix, 1µl forward primer, 
1µl reverse primer, 1µl gDNA, made up to 25µl with RNase-free water.  The final concentration 
in the reaction volume was 2.5U HotStar Taq DNA polymerase, 1xPCR buffer containing 
1.5mM MgCl2, 200µM of each dNTP, 0.4µM of each primer and a variable amount of gDNA.  
PCR was carried out on a DNA Engine Tetrad 2® Peltier Thermal Cycler using the conditions 
in table 2.2 below for 28 cycles. 5µl Orange J was added to each 25µl reaction mix and 15µl 
was run on a 1% agarose gel, stained with Ethidium bromide, and viewed with a ChemiDocTM 
Imager (Bio-Rad). The PCR product size was determined by comparison with a DNA ladder 
(molecular weight marker). 
 
 Temperature Time 
Activated 95 ºC 15 minutes 
Denatured 95 ºC 45 seconds 
Annealed 60ºC 45 seconds 
Extended 72ºC 45 seconds (28 cycles) 
Extended 72ºC 10 minutes 
Cooled 4ºC Ad infinitum 
 
Table 2.2: PCR conditions for genotyping Adamdec1+/+ and Adamdec1-/- mice. 
 
 
2.2.2 Other Mice Strains 
C57BL/6 mice were brought from Charles Rivers and C57BL/6JRccHsd germ free mice were 
obtained from isolator units at Hillcrest, Harlan laboratories. On transfer of mice into the animal 
unit at UCL they were rested for a week before experimentation in order to minimise the effect 
of stress compromising results. 
 
2.2.3 Mice Husbandry 
Colonies were generated from Adamdec1+/+ and Adamdec1-/- breeding pairs. Mice were bred 
and maintained in specific pathogen free (SPF) cages, and germ free mice were held in germ 
free isolators in a specialised Class II designated unit, in the Biological Sciences Unit, UCL. 
56 
The environmental conditions; temperature, humidity and hours of light were kept constant, 
and monitored by the Named Animal Care and Welfare Officer (NACWO) in the animal facility. 
The cages and bedding were changed weekly. Mice were fed with Harlan 2018 Teklad Global 
18%, whilst breeders were fed with Harlan 2019 Teklad Global 19%, protein rodent diet. 
Drinking water was sterilised. Routine health screens for infection were carried out for 
parasites and opportunistic infections. Mice between the ages nine and 12 weeks were used 
for experimentation. They were matched for age, sex and weight for each study. 
 
 
2.3 Cell Isolation, Culture and Stimulation Assays 
 
2.3.1 Human Peripheral Blood MDM 
100ml blood was taken from patients into two 50ml sterile syringes containing 5U/ml heparin 
(LEO laboratories, Princes Risborough, UK).  Peripheral blood monocytes (PBMC) were 
isolated as previously described [240].  25ml of blood was carefully layered onto 15ml 
Lymphoprep™ (Axis-Shield, Oslo, Norway) in 50ml Falcon tube.  PBMC were separated by 
differential centrifugation (2000rpm, 900g, 30 minutes, 20ºC, brakes off) over Lymphoprep.  
The lymphocyte-monocyte layer was isolated from the interface between the serum and 
lymphoprep.  The cell suspension was washed twice in sterile phosphate buffered saline 
(PBS) (GIBCO, Paisley, UK), at 1400rpm (575g, 5 minutes, 20ºC) and then at 1200rpm (325g, 
5 minutes, 20ºC).  The cells were resuspended in serum free RPMI-1640 medium (Invitrogen, 
Paisley, UK), supplemented with 100U/ml penicillin (GIBCO), 100µg/ml streptomycin (GIBCO) 
and 20nM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer pH 7.4 (Sigma 
Aldrich), and plated at approximately 5x106 cells onto 92mm NunclonTM Surface tissue culture 
dishes (Nunc, Roskilde, Denmark).  Cells were incubated at 37ºC, 5% CO2, in a tissue culture 
incubator, for two hours, to allow monocytic cells to adhere.  Non-adherent cells and serum 
free medium then were discarded and the adherent cells washed carefully with sterile PBS.  
10ml of RPMI-1640 medium supplemented with 10% Foetal Bovine Serum (FBS) (Sigma-
Aldrich), 100U/ml penicillin, 100µg/ml streptomycin and 20nM HEPES buffer pH 7.4 was 
added.  Cells were then incubated for 5 days at 37ºC, 5% CO2, for five days.  On day two, 
cultures were fed with a further 10ml of RPMI-1640 containing 10% FBS. 
Following five days of culture, adherent MDM were washed with PBS and harvested by 
scraping into 10ml of PBS.  Cells were then counted, pelleted by centrifugation at 1200 (375g, 
5 minutes, 20ºC) and resuspended in X-VIVO-15 medium (Lonza) at a density of 1x106 cells. 
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Cells were then replated at 106 cells/ well in 35mmx10mm NunclonTM coated tissue culture 
plates (Nunc) for ribonucleic acid (RNA) collection, 2.5x105 cells/well in Falcon® 24 well tissue 
culture plates for immunoblot and 105 cells/well in Falcon® 96 well tissue culture plates for 
cytokine secretion assays. MDM were incubated over night at 37ºC, 5% CO2, to adhere. 
 
TLR antigen stimulation of MDM 
Cells were then stimulated for up to 24 hours with 200ng/ml LPS (Alexis Biochemicals), 4µg/ml 
Pam3CSK4 (Alexis Biochemicals), 1µg/ml R848 (Alexis Biochemicals), 1µg/ml IFNγ, 1µg/ml 
MDP (Sigma), or HkEc NCTC 10418 at a multiplicity of infection (MOI) of 20 (see reagents 
section 2.16.1).  
 
2.3.2 THP1 Cell Culture and Stimulation 
THP1 cells (a human acute monocytic leukemia cell line) were cultured in RPMI-1640 medium, 
supplemented with 10% FBS, 100U/ml penicillin, 100µg/ml streptomycin, 20mM HEPES and 
20µM β-mercaptoethanol (GIBCO), plated and stimulated as MDM. 
 
2.3.3 Murine Large Bowel LP Cell Isolation 
Following dissection, murine large bowels were cut longitudinally and washed in ice cold PBS 
containing 100U/ml penicillin, 100µg/ml streptomycin (PAA) to remove faeces.  Epithelial cells 
were removed by incubation of each large bowel in 20ml of predigestion solution (Hanks 
balanced salt solution, HBSS (GIBCO) containing 10% FBS, 100U/ml penicillin, 100µg/ml 
streptomycin and 2mM ethylenediaminetetraacetic acid, EDTA) at 37°C, 250rpm for 1 hour.  
Epithelial cells were passed through a 70μm filter.  The remaining LP tissue was diced into 
1mm pieces and washed with PBS to remove EDTA.  LP tissue was incubated in 20ml 
digestion solution (HBSS containing 10% FBS, 100U/ml penicillin, 100µg/ml streptomycin, 
30mg collagenase (Sigma), 0.8mg DNase I (Sigma) and 15mg Dispase II (Sigma) at 37°C, 
250rpm for 30 minutes, and vortexed for 20s at the start, middle and end of incubation.  LP 
cells were passed through a 70μm filter, washed finally with PBS.  
A pilot study was performed to choose the optimal digestion time. The number of viable cells 
obtained after incubating LP tissue in digestion solution for 15, 30, 45 or 60 mins were 
assessed. Trypan Blue (0.4%) stained (non-viable) and unstained (viable) cells were counted 
using a haemocytometer.  30mins was chosen as the optimal digestion time. 
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2.3.4 Murine Bone-Marrow Cells 
Bone marrow cells were harvested from mice femurs, using a syringe, 21guage green needle 
and PBS flush. The cells were treated with red blood cell lysis buffer (Sigma) for 3 mins, 
washed in PBS. Cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) (GIBCO) 
containing 1 g/L D-glucose, 4mM L-glutamine, 25mM HEPES, 1mM pyruvate, 10% FBS 
(Sigma), 100U/ml penicillin, 100µg/ml streptomycin (PAA) and 20ng/ml macrophage-colony 
stimulating factor (M-CSF) (Peprotech) on 92mm Nunclon™ ∆ coated tissue culture plates 
(Nunc) for 5-10 days, with or without the addition of 200ng/ml LPS.   
 
2.3.5 Murine Peritoneal Cavity Cells 
Naïve peritoneal cells were harvested from peritoneum in cell dissociation buffer (GIBCO) and 
treated with red blood cell lysis buffer (Sigma) for 3 mins, washed in PBS.  
Thioglycollate-Induced Peritoneal Macrophages were obtained by injecting 1ml of sterile aged 
3% thioglycollate broth (Merck) intraperitoneally.  After 5 days, cells were harvested in cell 
dissociation buffer (GIBCO). Cells were then cultured in RPMI-1640, GlutaMAX™ Supplement 
(GIBCO) containing 10% FBS (Sigma), 100U/ml penicillin, 100µg/ml streptomycin (PAA), 
20mM HEPES (Sigma) for 5-10 days. 
 
 
2.4 Antibodies 
 
2.4.1 Human Antibodies 
The following antibodies were used for human MDM and THP1 immunoblots: Anti-
ADAMDEC1 antibody (against the N-terminal) raised in rabbit (Sigma Aldrich HPA028317 
1:1,000), Anti-ADAMDEC1 antibody (against the C-terminal) raised in rabbit (Aviva Systems 
Biology ARP55070_P050 1:1,000). Actin (Sigma A5060 1:2,000), EEA1 (Cell Signalling #3288 
1:1,000), LAMP1 (Abcam ab24170 1:1,000), GM130 (BD 610823 1:250), Rab-4 (santa cruz 
sc-376243 1;1000), Calnexin (Abcam ab10286 1:1000), Adaptin α (Abcam 91268 1:1000), 
Flotillin (Abcam ab41927 1:1000), Golgin-245 (Santa Cruz sc-102565 1:250), GAPDH (Santa 
Cruz sc-51906 1:2,000), anti-rabbit IgG-HRP (Cell Signalling #7074; 1:2,000 and anti-mouse 
IgG-HRP (GE Healthcare NA931; 1:2,000). LC3B (Sigma L7543 1:1,000) 
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A monoclonal anti-ADAMDEC1 antibody, raised in mouse (clone 6C4 Sigma WH0027299M1 
1:100) was used for immunohistochemistry staining. 
 
2.4.2 Mouse Antibodies 
An anti-mouse ADAMDEC1 antibody was produced in the laboratory by Dr Jenny Dunne, as 
a suitable commercial antibody was not available. ADAMDEC1 constructs for mouse and 
human were gifted by Dr Chris Mueller [392]. Both construct were successfully transfected 
into eukaryotic HEK293 cells by Dr Jenny Dunne, as previously described [310], confirmed by 
sequencing and western blot. However insufficient amounts of the eukaryotic protein were 
purified to send for antibody production.  
In order to express a larger volume of protein, Dr Dunne collaborated with Tracey Barrett, 
Birkbeck, UCL. The catalytic domain of murine ADAMDEC1 was cloned into a GB1-pBR22b 
expression construct. The protein was expressed in E. coli, as a bacterial expression vector 
has the potential to produce a much higher yield of protein than eukaryotic cells. The result 
was a GB1-ADAMDEC1 protein with the solubility enhancer GB1 at the N-terminus and a His 
tag at the C-terminus, confirmed by mass spectrometry. The His-tagged protein was purified 
with a nickel column and injected into rabbits to produce the anti-serum. The anti-serum was 
used for both immunoblot and immunohistochemistry staining of ADAMDEC1 in mouse bowel.  
The ADAMDEC1 recombinant protein produced could not be used for functional studies as 
the GB1 moiety interacts with the Fc domain of antibodies and enhances non-specific binding.  
It does however contain a 3C protease site which could potentially be targeted to allow 
cleavage and removal of the GB1 prior to functional studies in the future.  
 
 
2.5 Inhibitors of Vesicle Trafficking and Protein Degradation 
THP1 cells and human MDMs plated at 5x105 and stimulated for +/- 24 hours with HkEc at a 
MOI of 20 plus either RPMI (with 10% FCS, 100U/ml penicillin, 100µg/ml streptomycin) alone, 
or RPMI (with 10% FCS, 100U/ml penicillin, 100µg/ml streptomycin) with 2.5μM monensin 
(Sigma), 10mM NH4Cl (Sigma), 100μM chloroquine (Sigma), 2.5μM brefeldin A (Merck) or 
200nM bafilomycin A (Sigma).   
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2.6 Microarray Expression Studies 
Total RNA was harvested from peripheral blood MDM [241] and ileocolonic biopsies [244] 
using the RNeasy® Mini Kit (Qiagen).  Concentration of total RNA in RNase-free H2O (Qiagen) 
was measured using a NanoDrop ND-1000 spectrophotometer (Thermo Scientific).  Optical 
Density readings were determined for OD260/OD280 and OD260/OD230 to assess protein and 
solvent contamination.  RNA integrity was analysed by measuring ribosomal RNA band 
28S/18S ratios using high resolution electrophoresis on an Agilent Bioanalyzer (Agilent 
Technologies, Inc), which was >8. 
500ng of total RNA for each sample were amplified using the Illumina TotalPrep-96 RNA 
Amplification kit (Ambion) and normalised to 150ng/µl.  750ng was hybridised to Illumina 
Human-WG6 v3.0 Expression BeadChips (Illumina) for 16 hours at 58oC.  Following 
hybridisation Beadarrays were stained with streptavidin-Cy3 (GE Healthcare) and scanned 
using the Beadarray reader and processed with GenomeStudio® data analysis software 
(Illumina). 
The MDM transcriptomic data from the Primary Cohort was deposited in the Gene Expression 
Omnibus (GEO) with accession no. GSE60083 and the bowel biopsy data is accessible in 
GSE48634. For details on microarray, and outlier, analysis see statistical analysis section 2.17 
 
 
2.7 Quantitative Reverse Transcription PCR (qRT-PCR) 
Human MDM and THP1 cells were lysed in 350µl of Buffer RLT (Quiagen) containing 10 µl of 
2-mercaptoethanol (Sigma) per 1ml Buffer RLT.  5mm sections of ileal or colonic mouse tissue 
were homogenised in 600µl RNAlater (Qiagen) using the TissueLyser LT (Qiagen) for 5 
minutes at 50Hz. Tubes were then centrifuged at 14,000g for 3 minutes at 4oC. Supernatants 
were transferred into fresh tubes. RNA was harvested using the RNeasy® Mini kit (Qiagen).   
Total RNA was converted to complementary DNA (cDNA) using the QuantiTect® Reverse 
Transcription Kit (Qiagen) following the manufacturer’s instructions.  qRT-PCR was performed 
using the QuantiFast SYBR® Green PCR kit (Qiagen), in duplicate on a Mastercycler® ep 
realplex (Eppendorf) with primer sets (Appendix 1) created using Primer 3. Normalised mean 
gene expression values ± SD were determined from duplicate cycle threshold (Ct) values for 
each target gene and the housekeeping gene; peptidylprolyl isomerase A (PPIA) or HPRT 
(Hypoxanthine-guanine phosphoribosyltransferase).  Relative transcript levels were 
determined by the 2^ΔΔCt method [435]. 
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2.8 Sequencing of ADAMDEC1 Region 
Sequencing of ADAMDEC1 region in outlier individuals, including all exons and flanking 
sequence, was conducted by PCR amplification and automated Sanger chemistry. The 
referencing sequence of the ADAMDEC1 gene was obtained from the University of California, 
Santa Cruz (UCSC) genome browser. Forward and reverse primers were designed for specific 
amplification of ADAMDEC1 exons, promotor and flanking regions, using Primer 3 software. 
Sequences of these primers are shown in Appendix 2.  
PCR was carried out in 25µl reactions containing 12.5µl 2x Hotstar Taq master mix (Quiagen 
GmbH), 200pmol of the appropriate forward and reverse primers (Eurofins MWG operon), the 
equivalent of 20ng DNA per reaction, was made up to total volume of 25µl using DNAse free 
water (Quiagen GmbH). PCR was conducted using a DNA engine Tetrad 2 Peltier Thermal 
cycler (Bio-Rad, Hercules, USA). Reactions were initially heated at 95ºC for 2 mins, followed 
by 35 cycles of denaturation at 95ºC for (30 seconds), annealing at 56.4ºC (30 seconds), and 
extension at 72ºC (30 seconds). After 35 cycles, reactions were incubated at 72ºC for 10 
minutes. Negative control reactions containing no DNA template were performed in parallel to 
test for contamination. The annealing temperature as chosen after a temperature gradient was 
run for each primer pair. 
Following PCR, 5µl of the reaction were subjected to agarose gel electrophoresis, stained with 
ethidium bromide and visualised using a Chemi-Doc XRS system (Bio-Rad) to assess 
amplification of a specific PCR product of the appropriate size and absence of contamination. 
Prior to DNA sequencing, PCR products were purified using the QIAquick PCR purification kit 
(Quiagen GmbH), in accordance with the manufacturer’s instructions. DNA was eluted in 30µl 
DNAse free water, and the concentration measured using a NanoDrop ND-1000 
spectrophotomer (Fisher Scientific) and resuspended to obtain a concentration of 2-10ng/µl, 
depending on the fragment length. Sequencing of the fragments was conducted at the Wolfson 
Institute for Biomedical Research, UCL, by automated Sanger dideoxynucleotide sequencing 
reactions. 
DNA sequence chromatograms were viewed using FinchTV (Geospiza Inc., Seattle, WA, 
USA). The chromatogram quality and presence of heterozygous changes was inspected by 
eye. Sequences of amplified fragments were aligned with reference sequences using the 
ClustalW algorithm on the SDSC Biology workbench 3.2 website (http://workbench.sdsc.edu/), 
with default parameter settings. Sequences were searched for previously recognised variants 
in the ADAMDEC1 gene, as documented in the National Centre for Biotechnology Information 
(NCBI) SNP database (dbSNP). 
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Linkage disequilibrium between polymorphisms identified in the ADAMDEC1 outlier patients 
were determined using SNP annotation and proxy search (SNAP) software. This software 
package calculated pair-wise linkage disequilibrium between variants, using phased genotype 
data from the International HapMap and 1000 genomes projects. In order to assess whether 
any of the identified SNPs were associated with gene expression, data from expression 
quantitative trait loci (eQTL) studies were interrogated using Genevar (GENe Expression 
VARiation) software. 
 
 
2.9 Immunoblot 
MDMs, THP1 cells and homogenised mouse bowel were lysed in 3x Laemmli sample buffer 
containing β-mercaptoethanol (Sigma), protease inhibitors (Roche11697498001) and 
phosphatase inhibitors 2 and 3 (Sigma P5726 & P0044). Samples were scraped with sterile 
24cm cell scrapers (SLS 99002T), transferred into eppendorfs and pipetted up and down 10 
times to break DNA then boiled at 95oC for 5 minutes on an Eppendorf Thermostat plus and 
stored at -20oC.   SDS-PAGE gels were made (see section 2.16.5). 10% gels were used for 
all experiments except LC3 for which 15% gel was used.  10µl of sample were loaded onto 
10-well SDS-PAGE gels and run in 1x transfer buffer (see reagents section) without methanol 
at 30 mA per gel for 40 minutes.  
Four sheets of blotting paper (12cm x 8cm) was soaked in 1x transfer buffer containing 20% 
methanol and layered onto a Trans-Blot SD semi-dry transfer cell (Bio-Rad).  100% methanol 
was used to activate Hybond-P PVDF membranes (Amersham, Buckinghamshire, UK) and 
placed on the blotting paper. The SDS-PAGE gel was placed onto of the PVDF membrane. 
Four sheets of soaked blotting paper were placed on top.  The Transfer cell was run at 100mA 
for 60 minutes.  
Membranes were blocked in 5% non-fat skimmed milk (Marvel) for one hour, washed three 
times in TBS-Tween and then probed with primary antibody overnight at 40C followed by 
washing with TBS-Tween three times. Membranes were then probed with secondary antibody 
for one hour at room temperature and washed three times in TBS-Tween. Bound antibody 
was detected using ECL Plus (Amersham), exposed to Hyperfilm ECL (Amersham), quantified 
and normalised to actin using ImageJ (NIH). 
63 
Citrobacter rodentium (C. rodentium) protein lysates were blocked with bovine serum albumin 
(BSA) followed by serum from Adamdec1+/+ and Adamdec1-/- mice.  Anti-mouse-HRP was 
applied for 30 mins to detect anti- C. rodentium IgG. 
 
 
2.10 Histology and Immunohistochemistry 
 
2.10.1 Histology of Human Intestine 
Immunohistochemical staining of non-inflamed human intestinal tissue sections was 
performed by the histopathology department at UCLH.  The tissue was obtained from healthy 
resection margins from patients undergoing colorectal surgery, confirmed at the time of 
surgery macroscopically and latter histologically. Following resection the tissue was 
immediately preserved in formalin for 24 hours before paraffin embedding. 5µm sections were 
cut, underwent automated dewaxing and endogenous peroxidase was blocked using 3-4% 
(v/v) hydrogen peroxide.   
Following preliminary antigen retrieval optimisation, these sections were stained with 
monoclonal anti-ADAMDEC1 antibody, raised in mouse (clone 6C4 Sigma WH0027299M1) 
used at dilution of 1:100 with 30 minute of incubation at room temperature following heat 
induced epitope retrieval for 20 minutes using an EDTA based (pH 9.0) epitope retrieval 
solution. Signal visualisation using the Bond Polymer Refine Detection kit (DS9800) with DAB 
Enhancer (AR9432) was performed on the Bond-III automated staining platform (Leica).  Cell 
nuclei were counterstained with haematoxylin.  
 
2.10.2 Histology of Mouse Intestine 
Mouse large bowel tissue was fixed in 10% neutral buffered formalin (CellPath) overnight and 
then paraffin-embedded using a Leica TP1050 tissue processor.  5µm sections were cut, 
underwent automated dewaxing and endogenous peroxidase was blocked using 3-4% (v/v) 
hydrogen peroxide.  The tissue was blocked with 5% Goat Serum (Sigma G67G7) (diluted in 
distilled water) and stained in VFM Harris’ hematoxylin (CellPath), differentiated in 0.2% acid 
alcohol and stained in Eosin Y (VWR) using a Leica ST4040 linear stainer and mounted in 
Pertex (Leica).  
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For ADAMDEC1 staining of mouse intestine, preliminary experiments were performed to 
optimise antigen retrieval: The conditions were adjusting including the pH, (citrate or based 
solution), temperature, antibody dilution and incubation time.  Following optimisation anti-
mouse ADAMDEC1 antibody, raised in rabbit, was used at a dilution of 1:30 for 60 minutes at 
room temperature, following EDTA based epitope retrieval solution.  Goat anti-rabbit HRP-IgG 
was applied for 60 minutes at room temperature followed by DAB Enhancer solution for 10 
minutes.  Slides were imaged with a Hamamatsu NanoZoomer 2.0-HT C9600 (Hamamatsu, 
Hertfordshire, UK).   
 
 
2.11 In Situ Hybridisation 
Predesigned in situ probes were purchased from Source Bioscience (human ADAMDEC1 No 
2402230 and mouse Adamdec1 No 1511966).  Both probes were cloned into pT7T3D-PacI 
and expressed in One Shot® TOP10 Chemically Competent E.coli (Lifetechnologies, UK).  
Probes were linearised with NotI / EcoRI and riboprobes generated using the Roche DIG RNA 
Labelling Kit (SP6/T7) (Sigma, UK).  Surgical resection tissue from human colonic and small 
bowel tissue was collected at the time of surgery was immediately fixed in DepC treated 4% 
PFA overnight followed by cryoprotection in DepC treated 20% sucrose in PBS overnight at 
4ºC.  Mouse bowel was harvested from freshly culled C57Bl/6 mice fixed and cryoprotected 
as above.  Then the tissue was rinsed and fixed in OCT.  Sections of 20µm thickness were 
cut and mounted on SuperFrost plus coated slides and dried in a dessicator.  For hybridisation, 
the riboprobes were diluted 1/1000 in hybridisation buffer (50% deionised formamide, 1x 
Denhardt’s solution (Invitrogen, cat 750018), 10% dextran sulphate (Sigma, cat D8906), 0.1 
mg/ml yeast tRNA (Roche, cat 10109509001) and 1x ‘salts’ (0.2M NaCl, 5mM EDTA, 10mM 
Tris-HCl, 5mM NaH2PO4.2H2O and 5mM Na2HPO).  Sections were incubated at 65ºC 
overnight in a humidified chamber.  Slides were washed three times for 5 minutes in MABT 
buffer (100 mM Maleic Acid, 150mM NaCl and 0.1% Tween-20, pH7.5), then washed twice 
for 30 minutes at 65ºC in 1xSSC, 50% formamide and 0.1% Tween-20.  Slides were rinsed 
again for two 5 minute washes in MABT buffer.  Sections were blocked in 2% blocking reagent 
(Roche cat 1096176), 10% heat inactivated sheep serum (GenTex, cat GTX73209) in MABT 
buffer for one hour at room temp in a humidified chamber.  Then they were incubated with 
1:1000 AP conjugated anti-DIG Fab fragments (Roche 1093274) diluted in 2% blocking 
reagent overnight at 4ºC.  Slides were washed three times for ten minutes in MABT buffer, 
then twice for 2 minutes in GB3 buffer (100mM Tris, pH 9.8, 100mM NaCl and 50mM MgCl2).  
Slides were then incubated in developing buffer for nitroblue tetrazolium staining (100mM Tris 
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pH 9.8, 100mM NaCl, 50mM MgCl2, 5% PVA, 0.11mM BCIP and 0.12mM NBT) for 6 hours at 
37 0C, protected from light in a humidified chamber.  Slides were dehydrated and mounted in 
a xylene based mountant (DPX). 
 
 
2.12 Subcellular Fractionation 
Sucrose gradients were prepared by layering eight 5% step dilutions of a 50% sucrose solution 
containing 1mM EDTA pH 7.4 and 5U/ml heparin, which was left overnight to equilibrate at 
4°C.  2x108 THP1 cells were stimulated with HkEc at a MOI of 20 for 24 hours then dounced 
and sonicated 3x5 s twice in 10% sucrose containing 1mM EDTA pH 7.4, 5U/ml heparin and 
protease inhibitors on ice.  Cells were confirmed to be lysed on light microscopy and 
centrifuged at 750g for 10 minutes at 4°C.  The post-nuclear supernatant was layered onto 
the sucrose gradient and ultracentrifuged in a TST 41.14 Kontron swing-bucket rotor at 
220,000g for 3 hours at 4°C on a Beckman Optima™ LE-80K Ultracentrifuge.  The subcellular 
fractions were removed in 1ml fractions and lysed in Laemmli buffer as described above for 
immunoblot.  The percentage sucrose in each fraction was measured with a Bellingham + 
Stanley Abbe 60 Refractometer. 
 
 
2.13 Flow Cytometry 
Blood, bone marrow and peritoneal cell washouts and murine bowel LP cells were incubated 
with the LIVE/DEAD® fixable blue cell stain kit (Invitrogen L23105), blocked in CD16/CD32 
Fc block (eBioscience 16-0161; 1:500) prior to staining with CD45 PerCP-Cy™5.5 (BD 
550994; 1:200), CD11b V450 (BD 560455; 1:400) and Gr1 PE (BD 553128; 1:800), F4/80 
FITC (eBioscience 11-4801; 1:1000), CD3 PE-Cy™7 (BD 560591; 1:800), CD19 PerCP-
Cy™5.5 (BD 551001; 1:800) and Ly-6C APC (BD 560595; 1:800) or CD11c APC (Biolegend 
117309 1:400 antibodies then fixed in 1% formaldehyde.  After staining, cells were run on BD 
LSR II flow cytometer (BD 338301) after optimization with compensation beads (BD 552845) 
and analysed using FlowJo 7.6.4 (Tree Star, Inc). 
The following cells were identified using surface markers (see table 1.1): neutrophils (GR1+ 
CD11b+), monocytes (Ly6chi and CD11b+ Ly6clow), macrophages (CD11b+ CD11c- F480+ Ly6c 
low and CD11b+ CD11c+ F480int Ly6c low) DCs (CD11c+ CD11b- F480- Ly6c low), T cells (CD3+) 
and B cells (CD19+).   
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2.14 Cytokine Assays 
Mouse serum TNF, IL6, IL1β, IL10, IFNγ, IL12p40 and KC (CXCL1) and human serum TNF-
α, IL-6, IL1β, Il12p70, IL-8 and IL-10 levels were determined using the Mouse Pro-
inflammatory 7-plex Ultrasensitive plate (Meso Scale Discovery, Rockville, Maryland, US) and 
a custom designed Human Multiplex Assay (Meso Scale Discovery, Rockvilla, MD), 
respectively. The results were read on a SECTOR® Imager 6000 (Meso Scale Discovery).  
 
 
2.15 Mouse Colitis Models 
 
2.15.1 DSS Colitis 
Nine to twelve week old mice were given drinking water containing DSS (MW 36,000-50,000) 
(MP Biomedicals, Cambridge, UK).  Fresh DSS was administered on days 2 and 5 after the 
start of the experiment.  On day 7 the DSS was replaced with fresh sterilised drinking water in 
a new bottle.  Mice were weighed daily and sacrificed between 0 and 21 days for tissue and 
blood collection. Protocol adapted from the review by Wirtz et al [427]. 
 
Intestinal permeability. Mice were administered 600mg/kg of Fluorescein isothiocyanate 
conjugated dextran (FITC-Dextran), MW 4000 (Sigma Aldrich, FD4), dissolved in 200ul PBS 
for gavage following a three hour fast. After four hours serum samples were collected and 
serially diluted in PBS. The concentration of FITC in serum was determined by spectrophoto-
fluorometry with an excitation of 485 nm and an emission wavelength of 520 nm using as 
standard serially diluted FITC-Dextran. Serum from mice not administered FITC-Dextran was 
used to determine the background. 
 
2.15.2 C. Rodentium Colitis 
C. rodentium, strain ICC169, was kindly provided by Gad Frankel, Imperial College London, 
UK. C. rodentium was cultured overnight by adding 1µl glycerol stock to 10ml LB broth 
containing 50µg/ml nalidixic acid and incubating in a shaker incubator at 37oC, 250rpm. The 
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cultured bacteria was then centrifuged at 4000g, washed and resuspended in sterile PBS.  
Nine to twelve week old Adamdec1-/- and Adamdec1+/+ mice were orally gavaged with 200µl 
of C. rodentium in PBS using a 1 ml syringe attached to a curved 1 inch 20 G stainless steel 
2 mm ball-tipped gavage needle, giving each mouse ~108  or ~109 colony forming units (CFU) 
of C .rodentium.  
Mice were weighed daily.  Faeces and tail bleeds were collected for C .rodentium culture and 
serum cytokine analysis.  At set time points between 0 and 13 days, mice were culled using 
CO2.  Blood from cardiac punctures, large bowel and spleens were collected.  Blood, disrupted 
spleens and dispersed faeces in PBS were plated on LB agar plates overnight containing 
50µg/ml nalidixic acid to quantify the C. rodentium in spleen and faeces. 
 
2.15.3 S. Typhimurium Colitis 
S. typhimurium (JT11) was kindly provided by Dr Elizabeth de Pinna, Public Health England, 
UK.  S. typhimurium was cultured overnight, for 16 hours, in LB medium, centrifuged at 4000g, 
washed and resuspended in sterile PBS. Nine to twelve week old mice were pre-treated with 
metronidazole 750mg/L, diluted in drinking water, for 5 days.  After 5 days the mice were 
restarted on normal drinking water for 20 hours.  Following a 4 hour fast, mice were orally 
gavaged with 108 S. typhimurium.  Mice were monitored for 48 hours and weighed daily. 
 
 
2.16 Reagents 
2.16.1 HkEc Stock 
E.coli NCTC 10418, a fully antibiotic sensitive clinical isolate, was cultured by adding 1µl 
glycerol stock into 10ml LB broth (Sigma L3022) and incubating at 37oC, 250rpm in an 
InnovaTM 4000 incubator shaker (New Brunswick Scientific) overnight.  E.coli was centrifuged 
at 3000g for 20 minutes, room temperature in a Heraeus Multifuge X1R (Thermo Scientific), 
washed PBS, resuspended in 1ml PBS and counted at 1:20 dilution using a Cecil BioQuestTM 
CE2502 spectrophotometer.  The E.coli optical density at 600nm (OD600) of 1x108 bacteria/ml 
in PBS is 0.365.  Concentration of E.coli in PBS was adjusted to 1x1010 bacteria/ml and 
bacteria was heat killed by incubated at 60oC for 1 hour in a Grant GD100 circulating 
immersion bath and stored at -20oC.  Killing of E.coli was confirmed by plating 80µl of HkEc 
onto LB agar plates with no antibiotics and culturing overnight, it produces pink colonies when 
grown on MacConkey agar. 
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2.16.2 Buffers 
DNA extraction buffer: 
1ml 1M Tris pH8 (VWR 103156X), 100µl 0.5M EDTA (Sigma E6511), 2ml 1M NaCl (Sigma 
S7653) and 50µl 1% SDS (Sigma L3771) were added to 6.85ml of distilled water (dH2O). 
3x Laemmli sample buffer 
2.4ml 1M Tris-HCI pH 6.8 (VWR), 3ml 10% SDS (Sigma), 3ml 100% glycerol (BDH 101186M), 
1.6ml 2-mercaptoethanol (Sigma 63689) and 0.006g bromophenol blue (Sigma B0126). 
Stored at 4oC. 
10x Transfer buffer 
144g glycine (Sigma G7126), 3.74g SDS (Sigma L3771) and 30.25g Tris (VWR 103156X) 
were dissolved, using a magnetic stirrer, in dH2O and made up to 1L with dH2O. 
10x Tris-buffered saline (TBS) 
800g NaCl (Sigma), 20g KCI (Sigma P4054) and 300g Tris to dH2O, made up to 10 litres 
dH2O, pH 7.4.   
TBS-Tween 0.1% 
5ml of Tween-20 (Sigma P1379) were added to 500ml of 10x TBS and made up to 5L with 
dH2O, 
50x Tris-acetate-EDTA (TAE) buffer 
484g of Tris, 114.2ml of glacial acetic acid and 200ml of 0.5M EDTA pH8.0 was made up to 
2L of dH2O. 
FACS buffer (PBS containing 1% BSA and 0.01% azide) 
5g of bovine albumin (BSA)/albumin faction V (VWR 1120180100) was added to a new bottle 
of 500ml PBS pH7.2 (Gibco 20012).  500µl of 10% sodium azide in dH2O (Sigma S8032) was 
added to the 500ml of PBS and stored at 4oC. 
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2.16.3 Cell Culture Media 
Human MDM cell culture media (RPMI 10% FBS, 20mM HEPES, 100 U/ml 
penicillin/streptomycin) 
50ml of foetal bovine serum (Sigma F9665), 10ml of 1M HEPES (Sigma H0887), 5ml of 
10,000U/ml Penicillin/Streptomycin (Gibco 15140-122) were added to a new 500ml bottle of 
RPMI-1640, GlutaMAXTM Supplement (Gibco 61870). 
THP-1 cell culture media (RPMI 10% FBS, 20mM HEPES, 100 U/ml penicillin/streptomycin, 
20µM BME) 
50ml of foetal bovine serum (Sigma F9665), 10ml of 1M HEPES (Sigma H0887), 5ml of 
10,000U/ml Penicillin/Streptomycin (Gibco 15140-122), 200µl of 50mM 2-mercapthoethanol 
(Gibco 31350) were added to a new 500ml bottle of RPMI-1640, GlutaMAXTM Supplement 
(Gibco 61870). 
BMDM cell culture media (DMEM 10% FBS, 25mM HEPES, 100U/ml penicillin/streptomycin, 
1g/L D-glucose, 4mM L-glutamine, 1mM pyruvate) 
50ml of FBS (Sigma) and 5ml of 10,000U/ml Penicillin/Streptomycin (Gibco) were added to a 
500ml bottle of low-glucose Dulbecco’s Modified Eagle Medium (DMEM) (Gibco 22320) and 
stored at 4oC. 
Thioglycollate-induced peritoneal macrophage cell culture media (RPMI 10% FBS, 100U/ml 
penicillin/streptomycin, 20mM HEPES) 
50ml of FBS (Sigma), 10ml of 1M HEPES (Gibco) and 5ml of 10,000U/ml 
Penicillin/Streptomycin (Gibco) were added to a 500ml bottle of RPMI-1640, GlutaMAXTM 
Supplement (Gibco) and stored at 4oC. 
 
2.16.4 Bacterial Culture Broth 
3% thioglycollate broth 
30g of thioglycollate broth (Merck 108191) was dissolved in 1L of dH2O and autoclaved.  
Sterile 3% thioglycollate was aliquoted into sterile 50ml Falcon tubes and aged at 4oC for 1 
year prior to use. 
Luria-Bertani (LB) broth and agar plates 
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5g bacto-peptone (BD 211677), 2.5g bacto-yeast extract (Oxoid LP0021), 5g NaCl (Sigma), 
7.5g agar (Oxoid LP0011) were added to ~400ml dH2O, mixed with a magnetic stirrer and 
made up to 500ml then autoclaved and plated.  LB broth was made up as above without the 
agar. 
 
2.16.5 SDS-PAGE Gels 
Resolving and stacking gel were made up with 30% w/v Acrylamide/ProtoFLOWGel (SLS 
H16996), 1.5M Tris-HCI pH8.8 (resolving gel), 1M Tris-HCI pH6.8 (stacking gel), dH2O, 10% 
SDS (Sigma L3771), freshly made 10% ammonium persulphate (Sigma A7460) and TEMED 
(Sigma T9281) (added in the order listed with TEMED last, just prior to use). The gels were 
cast using the Mini-PROTEAN® System (Bio-Rad) 
 
 
2.17 Geo Dataset Analysis 
The Gene Expression Omnibus (GEO) is a public repository that archives and freely 
distributes microarray, next-generation sequencing, and other forms of high-throughput 
functional genomic data submitted by the scientific community. In addition to data storage, a 
collection of web-based interfaces and applications are available to help users analyse the 
raw data (GEO Data Sets) and gene expression patterns (GEO Profiles) stored in GEO and 
download the studies. 
A pubmed search for ADAMDEC1 in GEO Profiles was used to assess the expression of this 
molecule at extra-intestinal sites of inflammation such as psoriasis, sarcoidosis, dental caries 
in humans. 
A pubmed search of GEO Data Sets (GDS) was performed to identify data sets of interest: 
a) Endoscopic biopsies from human intestinal tract, in health and IBD 
b) Embryological samples from mice 
c) Intestinal tissue from germfree mice 
d) Mononuclear phagocyte populations from mice and humans 
e) Resident tissue macrophage populations from mice 
For each dataset the original article was reviewed to ascertain the method of sampling and 
details of samples included (i.e. the patient phenotypes, cell types, inflamed/ non-inflamed). 
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The raw microarray data was downloaded and analysed using Excel and GraphPad Prism. 
The gene expression of target genes, in particular ADAMDEC1, were compared within 
datasets using student t-tests (section 2.19). 
 
2.18 BioGPS 
BioGPS is a free online gene annotation portal. This publically available website enables 
researchers to search for a gene of choice and illustrates the tissue and cellular expression of 
the gene in a variety of animal species using data from published microarray studies. The 
whole genome expression data for human and mouse is based on a panel of RNAs derived 
from 79 human and 61 mouse tissues [284]. The expression data for ADAMDEC1 was 
extrapolated from this dataset (GSE1133), log 10 transformed and plotted using Graph Pad 
Prism. 
 
 
2.19 Statistical Analysis 
 
2.19.1 General statistical analysis 
Unless otherwise stated, all data were presented as mean ± standard error of the mean (SEM) 
using GraphPad Prism 4.03 (GraphPad Software, Inc) and/or Excel, Microsoft office 2013.  
Statistical significance was calculated using paired or Student’s unpaired, or paired, two-tailed 
t-test.  Mean differences were considered significant when p<0.05.  
Throughout the text * indicates p<0.05, **p<0.01, ***p<0.001.  
 
2.19.2 Statistical analysis of microarray data  
Microarray expression data was log2 transformation to stabilise the variance and cubic spline 
normalisation. This data was then exported from Genome Studio software (Illumina), prior to 
background subtraction, along with detection p-values associated with each probe expression 
value. Probes that reached a minimum detection p-value of p<0.01 in 50% of samples were 
included in the subsequent analysis, probes with detection p-values>0.01 in all chips were 
excluded. Batch variation was minimised using ComBat normalisation, an established R 
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algorithm for reducing batch effects in microarrays [285], with disease status as a covariate. 
Efficacy of normalisation was verified by principal component analysis (PCA), using the PCA 
tool of MultiExperiment viewer TM4 Microarray Software suite, with default settings. 
Differential gene expression between groups was performed using LIMMA software 
(Bioconductor) [286]. The P-value was adjusted for multiple testing as described by Benjamini 
and Hochberg [287], with a corrected P-value threshold for significance of 0.05. This analysis 
was performed by Dr Adam Levine and Dr Andrew Smith. 
Outlier analysis 
Gene expression outlier analysis was carried out on customised software developed in 
collaboration with Anna Lobley and Daniel Roden (Department of Computer Science, UCL).   
This software identifies outlier genes by comparing gene expression in individual CD patients 
with the cohort of HCs using p-value significance of the standardised deviation of CD test 
sample expression levels compared to the mean expression in HCs and log2 fold-change 
between CD test sample expression levels compared to the mean expression in HCs.  The p 
value was set at a threshold of p<0.005 and a minimum fold change of 1.0 on a log2 scale, 
compared to the mean expression in HCs. 
The correlation between cell markers for macrophages (CD11b, CD68 and MMP12) and 
ADAMDEC1 in the microarray datasets were ascertained using Spearman’s rank correlation 
co-efficient. A correlation was considered significant when p<0.05. 
 
2.19.3 Power calculations for animal models 
Pilot studies were performed to estimate the number of animals required to ensure statistical 
significance whilst minimising wastage of resources and number of animals used. For each 
colitis model, a baseline dose response was performed, using doses typically reported in the 
literature. The percentage weight loss for each mouse, at each set time point, was recorded 
and the means, standard deviation (SD), effect size (difference in means/SD) were calculated. 
Using the results of this data the sample size was then estimated by power analysis [288], 
assuming a power 80%, a significance level of 5% and a two sided test, using G*Power [289] 
power analysis tool. 
The sample size for each experiment was adjusted according to the expected number of mice 
to be culled during the experiment (mice were culled at set time points for samples for analysis 
and/or if they lost ≥15% weight): 
Corrected sample size = Sample size/ (1− [% culled animals/100])  
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3. Investigation of ADAMDEC1 Expression in Peripheral Blood MDM and 
Intestinal Tissue Biopsies from Patients with CD 
 
3.1 Introduction 
It is now widely accepted that CD is primarily due to a defective innate immune response to 
gut microflora invading the bowel wall in genetically susceptible individuals [247], [290]–[292].  
GWAS in CD have identified [108], [109], [198] numerous genetic variants in innate immune 
response genes providing further support to this hypothesis [199], [293], [294]. 
Macrophages are key orchestrators of the innate immune response.  They are professional 
phagocytes and sentinels of the immune system; they recognise PAMPs via PRRs such as 
TLRs and NLRs [295], [296], selectively phagocytose, digest and kill bacteria.  By the secretion 
of cytokines, chemokines and proteases [297]–[299], macrophages are able to contribute to 
the recruitment of additional leukocytes to sites of injury.  In addition to their antimicrobial 
effects, leukocytes also play a pivotal role in resolution of inflammation and wound healing 
[300].  
As previously discussed in section 1.3.9, previous studies have provided compelling evidence 
to implicate a dysregulated macrophage response to bacteria as central to the pathogenesis 
of CD.  Notably, CD is associated with an attenuated secretion of pro-inflammatory cytokines, 
in particular TNFα, from peripheral blood MDM following stimulation with bacterial antigens.  
A growing number of independent research groups have replicated these findings in MDM 
from patients with quiescent CD [122], [211], [301].  It has been proposed that attenuated 
secretion of cytokines by macrophages may account for the previously reported impaired 
neutrophil recruitment and delayed bacterial clearance in patients with CD [241], [243].  Failure 
to clear undigested bacteria at sites of ingress may act as the driving force for the ensuing 
chronic granulomatous inflammation, and secondary adaptive immune response 
characteristic of CD [247].  The defective secretion is likely to relate to aberrant post 
translational trafficking of pro-inflammatory cytokines [243]; however, the molecular 
mechanisms responsible are incompletely understood.  Recent work from our group has 
implicated defective expression of OPTN, which codes for an adapter molecule important in 
the sorting of proteins for transport at the Golgi complex [246]. However, this is likely to be 
only one of a number of contributory dysfunctional pathways in CD. 
The bacterial recognition receptor NOD2 is expressed by MDM and intestinal macrophages. 
CD patients who are homozygote or compound heterozygote for NOD2 polymorphisms are 
associated with an impaired cytokine secretion in response to MDP stimulation (see section 
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1.3.8). This is consistent with the aforementioned finding that macrophages isolated from 
patients with CD have an impaired response to bacterial stimulation.  However NOD2 
mutations do not account for the attenuated cytokine secretion observed in CD MDMs for a 
number of reasons.  Firstly, the majority of CD patients do not harbor CD-associated NOD2 
variants.  In the Caucasian population, only approximately 8% and 28% of CD patients are 
homozygous or heterozygous respectively for one of the three main NOD2 variants.  In 
comparison, approximately 0.5% and 15% of the healthy general population are homozygous 
or heterozygous for these same variants, respectively [302], [303].  Secondly, the majority of 
CD patients have normal cytokine secretion following stimulation with MDP [241].  Thirdly, the 
attenuated TNF secretion from CD MDM, following stimulation is unrelated to the presence of, 
one (heterozygote) or two (homozygote or compound heterozygote) CD risk NOD2 
polymorphisms [243], [244].  In fact, the impaired TNF secretion from CD MDM has been 
shown to be unrelated to a selection of 34 CD risk alleles identified by early CD GWAS [244].  
Similarly an independent group also demonstrated impaired response of CD MDM to E.coli 
regardless of CD genotype [122].  As such other molecular causes of attenuated cytokine 
secretion must be present in CD patients. 
 
3.1.1 Transcriptomic Profiling of MDM from IBD Patients and Controls 
In an attempt to discover molecules responsible for the observed macrophage defect, 
transcriptomic profiles were examined from cultured MDM from CD, UC patients and HCs 
using Illumina whole transcriptome microarrays [245].  All patients included were in remission 
and on no or minimal treatment.  
Over recent years a large number of microarray gene expression studies have been performed 
in CD and UC.  The majority have focused on bowel biopsies in various states of disease 
activation, in which a wide spectrum of changes are present, largely driven by the 
overwhelming inflammatory state [112], [304], [305].  Several studies have investigated the 
gene expression patterns of PBMC [306]–[308] or examined leukocytopheresis-induced 
changes in PBMC in UC but until recently, microarray analysis of differentiated peripheral 
MDM from quiescent CD and UC patients compared with HCs had not been published [245].  
The gene expression profiles of MDM are very different to PBMC [309].  A significant number 
of genes are up- or down- regulated during differentiation and thus many genes expressed in 
MDM are undetectable in PBMC.  
Previous studies used conventional group comparison methods for analysing their microarray 
data directly comparing the disease and control groups with a view to detecting genes for 
which the average value is significantly different between disease and control subjects.  
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However, CD is a heterogeneous disease and such a direct comparison between one group 
and the other may miss rare expression defects which play a causative role in sub groups of 
patients.  As such, our research group sought to find molecules abnormally expressed in 
subgroups of CD patients.  An analytical strategy was developed and implemented in a novel 
software package called ZODET [310], to look for genes which were significantly over- or 
under-expressed in individuals compared with a reference group [241] . mRNA from MDM 
from CD patients and HC were hybridised to microarray plates, each containing 56,000 probes 
specific for individual genes. The gene expression, detected by each probe, for every 
individual, was compared with the mean expression of that gene in the HC group. Genes that 
were over- or under-expressed and reached a significance threshold of p-value of p<0.005 
(calculated as a Z score of >2.58) and a minimum fold change of 1.0 (log2 scale) compared 
to the mean expression in the HC cohort were considered to be significant outliers in an 
individual subject, and termed ‘outlier genes’. A similar approach has successfully used in the 
oncology field to identify molecular abnormalities in subgroups within a complex disease 
population [311]. 
Outlier genes, identified as significantly under-expressed in MDM, were present in both patient 
and controls, however, what was unique about the CD population, was a number of these 
genes were common to more than three individuals with disease (Table 3.1).  
The most common outlier was found to be OPTN in ~12% (7/58) of the CD patients tested 
[245].  This molecule is known to play a role in vesicle trafficking and maintenance of the Golgi 
apparatus [312] as well as autophagy and clearance of intracellular bacteria [313]–[316].  An 
association between reduced OPTN expression and diminished TNF secretion [245], [246] 
has since been established and OPTN deficiency results in an increased susceptibility to 
bacterial induced colitis in animal models [246]. ADAMDEC1 was found to be the second most 
common under‐expressed outlier gene in CD patients [245].   
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Table 3.1: Gene outlier analysis using microarray data from unstimulated MDM from 
HC and CD patients.  Data from HC (n = 42) and CD patients (n = 58).  All probes identified 
as reaching ‘outlier’ significance (P<0.005 and a fold change of >1) in three or more CD 
subjects are shown. An outlier was defined as a gene which was under- or over-expressed in 
an individual compared with the mean expression of that gene in the HC group. ADAMDEC1 
gene is highlighted and was represented by two probes on the microarray. 
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Hypothesis for Chapter Three 
Attenuated expression of ADAMDEC1 is associated with CD in a subgroup of patients. This 
abnormal expression in CD is not related to disease activity or secondary to inflammation. 
 
Aims of Chapter Three 
a) To verify the attenuated expression of ADAMDEC1 in peripheral blood MDM observed, 
in the Primary Cohort, in a subset of patients with CD  
b) To replicate the Primary Cohort study, and outlier analysis, in a 2nd independent group, 
and examine MDM expression of ADAMDEC1 in CD patients compared with HC  
c) To investigate the intestinal expression of ADAMDEC1 in HC and IBD patients by 
analysing transcriptomic data from ileocolonoscopic biopsies 
d) To assess the expression of ADAMDEC1 in other inflammatory disorders using the 
publically available online repository of microarray datasets; Gene Expression 
Omnibus (GEO) [317]. 
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3.2 Results 
 
3.2.1 ADAMDEC1 was Significantly Under‐Expressed in MDM from CD Patients in The 
Primary Cohort 
ADAMDEC1 was found to be the second most common under‐expressed outlier gene in CD 
patients (Table 3.1; Figure 3.1A), observed in 7-9% of the CD patients tested (p<0.005, >1.0 
fold change), depending on the probe analysed [245].  Two probes on the microarray 
corresponded to ADAMDEC1: ILMN_2105441 and ILMN_2103107 which were significantly 
abnormal in 4/58 and 5/58 CD patients tested, respectively.  Although ADAMDEC1 was 
grossly under expressed in a subgroup of CD patients there were no ADAMDEC1low outliers 
in the HC or UC cohorts.  
 
3.2.2 Validation of Abnormal ADAMDEC1 Expression in Subset of CD Patients 
In order to validate the abnormal expression of the ADAMDEC1low CD patients in the primary 
cohort, TaqMan® real time quantitative PCR was performed.  The relative expression of the 
five ADAMDEC1low patients were quantified in comparison to five HCs selected at random 
from the HC microarray study cohort.  Results were normalised to expression levels of the 
housekeeping gene PPIA (Cyclophilin A), which has been evaluated as a suitable reference 
gene for normalisation in human LPS stimulated monocytes [318].  The outlier patients 
investigated had an attenuated relative expression of ADAMDEC1 compared to the HC 
individuals tested. This reduction was significant (p<0.05), as demonstrated by a two tailed 
unpaired t-test, (Figure 3.1B) and verified the abnormality in MDM ADAMDEC1 expression in 
these CD patients at the mRNA level. 
In addition to the low mRNA level, ADAMDEC1low subjects were found to have reduced 
intracellular protein levels in MDM cell lysates compared with HCs on western blot.  Samples 
from two representative ADAMDEC1low outlier patients were compared with two representative 
HC MDM cell lysates (Figure 3.1C).  These MDM were cultured 6-12 months after the original 
samples that were used for the microarray and quantitative PCR assays.  A band was 
detectable at 53KDa consistent with the predicted size of full length human ADAMDEC1 
protein.  The house-keeping protein β-actin was used as the loading control. Unfortunately it 
was not possible to obtain cell lysates from all outlier patients. 
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Figure 3.1: ADAMDEC1 is significantly under expressed in MDM from a subgroup of 
CD patients.  (A) Microarray gene expression (log2 scale) of ADAMDEC1 (probe 
ILMN_2103107) in unstimulated peripheral blood MDM from 58 CD, 42 HC subjects (Primary 
Cohort).  Outlier genes, with grossly attenuated expression, were identified using a threshold 
of p<0.005** and a minimum fold change of >1.0 (highlighted by the grey bar). Five CD 
individuals (within orange circle) had significantly low expression of ADAMDEC1 compared to 
the mean expression in HC.  (B) qPCR was performed to confirm the reduced expression of 
ADAMDEC1 outliers (n=5) compared with HC (n=5), relative to house-keeping gene, PPIA 
p<0.05*.  (C) Western blot analysis verified reduced ADAMDEC1 protein in MDM cell lysates 
from ADAMDEC1 outliers (AD1low) (n=2) compared with representative HC (n=2), B-actin was 
used as the loading control. Results expressed as the mean ± SEM, two tailed, unpaired t-
test, p<0.05*, p<0.01**, p<0.001***. 
 
3.2.3 ADAMDEC1 was Significantly Under‐Expressed in MDM of CD Patients in a 
Second, Independent, Replication Cohort 
In the replication cohort, patients with non-active CD were recruited as per previous study 
[245] apart from one alteration in the inclusion criteria made to permit a greater study sample 
size: Patients who had been on long term immunosuppression, with no change in medication 
within three months of sampling, were also included. 
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MDM were obtained, cultured and RNA was prepared in an identical manner to the primary 
cohort but hybridised to a new generation Illumina human expression bead chips (HT-12 v4) 
as the earlier version (HT-6 v3), was out of production.  Importantly, both arrays used identical 
ADAMDEC1 probes. 
A dot plot was used to illustrate the expression of ADAMDEC1 (on a Log2 scale) for each 
individual within the HC and CD groups (Figure 3.2).  First, a simple t-test was performed 
between HC, UC and CD groups.  Then in order to detect ADAMDEC1low outlier patients as 
previously, ADAMDEC1 probes which were significantly (p<0.005) under expressed 
compared with the mean of the HC group with a >1 fold change were identified. 
Similar to the original primary cohort, ADAMDEC1 was also found to be significantly under 
expressed in the replication cohort in MDM from a subgroup of patients with CD: ~10% of CD 
patients (5/47) (p<0.005, >1 fold change).  In this cohort a significant difference in ADAMDEC1 
expression was also observed on direct group analysis i.e. the whole of the CD population 
compared with the HC population (p<0.005). This difference in expression was not related to 
medication, in particular the use of thiopurines or anti-TNF therapy. OPTN, an outlier gene in 
>10% of CD patients in both cohorts, did not show a similar difference in mean gene 
expression on direct group analysis in this second study. 
As in the previous study [245], principal component analysis (PCA) did not reveal any 
differences in global macrophage gene expression profiles on the basis of disease and this 
ADAMDEC1low population could not be separated from the CD group by PCA (data not shown, 
PCA performed by Dr Adam Levine).  The inability to separate macrophages from CD and HC 
subjects by PCA provides evidence that the overall cellular phenotype following culturing of 
MDM is similar in the two groups.  
Furthermore regression analysis did not show an association between ADAMDEC1 
expression and CD68 or CD14.  These markers are commonly used to differentiate the stage 
of monocyte to macrophage maturation: CD68 is expressed in mature macrophages whereas 
CD14 is expressed on monocytes but lost during differentiation.  This analysis provides further 
support that the observed difference in ADAMDEC1 expression was not related to variability 
in the stage of macrophage differentiation or differences in preparation of the cells. 
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Figure 3.2: ADAMDEC1 is significantly under expressed in MDM in CD patients 
compared with HC in a second independent cohort.   Microarray gene expression (log2) 
of ADAMDEC1 in unstimulated peripheral blood MDM from 47 CD and 33 HC (Replication 
Cohort). ADAMDEC1 outliers, with grossly attenuated gene expression, were identified using 
a threshold of p<0.005** and a minimum fold change of >1.0 (highlighted by the grey bar): 
Five CD individuals (orange circle) and 1 HC had significantly low expression of ADAMDEC1 
compared to the mean expression in HC. The individual identified with a red arrow was 
subsequently found to have Chronic Myeloid Leukaemia (Individual A).  The HC identified with 
a green arrow is referred to as Individual B in the text.  A significant difference was also 
observed between HC and CD populations (p<0.005)**. Results expressed as the mean ± 
SEM, two tailed, unpaired t-test, p<0.05*, p<0.01**, p<0.001***. 
 
 
3.2.4 Individuals within HC Replication Group with Low Expression of ADAMDEC1 
In the replication cohort two individuals in the HC cohort displayed significantly low levels of 
ADAMDEC1 (individual A: p<0.01; individual B: p<0.005), albeit only one (Individual B) 
reached the criteria to be defined as an ‘outlier’.  Individual A has subsequently been 
diagnosed with chronic myeloid leukaemia, a cancer which arises from monocyte precursors.  
As such he does not fit the criteria for a ‘HC’ and should be excluded from the analysis. 
Individual B was found to have grossly abnormal cytokine secretion from MDM in response to 
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E.coli stimulation compared with other HC controls tested suggesting that this individual may 
have an undiagnosed subclinical disorder of macrophage secretion or may have been unwell 
at the time of sampling. 
 
 
3.2.5 Clinical Phenotype of ADAMDEC1low Outlier Patients in Primary and Replication 
Cohorts 
ADAMDEC1low CD patients from both the primary and replication groups were not observed 
to share an obvious clinical phenotype (Table 3.2).  No significant demographic differences 
were noted in the ADAMDEC1low CD patient group compared with the general CD population 
tested (Table 3.3).  
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Table 3.3: Demographic differences in the HC, general CD and ADAMDEC1low CD 
populations at the time of sampling, number (%) 
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3.2.6 Cytokine Secretion from MDM of ADAMDEC1low Outlier Patients 
ADAMDEC1low outliers from the primary cohort shared a similar cytokine profile to the rest of 
the CD population, with an attenuated secretion of TNF from MDM, following 24 hour 
stimulation with (HkEc), compared to HC, as reported in previous studies.  No significant 
differences were observed in IL12p70, IL1β, IL6, IL8 or IL10 secretion in the ADAMDEC1low 
outliers compared with general CD patients (Figure 3.3).  The secretion profiles from MDM, 
stimulated for 24 hours with HkEc, were not repeated in the replication cohort.  
 
Figure 3.3: Inflammatory cytokine release from peripheral blood MDM, stimulated 
with HkEc for 24 hours.  Cytokines were measured from quiescent CD patients (CD; n= 43), 
ADAMDEC1
low
 outlier CD patients (n=5) and HCs (n=39). Attenuated secretion of TNF was 
seen in CD patients compared with HC (p<0.05*).  No significant difference was observed 
between ADAMDEC1
low
 outlier patients and the general CD population tested.  No difference 
was seen between IL10, IL6, IL12p70, IL1β and IL8 in HC, CD and outlier patients. Results 
expressed as the mean ± SEM, two tailed, unpaired t-test; p<0.05*, n.s. non-significant. 
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3.2.7 Genotypes of ADAMDEC1low Outlier Patients 
In order to test whether there were any germline genetic variants within and upstream of 
ADAMDEC1 that might contribute to gene expression variation, DNA from all CD and HC 
subjects from the original primary cohort were examined by Sanger sequencing. 
The ADAMDEC1 gene is located on chromosome 8p12, in a region associated with tumour 
suppressor genes [263]. ADAMDEC1 has 4 transcripts, or splice variants, two of which are 
protein coding isoforms, verified in both Ensembl and HAVANA genome databases (Figure 
3.4A).  The largest, isoform 1, has 13 exons and codes for a protein containing 470 amino 
acids (Figure 3.4B), isoform 2 lacks exons 1 and 2 and codes for a shorter protein of 391 
amino acids.  
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Figure 3.4: Human ADAMDEC1 protein coding isoforms and amino acid composition 
(A) Schematic diagram of the two known protein coding isoforms for the ADAMDEC1 gene in 
humans: Isoforms 1 contains thirteen exons, illustrated with black vertical bars and numbered. 
Isoform 2 is missing the first two exons.  (B) The amino acid composition of the ADAMDEC1 
human protein, as coded by isoform 1, is 470 amino acid.  The prodomain is highlighted in 
purple, metalloprotease domain loop in pink, and truncated disintegrin domain in blue. 
 
 
All of the ADAMEC1 exons and flanking regions were sequenced from genomic DNA. In 
addition approximately 2000bp upstream of the ADAMDEC1 gene, including the promotor 
region, were sequenced.  No novel mutations were detected in these regions in any of the 
outlier patients tested.  All sequence variants identified had been previously documented in 
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dbSNP [319], HapMap (The international HapMap consortium) [320] and, or, the 1000 
Genomes Project (1000 genomes project consortium) [321].  
Although no novel mutations were identified, a number of recognised SNPs were identified in 
the outlier patients (Figure 3.9A).  All five patients with grossly attenuated levels of 
ADAMDEC1 were homozygous for the minor allele for four SNPs: rs12674766, rs4872231, 
rs2291577, rs3765124.  The minor allele frequency for these SNPs in the Caucasian 
population is between 42 – 49%, and the chance of an individual being homozygous for one 
of the minor alleles is between 17 – 24%. 
 
Region in 
ADAMDEC1 
Ref SNP 
number 
Genomic 
position 
Allele frequency in 
Caucasians (Major: 
minor) 
Amino acid 
change 
Promotor 
region 
rs12674766 8:24241732 C/T (0.567:0.43) - 
Intron 1-2 rs4872231 8:24247556 A/G (0.54:0.49) - 
Exon 9 rs2291577 8:24256470 C/T (0.58:0.42) - 
Exon  13 rs3765124 8:24261526 A/G (0.58:0.42) N to S 
 
Table 3.4: SNPs identified in the ADAMDEC1 region in outlier patients. 
 
SNP Annotation and Proxy search (SNAP) was subsequently used to determine whether any 
of the identified SNPs were in linkage disequilibrium (LD) [322].  This software package utilises 
genotype data from HapMap and the 1000 Genome Project to calculate LD data between 
polymorphisms and identify proxy SNPs.  All four SNPs identified in ADAMDEC1low outlier 
patients were in a block of LD using a threshold of r2>0.8 (Figure 3.7B).  This observation 
suggests that ADAMDEC1low outliers share a common haplotype, a combination of alleles at 
adjacent loci that are inherited together. 
This haplotype has previously been associated with Factor VIII levels in venous 
thromboembolism.  However to date none of the ADAMDEC1low patients have documented 
evidence of a deep vein thrombosis or thromboembolic event, which, incidentally, are more 
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common in both UC and CD patients.  Factor VIII levels were tested in three of the five 
ADAMDEC1low patients and were all observed to be within the normal range. 
Interestingly one of the SNPs, rs3765124, results in an amino acid change from Asparagine 
(N) to Serine (S) (N444S) (Figure 3.5).  The amino acid change results in an alteration in 
hydropathy (N -3.5, S -0.8) which could potentially alter the shape of the molecule affecting 
exposure to a binding site.  This SNP is in exon 13 is within a conserved region (Figure 3.6) 
within the disintegrin domain. 
 
 
 
Figure 3.5: SNP rs3765124 in exon 13 results in an amino acid change. (A) The SNP 
N444S results in a change in hydropathy: N=-3.5, S=-0.8.  (B) Representative DNA sequence 
chromatogram from an ADAMDEC1low outlier patient and control individual.  The outlier patient 
is homozygous for the minor allele (G) of rs3765124, the control patient is homozygous wild 
type (A). 
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Figure 3.6: The SNP rs3765124 codes for an amino acid in a conserved region.  Amino 
acid alignment for the disintegrin region of Adamdec1 in a number mammalian species.  The 
red box highlights the amino acid which is coded for by this SNP associated with low 
expression of Adamdec1 in macrophages.  * represent fully conserved residues, : represent 
conservation of strong groups,  . represent conservation of weak groups. 
 
 
 
In order to assess whether the common haplotype identified in the ADAMDEC1low patients is 
associated with reduced gene expression, all the HC and CD patients in the original 
experiment group were genotyped for these four SNPs.  Attenuated expression of 
ADAMDEC1 in MDM was found to be associated with inheritance of the minor alleles each of 
these four SNPs, as exemplified below by SNP rs3765124 (Figure 3.7A).  This finding was 
however further exaggerated in the ADAMDEC1low outliers.  
 
In order to ascertain whether these SNPs were known expression quantitative trait loci (eQTL) 
for monocytes, the eQTL databases were searched using Genevar (GENeExpression 
VARiation) software [323].  eQTL studies investigate association between thousands of 
genotyped SNPs and transcriptomic data in particular cell or tissue types derived from 
microarray analysis.  No eQTL data were available for the SNPs directly identified in the outlier 
patients.  However all four SNPs were in LD (r2~1) with two known eQTL for ADAMDEC1 in 
monocytes [324] (Figure 3.7B). 
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Figure 3.7: rs3765124 is an eQTL for ADAMDEC1 in peripheral blood derived MDM. 
(A) Association of rs3765124 genotype with log2 expression of ADAMDEC1, obtained from 
the primary cohort, in (i) CD and (ii) HC. The ADAMDEC1
low
 outlier patients, circled in orange, 
are homozygote for the minor allele GG.  Results expressed as the mean ± SEM, two tailed, 
unpaired t-test; *p<0.05, **p<0.01, ***p<0,001. (B) Linkage Disequilibrium (LD) between SNPs 
identified in ADAMDEC1
low
 outlier patients (light blue rows) and known expression quantitative 
loci (eQTL) in human monocytes for ADAMDEC1 (grey rows).  All the SNPs identified in 
ADAMDEC1low outlier patients are in LD with rs3765124, as determined by SNP annotation 
and proxy search software, using a threshold  R-squared, r
2
 >0.8. rs3765124 is in complete 
LD with the two known eQTL; r
2 
=1. The distance for each SNP from rs3765124 is shown. 
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The Ricopili tool (http://www.broadinstitute.org/mpg/ricopili/) was utilised to establish whether 
rs3765124, or indeed any of the SNPs within the ADAMDEC1low haplotype, were associated 
with an increased risk of CD in the IBD Genetics Consortium GWAS [108].  As illustrated in 
Figure 3.8, the rs3765124 SNP was not found to be significantly associated with CD (p=0.162) 
and well below the cut off for GWAS significance which requires p<5×10-8. 
 
 
3.2.8 NOD2 Polymorphisms 
In addition to ADAMDEC1, the ADAMDEC1low outlier patients in the primary cohort were also 
genotyped for the three main NOD2 polymorphisms.  One patient was heterozygous for NOD2 
L1007fs (Table 3.2).  All other ADAMDEC1low outlier patients were wild type.  As no association 
was found between ADAMDEC1low patients and NOD2 variants in the original cohort, the 
NOD2 status was not assessed in replication cohort. 
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3.2.9 ADAMDEC1 Expression in the Human Intestine 
As CD predominately affects the bowel, the pattern of ADAMDEC1 expression across the 
colon and TI was determined. Transcription profiles from histologically reported non-inflamed 
intestinal biopsies, of quiescent CD and UC patients and HC were compared (GSE48634).  
All sections of the bowel were not sampled in every subject (Table 3.5). 5 CD, 10 HC and 5 
UC had endoscopic procedures limited to the left side of the colon and the terminal ileum was 
not intubated in all patients undergoing colonoscopy.  
 
Table 3.5: Paired endoscopic pinch biopsies from each bowel location.  (A) Schematic 
diagram illustrating sites at which paired mucosal biopsies were taken from macroscopically 
normal mucosa in the rectum (A), descending colon (B) distal to splenic flexure, ascending 
colon (C) proximal to hepatic flexure and terminal ileum (D). At each site one sample was sent 
for microarray analysis the other was sent for histological examination. (B) Table showing total 
number of samples analysed on microarray at each site from the 18 CD, 22 UC and 31 HC 
patients undergoing routine lower GI endoscopy. 
 
Demographic data are shown in Table 3.6. A significant difference was noted between the 
mean age of patients with CD compared with UC and HC (p<0.05) and the duration of disease 
in the UC group compared to CD (p<0.05). The effect of age or disease duration on 
ADAMDEC1 expression was not assessed in this study but would be interesting to look at in 
the future. 
ID Location
Number of biopsies
CD HC UC
A Rectum 18 31 22
B Descending colon 13 21 21
C Ascending colon 8 15 16
D Terminal ileum 5 15 13
A B
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Table 3.6: Demographic data in the HC, CD and UC at time of ileocolonic biopsy.  IBD 
patients were genotyped according to the Montreal classification: Age at diagnosis (A1 <16, 
A2 17-40, A3 >40 years old); Location in CD (L1 ileal, L2 colonic, L3 ileocolonic); Extent of 
disease in UC (E1 proctitis, E2 left sided colitis, E3 pancolitis). Behaviour in CD (B1 non-
stricturing, non-penetrating, B2 stricturing, B3 penetrating), Perianal disease (p). The average 
age at diagnosis and duration of disease are shown ± SEM. Percentages were recorded in 
brackets (%). Two tailed, unpaired test, p<0.05*. 5-ASA, 5-aminosalicylates  
HC CD UC
n 31 18 22
Gender (M:F) 14:7 10:8 13:9
Mean age 49.2  4.8 33.1  2.1* 48.2  3.4
Disease duration 9.5  2.0* 18.4  3.9
Smoking status, n (%) Current smoker 5 (16.1) 2 (11.1) 3 (13.6)
Ex smoker 7 (22.5) 5 (27.8) 5 (22.7)
Never smoked 19 (61.3) 9 (50) 14 (63.6)
Medication Nil 11 (61.1) 5
5ASAs 2 (11.1) 15
Thiopurines 3 (16.7) 0
5ASAs & thiopurines 2 (11.1) 4
Montreal classification
Age onset A1: ≤16 3 4
A2: 17 – 40 14 16
A3: >40 1 2
Location L1 or E1 8 2
L2 or E2 3 10
L3 or E3 7 10
Behaviour B1 7
B2 5
B3 6
P 3
Indications IBD surveillance 0 2 (5.6) 15 (68.1)
IBD assessment 0 16 (88.9) 7 (31.8)
Polyp/ cancer surveillance 8 (25.8)
PR bleeding 13 (41.9)
Change in bowel habit 10 (32.3)
Bowel preparation Citramag &Senna 19 (61.3) 12 (66.7) 18 (81.8)
Moviprep 7 (22.6) 0 0
Klean prep 0 1 (5.6) 0
Phosphate enema 5 (16.1) 4 (22.2) 4 (18.2)
Nil 0 1 (5.6) 0
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In HCs, ADAMDEC1 was highly expressed in the small and large bowel.  The expression 
levels did not vary significantly across the colon but was significantly greater in the TI of the 
small bowel in HC (p<0.001) (Figure 3.9).  This finding is of particularly interest as CD can 
occur in the small and large bowels but has a preponderance for the TI and nine of the ten 
ADAMDEC1low outlier patients had a history of TI disease. 
 
 
 
Figure 3.9: ADAMDEC1 expression in ileocolonic biopsies (obtained endoscopically 
from the rectum, descending and ascending colon and terminal ileum) in 
macroscopically and microscopically quiescent CD (red) and UC (green) patients 
compared with HCs (blue).  ADAMDEC1 expression was significantly increased in the TI 
compared with the colon (p<0.001***) of all subjects.  Direct group comparison demonstrated 
significantly reduced expression of ADAMDEC1 in UC patients in the TI (<0.001***) and 
rectum (<0.05*) compared with HCs and in the TI of CD patients (<0.05*). The mean 
expression of ADAMDEC1 for each group is represented by the small black bars. 
 
***
*
***
*
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3.2.10 Ileocolonic Expression of ADAMDEC1 in CD 
ADAMDEC1 was found to be significantly reduced in biopsies taken from the TI of patients 
with quiescent CD compared with HC (p<0.02) (Figure 3.9).   
A recent publication supports these findings of low ADAMDEC1 expression in the TI of CD 
patients compared with HC (p<0.001) [268].  This study assessed the response of infliximab 
on the mucosal expression of metalloproteases in patients with IBD.  The authors reported a 
significant reduction in ADAMDEC1 expression in TI of CD patients with active ileitis.  Gene 
expression was measured in 18 CD patients with active disease (demonstrated histologically) 
who were then resampled 4-6 weeks post infliximab (Figure 3.10).  Analysis of the online data 
(GSE16879) revealed that ADAMDEC1 expression remained low in the TI following treatment 
with infliximab, both in patients with mucosal healing (n=8), confirmed macroscopically and 
microscopically at histology, and in those who did not respond to treatment (n=10), this data 
was unreported by the authors (Figure 3.10).  The authors did report that the attenuated 
expression of ADAMDEC1 in the TI did not correlate with indices of disease activity; in 
particular the gene expression of granulocyte markers (S100A8, S100A9, S100A12) and the 
inflammatory marker (IL8).  Further analysis of the raw data demonstrated that ADAMDEC1 
expression did not correlate with the expression of macrophage markers (CD68, MMP12) 
(Figure 3.10), suggesting that the observed difference in expression was unrelated to 
leucocyte recruitment during intestinal inflammation.  Unlike the majority of other 
metalloproteases the expression of ADAMDEC1 did not returned to HC baseline post 
treatment. 
 
In our study no significant difference was seen in ADAMDEC1 expression in colonic or rectal 
biopsies from CD patients compared with controls. Similar findings were found in the study by 
De Bruyn et al [268] and in two further GEO datasets in which colorectal expression of 
ADAMDEC1 showed no significant difference in either active or quiescent Crohn’s colitis 
compared with HC [268], [304], [305] (Figure 3.9, 3.10).  In only one GEO dataset was 
ADAMDEC1 significantly lower level in the rectum in quiescent CD compared with HC 
(p<0.05), in this dataset the expression level was normal in active disease [112].  
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Figure 3.10: Comparison of ADAMDEC1, CD68 and MMP12 expression in the small 
bowel of IBD patients compared with HCs.  ADAMDEC1 expression was significantly 
reduced in actively inflamed small bowel of CD patients compared with HC and remained low 
despite clinical response to infliximab treatment. Macrophage markers CD68 and MMP12 did 
not mirror the expression of ADAMDEC1 in the small bowel. Raw data from online dataset, 
GSE16879, was analysed.Two tailed, unpaired t-test; p<0.001***, the black bar represents the 
mean value for each group. 
 
 
3.2.11 Ileocolonic Expression of ADAMDEC1 in UC 
ADAMDEC1 was reduced in the rectum (p<0.05) and in the TI (p<0.001) of patients with 
quiescent UC undergoing surveillance colonoscopy.  
Interrogation of microarray datasets from other research groups, publically available on GEO, 
also revealed significantly reduced expression of ADAMDEC1 in colorectal biopsies from 
patients with UC (Table 3.7).  However in all the datasets this aberrant expression was seen 
only in patients with active disease [112], [305], [325], not quiescent disease [112], [268], [304].  
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Table 3.7: Comparison of ADAMDEC1 mRNA expression in the large bowel of UC 
and CD patients, compared with HCs.  Data obtained from published online GEO data sets. 
Two tailed unpaired t test; p<0.05*, p<0.01**, p<0.001***, n.s: not significant.  
 
 
3.2.12 ADAMDEC1 Expression in Colonic Adenoma and GI Cancers 
Examination of online GEO datasets revealed that ADAMDEC1 expression is low in colonic 
adenomas and colorectal cancer suggesting it is an important in gut homeostasis (Figure 3.11) 
[305], [326].  In accordance with these data, the expression of ADAMDEC1 at the mRNA and 
protein level decreased during tumor progression of colorectal cancer [327].  Interestingly, 
treatment of a human hepatoma cell line (SK-HEP1) with an anti-metastatic drug, allyl 
Site of tissue Disease 
(sample n0)
Disease activity Change in 
expression
P value Reference
data set
Rectal pinch 
biopsies
UC (21)
CD (18)
Non-inflamed
Non-inflamed
Down
n.s
<0.05*
n.s
GSE48634
[352]
Colonic pinch 
biopsies
UC (21)
CD (13)
Non-inflamed
Non-inflamed
n.s
n.s
n.s
n.s
GSE48634
[352]
Ileal pinch 
biopsies
UC (13)
CD (5)
Non-inflamed
Non-inflamed
Down
Down
<0.001***
<0.05*
GSE48634
[352]
Colonic pinch 
biopsies 
UC (24)
UC (24)
CD (19)
CD post 
infliximab (19) 
Inflamed (24)
Responders (8)
Non responders (16)
Inflamed (19)
Responders (9)
Non responders (10) 
n.s
n.s
n.s
n.s
n.s
n.s
n.s
n.s
n.s
n.s
GSE16879
[268]
Ileal pinch
biopsies
CD (18)
CD post 
infliximab (18)
Inflamed
Responders (8)
Non responders (10)
Down
Down
Down
<0.001***
<0.001***
<0.001***
GSE16879
[304]
Colonic pinch 
biopsies
CD Non-inflamed
Inflamed
n.s
n.s
n.s
n.s
GSE20881
[304] 
Colonic pinch 
biopsies
UC (25)
UC (31)
Non-inflamed
Inflamed
n.s
Down
n.s
0.009**
GSE11223
[325]
Colorectal pinch 
biopsies
UC (9) 
CD (5)
Inflamed
Inflamed
Down
n.s
9.4x10-6 ***
n.s
GSE10714
[305]
Rectal pinch 
biopsies 
UC (4)
UC (5)
CD (12)
CD (7)
Non-inflamed
Inflamed
Non-inflamed
Inflamed
n.s
Down
Down
n.s
n.s
<0.001***
<0.05*
n.s
GDS2642
[112]
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isothiocyanate, a component of mustard and cruciferous vegetables, was associated with an 
increase in ADAMDEC1 expression, along with other known tumour suppressor or anti-
metastatic genes, and inhibited cell migration [328].  Preoperative radiotherapy up-regulates 
ADAMDEC1 in rectal tumours [326].  Reduced ADAMDEC1 expression has also been 
proposed recently as a predictor for gastric cancer as it was significantly under expressed and 
negatively correlates with disease activity [329].  This group found reduced expression of 
ADAMDEC1 to be associated with a gene expression profile in the tumour microenvironment 
which correlated with a dampened immune response. 
These data suggest that reduced expression of ADAMDEC1 is associated with a 
predisposition to chronic inflammation and potentially tumourogenesis in the GI tract.  
 
 
Figure 3.11: Comparison of ADAMDEC1 expression in targeted endoscopic pinch 
biopsies from areas of colitis (IBD), colonic adenomas and colorectal cancers (CRC) 
compared with HCs.  Analysis of online data set (GEO 10714) [305]. ADAMDEC1 mRNA 
expression was significantly reduced in the inflamed bowel of IBD patients (p=0.001), colonic 
adenomas (p=2.8x10
-15
) and colorectal cancer (CRC) (p=8x10
-5
) compared with non IBD HCs. 
Two tailed unpaired test, ***p<0.001. 
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3.2.13 ADAMDEC1 Expression in Extra-Intestinal Chronic Inflammatory States 
In order to ascertain whether this aberrant expression of ADAMDEC1 is specific to the gut or 
whether it is also seen in other organs and extra-intestinal inflammatory conditions, publically 
available online GEO datasets were analysed.  In contrast to the bowel, ADAMDEC1 is 
significantly up-regulated during chronic inflammatory states in extra-intestinal systems: in the 
skin (psoriasis and discoid lupus)  (GDS4602) [330], GDS4891 (Figure 3.12A), in lung 
(sarcoidosis) (GDS3580) [331] (Figure 3.12B), in tooth pulp (dental caries) (GDS1850) [332], 
(Figure 3.12C), synovial joint fluid (osteoarthritis) [333] and in endothelium (unstable carotid 
artery plaques) [334]. It is noteworthy that ADAMDEC1 expression in the naïve (non-inflamed) 
extra intestinal tissues at these sites was essentially ‘undetectable’.  
 
 
Figure 3.12: Comparison of ADAMDEC1 expression in extra intestinal inflammation.  
Data analysed from online data sets. ADAMDEC1 mRNA expression was significantly 
increased in: A) actively inflamed psoriatic plaque lesions (GDS4602); B) actively inflamed 
pulmonary sarcoid lesions (GDS3580); and C) inflamed dental caries (GDS1850), compared 
with healthy non-inflamed skin, lung and dental pulp respectively. Results expressed as the 
mean ± SEM, two tailed, unpaired t-test; p<0.01**, p<0.001***. 
 
 
3.3 Discussion 
In this chapter, ADAMDEC1 was identified as one of the most common (~10%) under-
expressed genes in peripheral blood MDM from CD patients [245].  The microarray 
transcriptomic profiling study of MDM was initially performed to investigate the phenotype of 
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defective MDM cytokine secretion, impaired leukocyte recruitment and defective bacterial 
clearance in CD.  The finding of ADAMDEC1, a member of the proteolytically active ADAMs 
family, was therefore an interesting finding and a candidate gene which was deemed worthy 
of further investigation.  The attenuated expression of ADAMDEC1 in the subgroup of CD 
patients was verified by qPCR and was demonstrated to translate to a low protein level in 
these subjects. These findings were replicated in a second independent cohort of patients.  
The aberrant expression of ADAMDEC1 in MDM in this subgroup of patients was not related 
to disease activity, and could not be attributed to previous bowel inflammation or concurrent 
medication.  Significantly low levels of ADAMDEC1 were not seen in MDM of other CD or UC 
patients who had experienced a similar disease course.   A limitation of this study, and a 
potential confounding factor, was that a detailed smoking history was not taken from the HC 
and the effect of smoking on ADAMDEC1 expression in the CD and HC populations was not 
assessed.  
No apparent phenotypic difference distinguished the ADAMDEC1low outlier patients from the 
general CD population.  In particular, medication and smoking did not appear to be 
confounding factors. ADAMDEC1low outlier patients share the phenotype of attenuated TNF 
secretion previously shown to be associated with CD but ADAMDEC1 expression did not 
appear to influence secretion of TNF.  ADAMDEC1 is likely therefore to moderate inflammation 
similar to NOD2 which has not previously been found to influence the TNF secretion from 
MDM or neutrophil accumulation in CD patients in response to LPS and E.coli. In a similar 
manner to NOD2, loss of ADAMDEC1 may cause an additional failure of bacterial clearance 
and thereby contribute to disease phenotype. 
The ADAMDEC1low patients were found to share a genotype; a haplotype of SNPs associated 
with gene expression which were in LD with known eQTL in monocytes (Zeller et al, 2010). 
Although common to the ADAMDEC1low outliers in both the primary and replication cohorts, 
these SNPs are also present in the HC population. One of these SNPs identified in the 
ADAMDEC1low outliers results in a potentially damaging amino acid change N444S (Figure 
3.5).  Asparagine (N) and Serine (S) are both polar (hydrophilic) and neutral amino acids but 
their hydropathy differs.  Asparagine is strongly hydrophilic (-3.5) and Serine is weakly 
hydrophilic (-0.8).  Hydrophilic amino acids reside on the outside surface of molecules in 
contrast to hydrophobic which prefer the inner surface.  As such this amino acid change could 
potentially alter the structure or shape of the molecule and theoretically expose or conceal a 
binding site.  This SNP is in exon 13 and falls within the truncated disintegrin domain.  It has 
previously been postulated that the disintegrin site is non-functional as the disintegrin loop, 
which has been demonstrated as the active site in other ADAMs and snake venom, is absent 
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[263].  However, evidence exists which suggests that this loop may not be required for 
disintegrin activity in ADAM molecules.  
The disintegrin-like domain in ADAMs is located downstream of the metalloprotease domain 
and demonstrates extensive sequence similarity to snake venom disintegrins that are well-
known integrin antagonists [335], [336].  The P-II type snake venom metalloproteases usually 
contain a tripeptide Arg-Gly-Asp (RGD) motif in the disintegrin domain surrounded by disulfide 
bonds which form a loop structure that interacts with integrins and allows cell-cell interactions. 
Apart from ADAM15, ADAMs do not have an RGD sequence, but despite this many of the 
ADAMs have been shown to interact and block integrins in vitro cell attachment assays [337], 
[338].  Furthermore, x-ray crystallography has demonstrated that the putative disintegrin loop 
is buried internally in the ADAM molecules and inaccessible for protein binding indicating that 
ADAMs- integrin interaction occurs in a different way to the snake venom proteins and may 
not actually require a disintegrin loop [339]. Indeed integrin α4β1 cell adhesion to ADAM28 is 
reliant on residues located outside the disintegrin loop (towards the N terminus) [340].  A 
number of essential charged residues were identified; Lys437, 442, 455, 459, 460, 469, some 
of which (237, 440, 442) are conserved in ADAMDEC1. 
To date there have been no studies looking at the interaction of ADAMDEC1 with integrins. 
Interestingly, ADAM7 and ADAM28, which share significant homology to ADAMDEC1 (Figure 
3.13) at a nucleotide and amino acid level [263] are the only two ADAMs known to interact 
with the integrin α4β7 [255] (Table 3.8).   
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Figure 3.13: The ADAMs family phylogenetic tree based on the metalloprotease 
sequences.  The scale bar represents amino acid substitutions per site: 0.1=10% of sites 
having a substitution.  The red circle identifies the ADAMs clustered on Chromosome 8p12 
along with ADAMDEC1, suggesting a common origin from an ancestral gene duplication [263]. 
This diagram has been adapted from Edward et al, 2008 [255]. 
 
 
This integrin is of interest in the context of gut inflammation as it is highly expressed on subsets 
of leukocytes which home to the GI tract and is of particular importance in lymphocyte 
recruitment [37].  α4β7 has been shown to bind to mucosal addressin cell adhesion molecule-
1, MAdCAM-1, on mucosal vascular endothelium in the small and large bowel.  A monoclonal 
antibody which specifically blocks α4β7, Vedolizumab, has recently been licensed and 
approved by NICE for use in moderate to severe UC and CD.  Trials using this antibody have 
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shown promising results in reducing leukocyte recruitment to the GI tract and inducing and 
maintaining remission in active UC [91] and CD [92].  It is tempting to speculate that 
ADAMDEC1 may interact with α4β7, despite its truncated disintegrin domain.  Subtle 
alterations within the disintegrin region may potentially influence α4β7 dependent leukocyte 
recruitment to the gut and predispose to a chronic inflammatory state. 
 
 
Table 3.8: ADAM-integrin associations.  ADAM 7 and 28 (highlighted in red) which 
share significant homology with ADAMDEC1 are the only two Adams to interact with α4β7, an 
integrin highly expressed on leukocytes known to home to the gut. Adapted from Edwards 
2008 [255] 
 
 
In addition to binding integrins, the disintegrin-like and/or cysteine-rich domains have been 
reported to regulate the catalytic activity of the metalloprotease domain of ADAM proteins; 
[341], [342].  Mutations in the disintegrin region may therefore indirectly affect the enzymatic 
activity of ADAMDEC1 rather than influence cell adhesive properties.  
Although the SNPs identified in our ADAMDEC1low patients were enriched in our CD 
population they were not significantly associated with CD in the UK IBD consortium GWAS 
and do occur in the general healthy population.  GWAS were founded on a common disease, 
common variant hypothesis and as such these studies may fail to identify rare SNPs of strong 
effect or indeed common SNPs with low penetrance [343].  It is predicted that only 23% of the 
heritability of CD has been identified through GWAS [108], [109], [198].  In recent years a 
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number of variants, which were not identified by GWAS, have been found to be significantly 
associated with an increased susceptibility to CD using exome sequencing and functional 
studies.  Two examples are the X-linked inhibitor of apoptosis protein (XIAP) variant, 
associated with male CD and defective NOD2 function in monocytes [344], and the loss of 
function nuclear domain 10 protein 52 (NDP52) variant; which results in deregulation of NF-
κB activation downstream of TLR pathways [345].  
In addition to the results from recent GWAS, candidate genes have identified through a 
classical hypothesis based approach.  Following identification of the role of XBP1 in 
endoplasmic reticulum (ER) stress in a mouse xbp1 knock-out model, polymorphisms in this 
gene were detected in IBD patients[346] The associations detected at this locus were well 
below the p–value detection limit for GWAS. These findings emphasise why hypothesis-based 
candidate gene approaches continues to have a role in deciphering the genetics of CD 
disease. 
It is important to note that whilst the ADAMDEC1 SNPs identified in this study, regulate 
ADAMDEC1 expression both in CD and in the healthy population, the effect is insufficient to 
completely explain the grossly attenuated expression of ADAMDEC1 seen in our CD outliers.  
HCs with the haplotype did not demonstrate such a gross reduction in ADAMDEC1 
expression.  All the SNPs identified were cis-eQTL, i.e. on the same chromosome and within 
500b of the regulated gene.  It is possible that an unidentified SNP, a trans-eQTL, influences 
ADAMDEC1 expression, from a more distant position, i.e. on a different chromosome. It is 
also feasible that another currently unknown factor(s) is contributing to the reduced expression 
in these patients, possibly epigenetic or environmental.  Epstein Barr Virus (EBV) has the 
potential to downregulate ADAMDEC1 expression along with ADAM28 (with which it shares 
significant homology), and a number of integrin genes and chemokines [347].  The presence 
of EBV antibodies, indicating previous infection, was not known to be a common feature in all 
the outlier patients although not all the patients have been tested.  
 
Having identified ADAMDEC1 as abnormally expressed in MDM from a group of patients with 
a predisposition to bowel inflammation, ADAMDEC1 was demonstrated to be constitutively 
expressed throughout the naïve human bowel.  It is salient to highlight that whilst expression 
levels are similar throughout the colon the expression in the TI is significantly greater.  
Incidentally the TI is most common site for CD pathology both in the general CD population 
and in the ADAMDEC1low patients.  
107 
In the TI, ADAMDEC1 has been reported as significantly reduced in patients with ileal CD 
[268] and this was found to be irrespective of the disease activity.  Our study supports these 
findings of attenuated expression of ADAMDEC1 in the TI of patients with quiescent CD 
compared with controls.  Unfortunately, ileal biopsies were only taken from five CD patients 
and these patients were not analysed according to disease location.  This is a limitation and 
in order to provide more convincing evidence a further study, which is better powered, needs 
to be performed. In addition, it would be interesting to take biopsies at the time of gastroscopy, 
and/or double balloon enteroscopy, to further assess the expression of ADAMDEC1 in the 
upper GIT. 
In contrast to the TI, a number of GEO datasets, including our own, have demonstrated the 
colorectal expression of ADAMDEC1 to be comparable to HC in active [112], [268], [304], 
[305] and quiescent CD disease [112], [268], [304].  It is not surprising that colonic expression 
of ADAMDEC1 is normal in the majority of datasets, many patients with CD have isolated 
small bowel pathology and do not develop colonic disease. In patients with colonic CD, the 
distribution of disease is often patchy.  A caveat to our study, and indeed many of the publicly 
available data, is that the results were not analysed according to disease location.  This is of 
particular relevance in CD in which phenotypic variation could potentially influence the results. 
In UC, the picture is different.  In our study we found ADAMDEC1 to be significantly under-
expressed in the TI and colorectal samples from clinically, endoscopically and histologically 
quiescent UC patients.  This result contrasts with the results from a number of publicly 
available data in which ileocolonic expression of ADAMDEC1 in patients with quiescent UC is 
similar to HC [112], [268], [325].  Interestingly, in these datasets ADAMDEC1 was consistently 
found to be under-expressed in colorectal biopsies from patients with active UC [112], [305], 
[325].  It is possible that our UC patients had subclinical activity which influenced the results. 
The significance of attenuated ADAMDEC1 in quiescent CD and the reason for the 
discrepancy between studies in UC patients, particularly in the TI, is yet to be determined.  By 
definition UC is a disease of the large bowel, unlike CD it does not affect the small bowel.  
Some patients with pan-UC develop backwash ileitis, an inflammatory process in the TI.  
Patients from our UC cohort with low levels of TI ADAMDEC1 did not, however, display, or 
have a history of, such a phenomenon.  What is not clear is the extent to which disease 
location, longevity, previous activity and treatment history affect the subsequent expression 
profile; studies of large numbers of samples, from multiple bowel locations in accurately 
phenotyped patients and healthy individuals are required. 
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Unfortunately it was not practical to obtain ileocolonic tissue from the outlier patients as there 
was no clinical indication for colonoscopy. As such, a correlation between ADAMDEC1 
expression in MDM and bowel in the outlier patients has currently not been demonstrated. 
 
A literature review revealed that a number of the ADAMs (ADAM15 [348], ADAM9, ADAM10, 
ADAM19 [268], [349], ADAM17 [268]) and MMPs (MMP-2, MMP3, MMP7, MT1-MMP, 
MMP28) are also constitutively, but not exclusively, expressed in the bowel [268], [350], [351].  
Extraction of ADAMDEC1 expression levels from GEO datasets demonstrated that it is one of 
the most highly expressed member of this metalloprotease family in the naïve bowel [268], 
[352]. 
During ileocolonic inflammation, many of the metalloproteases constitutively expressed in the 
bowel are upregulated.  Other metalloproteases (MMP1, MMP8, MMP9, MMP10, MMP12, 
MMP13) usually undetectable in the healthy gut are also highly expressed in the inflamed 
intestine [268], [349].  The first reports of aberrant expression of metalloproteases in IBD were 
published in the early 1990s and subsequently a large number of studies have demonstrated 
increased expression in intestinal biopsy samples from patients with active UC and CD: 
ADAM9 [268], ADAM15 [353], ADAM17 [349], ADAM19 [268], [349].  ADAM28 [268], MMP1 
[354]–[358] MMP2 [354], [356], [359], MMP3 [354]–[356], [360] and MMP7 [355], [361]–[363], 
MMP9 [354], [364], MMP10 [354], [363], [365], [366], MMP12 [365] MMP13 [362], [365], [367] 
and the tissue inhibitors of metalloproteases; TIMP1 [356], [360], TIMP3 [365], [366] have all 
been reported as upregulated in colitis and intestinal ulceration in IBD.  A more detailed 
description of MMPs in IBD may be found in the review on this theme in section 5  [21].  Until 
the recent publication by De Bruyn and colleagues [268], ADAMDEC1 had not been reported 
as dysregulated in IBD and to date has not been implicated in bowel inflammation. 
Antibiotics and immunosuppressive therapies aimed at resolving the  inflammation in IBD have 
been shown to restore normal expression of metalloproteases when clinical and histological 
remission is achieved in adults [366], [368], [369]  and paediatric cohorts [366].  This is 
illustrated by the recent study by De Bruyn and colleagues examining the effect of infliximab, 
a monoclonal antibody against TNFα, on the mucosal expression of MMPs in active IBD [268].  
Before infliximab treatment the majority of MMPs were found to be significantly up-regulated 
in inflamed compared with healthy bowels.  Following infliximab treatment, the MMP levels in 
IBD patients who demonstrated mucosal healing returned to that seen in non-inflamed HCs.  
However this was not the case for ADAMDEC1.  The abnormally low levels of ADAMDEC1 
found in the small bowel of CD patients were not corrected by infliximab treatment despite 
clinical response to therapy. 
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ADAMDEC1 is not the only metalloprotease to be downregulated in IBD.  MMP28 is 
constitutively expressed in epithelial cells in the healthy intestine, however in the actively 
inflamed bowel of IBD patients MMP28 expression is not augmented [370] but is significantly 
reduced [370].  As the major cellular source of MMP28 is the shedding epithelium and non-
migrating enterocytes in both healthy and inflamed mucosa in the case of MMP28 this 
observed decrease in expression maybe secondary to colitis associated epithelial destruction 
and loss of cryptal architecture.  Although this may explain why ADAMDEC1 is low in active 
UC it does not explain why ADAMDEC1 is attenuated in the terminal ileum of quiescent CD 
patients, where crypt architecture is intact and there is no evidence of microscopic colitis or 
related cellular infiltration. 
Could the reduced ileal expression of ADAMDEC1 in patients with CD be due to a genetic 
variation such as an eQTL?  It is unlikely, but possible, that the SNPs identified in the CD 
patients with low ADAMDEC1 are responsible for the gut expression of ADAMDEC1 as 30%–
40% of cis-eQTL previously identified in cell types, including lymphocytes, monocytes, and 
fibroblasts, have also now been characterised as cis-eQTL in ileal tissue [371].  However, the 
majority of ileal cis-eQTL had not previously been described and increasing evidence has 
demonstrated that eQTL may be tissue-specific [372].  Indeed the known ADAMDEC1 eQTL 
SNPs in monocytes, and those we identified in the MDM from ADAMDEC1low CD outliers, 
were not significantly associated with ileal expression of ADAMDEC1, in a recent paper which 
reported eQTL in the small bowel [373].  In support of this a recent study by our group 
examining eQTL in the rectum reaffirmed the tissue specific nature of some eQTL; 26% of 
genes had not been identified with eQTL in previous studies and rectal eQTL showed 
incomplete overlap with those in other cell types including closely related tissues such as the 
ileum [374]. 
A more plausible explanation is that the reduced intestinal expression of ADAMDEC1 is 
secondary to a change in the tissue environment of patients with IBD either as a consequence 
of previous inflammation, medication or the underlying pathology: 
ADAMDEC1 expression may be Influenced Locally by Changes in the Inflammatory Milieu of 
Intestine: 
 Modulation of the bowel microflora in patients with IBD has been shown to influence 
the expression of genes locally in the gut mucosa [375]. Dysbiosis is present and 
persists in both CD and UC despite resolution of inflammation [151] and may 
potentially alter the intestinal expression of ADAMDEC1 even in the quiescent state. 
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 Alternatively a component of the intestinal inflammatory milieu may inhibit expression.  
MMPs and ADAMs are exquisitely sensitive to the local environmental conditions and 
are either augmented or moderated by a multitude of stimuli including inflammatory 
cytokines such as TNFα [376], [377], IL1β [378]–[380], microbial antigens i.e. LPS, 
DAMPs and PAMPs [381]–[384], colony stimulating factors [385], [386] and growth 
factors; EGF [387] and TGF-β [388], [389], all of which are abnormally expressed 
during intestinal inflammation.  
ADAMDEC1 Expression may be regulated by a Feedback Loop: 
 Activation of ADAMDEC1 could result in a negative feedback following prolonged 
inflammation and inhibit synthesis in the chronic inflammatory state.  
 Alternatively ADAMDEC1 may positively feedback to stimulate synthesis but could be 
degraded or sequestered by a component of the chronic inflammatory state in IBD over 
time, inhibiting the feedback loop. 
o The natural tissue inhibitors of MMPs and ADAMs, the TIMPs, regulate 
metalloprotease levels locally under physiological conditions by competing in a 
relatively non-selective, and reversible, manner for the zinc binding site thereby 
preventing the catalytic domain interacting with substrates [390].  
o TIMPs are not the only endogenous inhibitors of metalloprotesases. Alpha-2-
macroglobulin, for example, an abundant plasma protein, forms an irreversible 
complex with MMPs and ADAMs in the extracellular fluid which is then cleared 
by scavenger receptor mediated endocytosis [391]. Recombinant ADAMDEC1 
has been shown to interact with α-2-macroglobulin in vitro [265] 
o Isolated prodomains of ADAMs have also been reported as selective inhibitors 
of the mature and active forms of the protease domain in a number of 
ADAMs/MMPs [392], [393]. 
However a recent publication has reported that ADAMDEC1 displays a lack of 
responsiveness to the classical ADAMs inhibitors, TIMP1-3 and α-2-macroglobulin, 
[394] which make this possibility less likely and suggests that ADAMDEC1 may have 
evolved to escape inhibition by endogenous metalloprotease inhibitors. 
ADAMDEC1 expression maybe due to the recruitment or maturation of cells:  
The most plausible explanation is that the change in tissue expression of ADAMDEC1 is due 
to a modification in the composition, or stage of differentiation, of cells in the local environment, 
albeit this was not obvious in the microarray studies performed.   
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 During inflammation ‘resident’ immune cells will be replaced by ‘inflammatory’ immune 
cells recruited to the sites of injury.  As a result, changes in tissue expression of genes 
are seen.  For example MMP9, which has been extensively associated with disease 
activity in UC and CD [395], is undetectable in the intestine of HCs but significantly 
upregulated in active disease due to an influx of MDM and neutrophils, both of which 
express MMP9, to the site of tissue injury.  Similarly, MMP12 and MMP8 are both up-
regulated during inflammation of the bowel as they are expressed on macrophages 
and neutrophils respectively [350], [364], [396]–[398], 2006).  Perhaps a cell type which 
expresses ADAMDEC1 is proportionally reduced in the intestine following chronic 
inflammation or during the healing stage. 
 
In contrast to IBD, ADAMDEC1 is significantly upregulated, along with related 
metalloproteases, at sites of extra-intestinal inflammation in conditions such as sarcoidosis in 
the lung, dental caries in teeth, psoriatic plaques and discoid lesions in the skin, osteoarthritis 
in synovial joint fluid and unstable carotid plaques in the arteries. As such it is unlikely that the 
low tissue expression of ADAMDEC1 observed in quiescent CD is a response to inflammation 
per se but appears to be either organ or disease specific. Unfortunately no robust microarray 
data sets exist in humans, which include ADAMDEC1 expression, for non-IBD inflammatory 
conditions in the bowel such as diverticulitis or infective colitis.  As such it is difficult to predict 
whether the observation of low levels of ADAMDEC1 in the intestine of patients with IBD is 
disease or organ specific in humans. In one small study which compared expression profiles 
from colonoscopic biopsies taken from infective colitis (n=2) compared with HC (n=4), 
ADAMDEC1 was significantly reduced (p<0.05) [112].  However this result is difficult to 
interpret in light of the small sample size.  Another study carried out in six patients with rectal 
cancer reported ADAMDEC1 as one of 31 genes up-regulated in rectal biopsies one hour 
following radiotherapy [326].   
In order to further investigate the expression of ADAMDEC1 in the bowel during acute and 
chronic intestinal inflammation, an experimental colitis model would be useful in which gut 
expression levels could be measured before, during and after an acute or chronic colitis. A 
number of animal models exist.  These models are discussed further in Chapters 5 and 6.  
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3.4 Conclusion 
The association between an aberrant intestinal expression of MMPs and IBD is well 
established.  However, until recently ADAMDEC1 had not been reported in the context of IBD 
and was unknown in the GI community.  For the first time we have demonstrated a possible 
association between MDM expression of ADAMDEC1 and CD.  A number of publicly available 
gene expression datasets support abnormal expression in the bowel of patients with IBD; a 
recent publication observed the abnormal small bowel expression of ADAMDEC1 in CD 
patients and our data has strengthened this association between bowel inflammation and 
reduced expression of ADAMDEC1.   
Whether the aberrant tissue expression of metalloproteases and, in particular ADAMDEC1, is 
a consequence, or pathogenic cause, of the chronic active inflammation seen in IBD is 
currently unknown.  A growing body of evidence suggests that the unique inflammatory milieu 
of IBD may influence the tissue expression and function of metalloproteases atypically.  
Elevated cytokines, both local and systemic, unidentified circulating factors and changes to 
the luminal microbiota composition, may all contribute to alterations in metalloprotease 
expression which could potentially amplify tissue destruction and impair wound healing.  A 
number of enteric pathogens; Bacteroides fragilis [399] and Enterococcus faecalis [400], have 
been shown to secrete MMPs which degrade ECM, cleave junctional proteins and induce 
transmural colonic inflammation in animals models.  The effect of these commensal bacterial-
derived proteases on the MMPs expression in the host intestine remains undetermined. 
Environmental factors, such as smoking, which is detrimental in CD but protective in UC, may 
also contribute to an alteration in expression [401].  
In general, the abnormal expression of metalloproteases seen during chronic active 
inflammation return to a normal baseline level on resolution of inflammation.  In contrast, the 
reduced levels of ADAMDEC1 reported in MDM and bowel specimens have been identified in 
non-inflamed CD patients (confirmed both histologically and using transcriptomic expression 
profiles).  This observation and its biological significance are intriguing and pose the question 
as to whether an underlying reduced expression of ADAMDEC1 contributes to an increased 
susceptibility to intestinal inflammation in CD.  It is likely that ADAMDEC1, like other members 
of the metalloprotease family, may act on matrix proteins, chemokines, cytokines and 
antimicrobial peptides, directed at inducing tissue homeostasis under physiological conditions.  
Considering its distinct expression profile, it is plausible that ADAMDEC1 is primarily important 
for gut homeostasis.  It is tempting therefore to postulate that loss of ADAMDEC1, or reduced 
expression, could predispose to GI inflammation and perhaps even tumour development.  
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4. Investigation of Tissue, Cellular and Subcellular Location in Health, and 
Bacterial Response, of ADAMDEC1 
 
4.1 Introduction 
In Chapter Three, ADAMDEC1 was identified as significantly under-expressed in MDM and 
intestinal tissue biopsies from patients with CD.  In this chapter the normal expression and 
distribution of ADAMDEC1 in the steady state and the altered expression in response to 
inflammation and enteric bacterial antigens is explored further. 
ADAMDEC1 belongs to a large family of metalloproteases, including the MMPs and ADAMs.  
The tissue expression profiles of these family members vary considerably in the steady state.  
The expression of many are limited to the testes, and germ line cells, whilst others display a 
broad somatic distribution throughout the body and can be expressed in a myriad of cells, 
depending on their state of activation (Table 4.1). It is uncommon for a member of the family 
to be organ specific (apart from the testes). 
In the intestine, a number of metalloproteases are expressed at detectable levels in the healthy, 
non-inflamed, steady state as discussed in Chapter Three.  A literature search reveals the 
metalloproteases are found in a variety of cells within the intestinal wall; the IEC (MMP2, -3, -
7, -28, ADAM15 [348], mesenchymal stromal cells (MMP2, -3) and resident immune cells in 
the lamina propria (LP) (MMP3, ADAM 8, 9, 10, 17, 19), reviewed by O’Shea & Smith [21]. 
A number of metalloproteases which are undetectable in the healthy gut, are expressed in the 
actively inflamed or healing intestine. Modifications in transcription and activation of resident 
cells may alter gene expression in the resident tissue cells, for example, MMP-1, MMP-13 in 
activated IEC [272] and MMP-14 in activated intestinal stromal cells are reported as 
upregulated. The immune cells recruited to sites of injury also make a significant contribution 
to the adaptation in tissue expression of metalloproteases during inflammation. Macrophage 
metalloelastase (MMP-12) and neutrophil collagenase (MMP-8) are selectively expressed in 
macrophages and neutrophils, respectively, and MMP-9, ADAM17 and ADAM10 are 
ubiquitously expressed by haemopoietic cells [396], [397]. 
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Table 4.1: Cellular distribution of ADAMs and MMPs.  MMPs and ADAMs are 
expressed in a myriad of cells in the intestine. A few are specific to a particular cell type; 
MMP12 is specific to macrophages, whilst, MMP 8 is expressed in neutrophils. A number are 
ubiquitously expressed, such as ADAM 10 and 17. 
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Hypothesis for Chapter Four 
a) ADAMDEC1 is expressed in macrophages within the intestinal tract. 
b) ADAMDEC1 is a bacterial response gene, upregulated in response to bacterial stimuli. 
c) The subcellular location of ADAMDEC1 may provide an insight into the cellular 
processes with which it is involved. 
 
 
Aims of Chapter Four 
a) To ascertain the location of ADAMDEC1 at a tissue, cellular and subcellular level. 
b) To investigate the regulation of mRNA and protein expression of ADAMDEC1 by 
inflammatory mediators and bacterial antigens, in an attempt to understand the 
aberrant expression of ADAMDEC1 observed in IBD, as described in the Chapter three. 
c) To ascertain whether ADAMDEC1 is a secreted or cytosolic protein. 
d) To investigate the expression of ADAMDEC1 in response to inhibitors of vesicle 
trafficking and protein degradation. 
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4.2 Results 
 
4.2.1 In Humans ADAMDEC1 is almost exclusively expressed in GI Tract 
Examination of mRNA expression data from the online gene atlas database BioGPS  [396], a 
gene portal which combines the expression data from numerous publically available datasets, 
revealed that human ADAMDEC1 is highly and almost exclusively, expressed in the small and 
large bowels of HCs (Figure 4.1).  ADAMDEC1 is also expressed at a lower level in the spleen, 
tonsils and lymph nodes, all of which are secondary lymphoid organs. 
 
 
Figure 4.1: In humans ADAMDEC1 tissue expression is highly and almost 
exclusively expressed in the gastrointestinal tract, predominately the small bowel.  
ADAMDEC1 is expressed at a lesser extent in the tonsils, lymph nodes and spleen 
(Expression > log10
3
: red bars, >log10
2
:
 
orange bars, >log10
1
: yellow bars, undetectable 
levels: white bars). http://ds.biogps.org/?dataset=GSE1133&gene=27299. Raw data 
extrapolated from GSE1133 [284].  
 
117 
4.2.2 ADAMDEC1 Expression is Consistent across the Colon but Increased in TI 
Expression data was obtained from ileocolonic biopsies taken from patients, scoped on 2WW 
and symptomatic lists, who had no macroscopic or microscopic evidence of lower GI pathology 
(section 3.2.9 for patient details). No significant difference in ADAMDEC1 expression was 
seen in rectum compared with the sigmoid, descending and/or ascending colon. A significant 
increase in ADAMDEC1 expression was, however, observed in the terminal ileum compared 
with rectum, and colonic sites examined (Figure 4.2), similar to the findings in the BioGPS 
dataset.  
 
Figure 4.2: ADAMDEC1 expression measured in ileocolonic biopsies taken at 
endoscopy from healthy non inflamed HC.  ADAMDEC1 is expressed at a significantly 
higher levels in the terminal ileum of the small bowel compared with rectum (n=31), sigmoid 
(n=30), descending (descend) (n=21) and ascending (ascend) (n=15) colon and terminal ileum 
(n=15).  Similar levels of expression of ADAMDEC1 were found in the rectum and throughout 
the colon. Two tailed, unpaired t-test p<0.001***, n.s non-significant. Data displayed by box-
and-whisker plots, representing the median (straight line within box) and quartiles (the upper 
and lower quartiles are represented by the vertical lines outside the box; the whiskers). 
 
4.2.3 Tissue Expression of Adamdec1 is Highly Conserved across Animal Species 
The tissue expression of Adamdec1 is highly conserved across species.  Using a panel of 
mouse tissues, Adamdec1 gene expression was shown to be identical to that observed in 
118 
humans, with high expression in the GI tract and a low level of expression in the spleen and 
lymph nodes (Figure 4.3).  It is worth noting that the expression of Adamdec1 in the upper 
GIT, as represented here by the murine stomach, is reduced compared with the lower GI tract. 
By exploiting the online tool BioGPS, it was confirmed that this pattern of expression for 
Adamdec1 is also replicated in other mammals including pigs. The pig dataset also 
demonstrates Adamdec1 expression in the duodenum and jejunum. 
 
Figure 4.3: The tissue distribution of Adamdec1 (AD1) in mice is similar to that in 
humans.  A panel of mouse organs demonstrates that AD1 expression is restricted to the 
gastrointestinal tract and to a lesser extent in the spleen in mice.  The house keeping gene 
used was HPRT. 
 
4.2.4 ADAMDEC1 is expressed within the LP of Intestine 
Immunohistochemical staining of non-inflamed human small intestinal tissue sections was 
performed by the Department of Histopathology at UCLH.  The tissue was obtained from 
healthy resection margins from a patient undergoing intestinal surgery to resect colorectal 
cancer (see methods section 2.1.1). This tissue sample was then stained with a monoclonal 
antibody, raised in mouse, against human ADAMDEC1.  Staining for ADAMDEC1 was found 
to be present in the LP layer but not the epithelium (Figure 4.4A).  In situ hybridisation of 
intestinal tissue sections from resected non-inflamed bowel confirmed this distribution of 
ADAMDEC1 in the intestinal LP cells (Figure 4.4B).  
These results clearly demonstrate that ADAMDEC1 is present both at a message and protein 
level in the LP, but not in epithelial cells, of the human gut.  Western blot analysis of an 
epithelial colonic cell line, HCT116 and colonic tissue lysate (obtained from an endoscopic 
pinch biopsy from the sigmoid colon of a HC) supports an absence of ADAMDEC1 expression 
in the intestinal epithelium (Figure 4.4C).  Collagenase digestion of mouse colon, following 
removal of the epithelial layer with EDTA, demonstrates high expression of ADAMDEC1 in 
murine LP cells relative to the whole mouse colon (Figure 4.4D). 
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Figure 4.4: ADAMDEC1 expression is restricted to the lamina propria (LP) of the gut.  
(A) Immunohistochemistry revealed ADAMDEC1 protein was highly expressed in 
mononuclear cells located in the LP (brown staining, yellow arrow), not in the epithelial cells 
(green arrow). (B) In situ hybridisation (i) using an antisense probe demonstrated ADAMDEC1 
mRNA was restricted to the LP (blue stain), (ii) the control sense probe did not show binding. 
Human colonic specimens from clear surgical resection margins were used. (C) The epithelial 
cell line (HTC116) did not express ADAMDEC1 as compared with human colonic biopsy tissue 
lysate from a heathy control patient. (D) qRT-PCR of murine LP cells, isolated by collagenase 
digestion following incubation with EDTA to remove the epithelial layer, demonstrated high 
levels of Adamdec1 mRNA, relative to whole mouse colon (LB), immediately post isolation 
(LPD0). Following one day of culture in sterile conditions, the unstimulated LP cells (UnD1) 
demonstrated reduced expression of Adamdec1 compared with freshly isolated cells.   
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4.2.5 ADAMDEC1 is expressed in Mononuclear Phagocytes within Intestinal LP 
Immunohistochemical staining for ADAMDEC1 in human intestinal tissue illustrates that the 
cells within the LP which express ADAMDEC1 are mononuclear, and morphologically look like 
resident macrophages (Figure 4.4A).  These observations were verified independently by two 
UCLH Consultant Histopathologists with a specialist interest in GI pathology, and are 
consistent with previous reports of ADAMDEC1 expression in macrophages isolated from non-
inflamed colon [403].  A low level of expression has also been reported in activated DCs, from 
secondary lymphoid organs, in humans [403], [404] and mice [404].  In addition ADAMDEC1 
has been reported at a low level in B cells from human tonsils [248] and mouse spleen [405], 
but not from mouse peritoneal B cells.  ADAMDEC1 has also not been identified in T 
lymphocytes [248] and staining was not seen in polymorphonuclear cells (i.e. neutrophils, 
eosinophils) in the intestinal tissue samples examined in Figure 4.4. 
In order to further investigate the cellular expression of ADAMDEC1 in the steady state, 
intestinal LP cells, isolated by collagenase digestion of the colon from healthy wild type 
C57BL/6 mice, were FACS sorted.  Following optimisation of this method the average yield of 
live LP cells isolated was 34%.  32% of these cells were found to be haemopoietic in origin 
(CD45+), of which 24% were T cells (CD3+), <1% were neutrophils (CD11b+, GR1+), 18% were 
macrophages (CD11b+) and 6% were DCs (CD11c+)  (Figure 4.5). 
 
Figure 4.5: FACs analysis of Lamina Propria (LP) cells from wild type mice. Intestinal 
LP cells, isolated by collagenase digestion of the colon from healthy wild type C57BL/6 mice, 
were FACS sorted to demonstrate the cell populations present. Doublets and triplets were 
excluded to minimise the inclusion of clumped cells and dead cells were excluded.  
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By analysing the GEO dataset (GSE27859), containing transcriptomic data from murine 
colonic LP cells, isolated using the same methodology [406], Adamdec1 was found to be 
highly expressed, by F480+CD11c+ CD11b+ cells.   
 
Figure 4.6: Adamdec1 is highly expressed in LP mononuclear phagocyte 
populations.  (A) Representative FACS plot illustrating the gating strategy employed to 
isolate colonic LP macrophages and DCs in C57BL/6 wild type mice.  After pre-gating on 
CD45
+
 cells, three populations of iMNP cells were identified (i) CD11c+ F480- DC population 
(ii and iii) CD11b+ F480+ intestinal macrophage populations.  (B) The gene expression profile 
of Adamdec1 in these cell populations was extracted from a GEO online data set (GDS4369) 
[406].  Adamdec1 was revealed to be most highly expressed in F480+CD11b+ macrophages. 
Data represented as mean ± SEM. Two tailed unpaired t-test, p<0.05*, p<0.01** 
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This population of intestinal cells (F480+CD11c+CD11b+) have been extensively 
characterised in the literature [24], [31], [407], they represent iMNP, and are widely described 
as a macrophage population.  These lamina propia macrophages have been demonstrated to 
be Ly6chi monocyte-derived in the non-inflamed (steady) state [26].  Adamdec1 was also 
expressed by the F480+ CD11b+ CD11c- macrophage and, albeit to a lesser extent, on F480- 
CD11b- CD11c+ DC populations (Figure 4.6B).  These results are corroborated by other 
publically datasets in which Adamdec1 is highly expressed in CX3CR1+ (GSE42101) [408] 
and CD11b+ (GDS2982) [409] mononuclear phagocytes in the intestinal LP. 
 
 
4.2.6 Adamdec1 is the Most Highly Expressed Member of the ADAM Family in 
Resident Intestinal CD11b+ Macrophages 
By comparing the gene expression profiles of ADAMs in CD11b+ F480+ CD11c- resident 
intestinal tissue macrophages from GEO datasets it was evident that Adamdec1 is one of, if 
not, the most highly expressed member of the ADAM family in this cell population. (GDS2982) 
[409] (Figure 4.7). 
 
Figure 4.7: The relative expression of ADAMs in CD11b+ CD11c- LP cells isolated 
from the colon of C57BL/6 mice, in the steady state.  Adam 1, 2, 3, 7, 18, 29, 33 are 
undetectable in the colon in the steady state. (Raw data extracted from GDS 2982) [409]. 
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In comparison splenic CD11b+ CD11c- macrophages express significantly less Adamdec1 
than intestinal CD11b+ CD11c- macrophages (GDS2982) and other ADAMs, in particular 
ADAM8, are more preferentially expressed by the equivalent CD11b+ splenic cells (Figure 
4.8).  
 
Figure 4.8: The relative expression of ADAMs in CD11b+ CD11c- intestinal colonic 
macrophages compared with CD11b+ splenic macrophages, isolated from C57BL/6 
mice in the steady state. CD68 is a macrophage marker which is expressed at a similar level 
in spleen and bowel. In comparison Adamdec1 is highly expressed in the lamina propria 
macrophages but less so in splenic macrophages. Raw data extracted from GDS 2982 [409].  
 
 
4.2.7 ADAMDEC1 is Undetectable in Extra-Intestinal Tissue Macrophages Relative to 
Resident Intestinal Macrophages 
Extraction of Adamdec1 expression levels from a GEO dataset comparing gene expression 
profiles of resident tissue macrophages demonstrated that in the steady state, as previously 
shown, Adamdec1 was highly expressed in intestinal macrophages and moderately 
expressed in mature splenic macrophages.  However Adamdec1 was comparatively 
undetectable in mature resident macrophage populations resident in extra-intestinal organs 
such as the peritoneum, lung liver and adipose relative to intestinal macrophages.  In addition 
bone marrow derived macrophages differentiated in sterile culture for seven days with m-CSF 
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did not express Adamdec1 (Figure 4.9) GSE56711) [410].  We were also unable to detect 
Adamdec1 in cultured BMDM and peritoneal cells despite priming with LPS and stimulation 
with HkEc in vitro (data not shown). 
 
 
Figure 4.9: Relative expression of Adamdec1 in mouse resident tissue macrophages 
in the steady state.  Resident macrophages from the intestine have significantly higher levels 
of Adamdec1 expression that other resident tissue macrophages (p<0.001). BMDM were 
cultured for 7 days in m-CSF (n=3). Resting peritoneal macrophages were collected in a 
peritoneal lavage (n=2). Macrophages from the lung (n=1), liver (n=1), adipose tissue (n=2) 
and spleen (n=1) were digested by liberase, followed by density gradient separation. Small 
bowel macrophages (n=2) were obtained in a similar way following excision of peyer’s patches 
and incubation with EDTA to remove epithelial cells. F4/80, CD11b positive cells were FACS 
sorted, RNA was hybridised to Illumina MouseWG-6 expression bead chips. Expression data 
was extrapolated from online dataset GSE56711 [410]. Two tailed unpaired t test, p<0.001***.  
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4.2.8 ADAMDEC1 is Up-Regulated during Monocyte to Macrophage Differentiation 
ADAMDEC1 is not expressed in undifferentiated monocytes but was found to be up-regulated 
over 5-7 days during differentiation of peripheral blood monocytes to macrophages, in sterile 
culture conditions with foetal calf serum (FCS), following a two hour serum starvation 
(p<0.001) (Figure 4.10A).  
 
Figure 4.10: ADAMDEC1 is undetectable in un-differentiated peripheral blood 
monocyte (PBMC) lysates but is significantly up regulated during monocyte to 
macrophage differentiation in vitro. (A) qPCR of ADAMDEC1, relative to Ppia, in lysates 
from PBMC cultured, in foetal calf serum (FCS), under sterile culture conditions, over seven 
days. (B) ADAMDEC1 expression in MDM differentiated with FCS and m-CSF for seven days 
(raw microarray data from GSE5099). Minimal change in ADAMDEC1 expression in 
monocytes differentiated for the first 24–72 hours in culture. After seven days, ADAMDEC1 
expression was significantly increased, further polarisation with 24 hours of LPS or IL-4 to 
classically activated M1 or alternative activated M2 macrophages, respectively, did not result 
in a significant difference in ADAMDEC1 expression. Two tailed unpaired tests were used to 
compare each group: p <0.05*, p<0.01**, p<0.001*** Data represented as mean ± SEM. 
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Publically available GEO datasets support this finding in cultured MDM with M-CSF 
(GSE5099) [411] and foetal bovine serum, FBS (GSE8286) [412].  In the former data set no 
significant difference in ADAMDEC1 expression was seen in classically activated, M1 (with 
LPS) or alternative activated, M2 (with IL4) MDM (GSE5099) (Figure 4.10B). 
A similar result was observed with THP1 cells differentiated under the same culture conditions 
for 5-7 days following a 2 hour serum starvation, minimal changes to expression are seen 
within the first 24 hours in sterile conditions (Figure 4.11).  The THP1 cell line was originally 
derived from a patient with acute monocytic leukaemia [413] and is widely used by researchers 
to investigate the function and regulation of monocytes and macrophages [414]. 
 
 
4.2.9 ADAMDEC1 Expression is Up-Regulated in Monocytes by Exposure to Bacterial 
Antigens 
A more rapid and stronger induction of ADAMDEC1 was seen on stimulation of monocytes 
with enteric bacteria HkEc than sterile culture (Figure 4.11). 
Over a 24 hour period ADAMDEC1 was significantly up-regulated with HkEc (p<0.001) and 
bacterial components LPS, a TLR4 antigen (p<0.001) and to a lesser extent PAM3 (a TLR2 
ligand) (p<0.001) both at a message (Figure 4.11A) and protein level (Figure 4.11B). 
ADAMDEC1 was not up-regulated in response to MDP, the ligand for NOD2, cytokines TNF 
and IFNγ or viral antigen R848 (TLR7/8) at 24 hours, as demonstrated by western blot (Figure 
4.11B).   
PBMDM from a random selection of patients in the Primary Cohort, described in chapter 3, 
were stimulated with HkEc for 24 hours to compare gene expression in activated macrophages 
from CD patients and HC. Four of the ADAMDEC1 outliers were included (Figure 4.12). 
ADAMDEC1 was significantly upregulated in HC, CD and outlier patients indicating that there 
is not a defect of ADAMDEC1 transcription, in response to bacterial stimulation, in CD or 
outlier patients. It is important to note that despite upregulation of ADAMDEC1 with HkEc, the 
expression levels in ADAMDEC1 outliers remain below the normal range observed for 
unstimulated or HkEc stimulated macrophages from CD patients and HC (p<0.001).  
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Figure 4.11: ADAMDEC1 is rapidly up-regulated, over 24 hours, by bacterial 
stimulation with HkEc, and activation of TLR4 (LPS) and TLR2 (PAM
3
).  (A) qPCR of 
ADAMDEC1 expression in THP1 cells, following two hour serum starvation, in sterile culture 
conditions compared with bacterial antigen stimulation (A). Minimal change is seen in 
ADAMDEC1 expression following 24 hour culture in sterile conditions, compared with HkEc, 
TLR2 & TLR4 which demonstrate significant upregulation of ADAMDEC1 over 24 hours. (B) 
ADAMDEC1 is upregulated at a protein level in human peripheral blood monocytes, as 
demonstrated by western blot.  ADAMDEC1 protein is not up-regulated in monocytes following 
stimulation with TNF, INFγ, NOD like receptor (MDP) and TLR7 (R848) antigens at 24 hours. 
Results presented as mean ± SEM.  
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Figure 4.12: ADAMDEC1 is upregulated in PBMDM from HC, CD and ADAMDEC1 outlier 
patients following HkEc stimulation. Microarray gene expression (log2) of ADAMDEC1 in 
unstimulated (U), and 24 hours of heat killed E.coli (Ec) stimulated peripheral blood monocyte 
derived macrophages (PBMDM) from HC (n=14), CD (n=24) and ADAMDEC1low (AD) outlier 
(n=4) patients, from the Primary Cohort. Black bar represents the mean. Two tailed, unpaired 
t-test p<0.01**, p<0.001***. 
 
 
4.2.10 Intestinal Expression of Adamdec1 under Germ Free Conditions 
As Adamdec1 expression is up regulated in monocytes and MDM by enteric bacteria and its 
components LPS and PAM3, it was of interest to ascertain whether the exclusive expression 
in the intestine of both humans and mice could be secondary to a background exposure to 
bacterial antigens in vivo.  In order to answer this question in situ hybridization was performed 
on the intestine of germ free mice and compared with control wild type C57BL/6 mice, bred 
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and maintained under normal SPF conditions.  The results were not as predicted, Adamdec1 
was expressed in the intestine of wildtype mice (Figure 4.13A) and germ free mice (Figure 
4.12B). qPCR confirmed similar levels of Adamdec1 expression in the germfree mice 
compared with wildtype (Figure 4.13C). 
Figure 4.13: Adamdec1 is expressed in germ free (GF) mice.  In situ hybridisation using 
an anti-sense probe for Adamdec1 was performed on  large (LB) and small bowel (SB) 
sections from (A) C57BL/6 wild type and (B) GF mice (20x magnification). The presence of 
Adamdec1 specific mRNA was confirmed in the GF tissue (blue) and the distribution was 
identical to that seen in the conventional wild type mice. Adamdec1 was expressed in the 
lamina propria (yellow arrow) but not the epithelium (red arrow). (C) Equivalent expression of 
Adamdec1 was seen in wild type (WT) (n=3) and GF (n=1) colons using qPCR. 
  
In order to confirm the presence of Adamdec1 in an intestine which had not been exposed to 
bacteria, an online data base search was performed for microarray data from embryological 
bowel specimens.  A publically available mouse atlas data bases confirmed that Adamdec1 
was expressed prenatally in the intestine as early as embryological day 14.5 (E14.5) [415] 
(Figure 4.14).   
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Figure 4.14: Adamdec1 is expressed in the developing gut in mouse embryos.  (A) 
Sagittal sections cut through the embryonic day 14.5 (E14.5) mouse embryo, illustrated by red 
lines labelled: 1-3. (B 1-3) Histological staining of sections 1-3 demonstrate anatomical 
position of organs. (C 1-3) In situ hybridisation for Adamdec1 was performed on equivalent 
sections of tissue. Strong expression of Adamdec1 was seen in the midgut. (C 1, 2). Staining 
for Adamdec1 was absent of staining in section (C3) which did not contain intestinal tissue. 
Data and images extrapolated and adapted from Eurexpress mouse embryo atlas [415]. 
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A second dataset corroborated the finding of Adamdec1 in the prenatal gut; mesenchymal 
cells isolated from the small intestine of embryonic mice at E18.5 were found to express 
significantly higher levels of Adamdec1 than IEC [416], similar to adults (Figure 4.15). 
 
Figure 4.15: Adamdec1 is expressed in the mesenchyme, not the epithelium, in the 
prenatal intestine.  Analysis of the raw data from a microarray study comparing gene 
expression in mesenchymal cells (MC) with epithelial cells (EC), isolated from the small 
intestine of mouse embryos on embryonic day 18.5 (E18.5). The expression of Adamdec1 
was significantly higher in the intestinal MC compared with EC. GSE 6383 [416]. Two tailed, 
unpaired t-test p<0.001, mean represented by small black bar (n=3 mice). 
 
 
4.2.11 Is ADAMDEC1 secreted from MDM 
Following transcription the majority of ADAMs are transported via the endoplasmic reticulum 
(ER) and Golgi (where they are processed and cleaved by furin-like proprotein convertase or 
autocatalysis into a mature protein), to the cell membrane and act as transmembrane proteins. 
In contrast to other members of the family, ADAMDEC1 is truncated; it does not contain a 
cytoplasmic domain and transmembrane tail.  As a consequence it has been proposed to be 
a secreted protein which may act extracellularly similar to MMPs, ADAMTS and the soluble 
splice variants such as ADAM12s [417].  Consistent with this idea, Lund and colleagues [265] 
detected an ‘activated’ 33KDa form of recombinant ADAMDEC1 in the supernatant from un-
stimulated ADAMDEC1-transfected HEK293 cells. 
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In order to demonstrate that ADAMDEC1 is secreted extracellularly from mature activated 
macrophages, human MDM were cultured in vitro, to induce expression of ADAMDEC1.  
These mature cells were then stimulated with HkEc for 4-24 hours.  At 24 hours a significant 
increase in mRNA ADAMDEC1 was observed (Figure 4.12).  No change was seen at 4 hours.  
Analysis of ADAMDEC1 protein levels in the cell lysate by western blot did not however 
demonstrate an increase in protein after stimulation (Figure 4.17).  These results indicate that 
despite the continued transcription of ADAMDEC1, in mature macrophages stimulated with 
bacteria, intracellular levels of ADAMDEC1 protein are reduced, suggesting ADAMDEC1 is 
either secreted or degraded upon activation of MDMs. 
Western blot analysis was subsequently performed on the supernatant from these cells. 
Interestingly, ADAMDEC1 was undetectable in both the un-stimulated and HkEc stimulated 
human MDM cell supernatants.  ADAMDEC1 was also undetectable in the supernatant from 
LPS and HkEc stimulated and un-stimulated peripheral blood derived monocytes, THP1 cells, 
collagenase digested colonic LP cells and CD11b+, MACs bead sorted, colonic LP 
mononuclear cells from C57BL/6 mice, cultured for 4 and 24 hours with and without HkEc.  
These results were unexpected and challenged the presupposition that ADAMDEC1 is 
secreted extracellularly from monocyte derived, and intestinal, macrophages. It is possible 
however that this method was not sensitive enough for detection.  Lund and colleagues 
concentrated the HEK293 cell supernatant prior to analysis. 
 
Figure 4.16: Immunoblot of ADAMDEC1-transfected HEK293 cells and supernatant. 
Cells were stimulated with (+) and without (-) Brefeldin A (BA). The protein lysates were probed 
with an antibody targeting the N-terminus of human ADAMDEC1. A band was present in the 
lysates from ADAMDEC1 (A) transfected cells at ~70KDa, which increased with BA 
stimulation. The supernatant from unstimulated transfected cells demonstrated a band at 
~25KDa, not present in the vector alone (V).   
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When the work by Lund and colleagues was replicated in our laboratory, a western blot of the 
supernatant from HEK293 cells transfected with ADAMDEC1, revealed a band at about 
25KDa, which was absent in the vector supernatant (figure 4.16). This molecular weight would 
be consistent with the processed prodomain of ADAMDEC1, and was clearly visible without 
first concentrating the supernatant. 
The HEK293 cell line, originally derived from embryonic kidney cells, is phenotypically very 
different from macrophages and is unlikely to contain many of the characteristics of a 
macrophage such the ‘machinery’ required for vesicle trafficking, protein secretion or indeed 
many of the signalling pathways.  As such it is probable that the observed secretion of 
ADAMDEC1 from the transfected HEK293 cell supernatant is not what happens 
physiologically in macrophages. 
It is possible, however, that ADAMDEC1 maybe rapidly sequestered and/or degraded 
extracellularly following secretion and as such may not be detected.  It is recognised that 
alpha-2-macroglobulin, an abundant plasma protein, forms an irreversible complex with MMPs 
in the extracellular fluid which is then cleared by scavenger receptor mediated endocytosis 
[391].  Recombinant ADAMDEC1 has been shown to cleave plasma derived human alpha-2 
macroglobulin (α2M) and form stable α2M-ADAMDEC1 complexes in vitro [265]. 
An alternative explanation for the loss of protein expression following bacterial stimulation of 
MDM could be that ADAMDEC1 is secreted into the phagolysosome. MMP12 is secreted into 
the phagosome where it is involved in bacterial killing [418]. Intestinal macrophages are 
classically highly phagocytic and bactericidal compared with inflammatory MDM [419], 
perhaps ADAMDEC1 is important in intracellular bacterial killing and degraded along with the 
bacteria within the lysosome?   
 
4.2.12 Intracellular Location and Processing of ADAMDEC1 
In order to investigate where ADAMDEC1 is located within the naïve MDM and ascertain 
where it is transported, and how it is processed, following bacterial stimulation, THP1 cells 
and human MDMs were stimulated with HkEc in the presence or absence of inhibitors of 
vesicle trafficking.  The protein expression of ADAMDEC1 was measured by western blot in 
cell lysates and supernatant.  
Brefeldin A, an inhibitor of ER to Golgi transport, was not found to alter the expression of 
ADAMDEC1 in human MDM (Figure 4.17-4.18).  This result differs from that seen with 
HEK293 cells where brefeldin A increased intracellular levels of ADAMDEC1 and blocked 
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secretion into the supernatant (Figure 4.16).  This observation in MDM supports the previous 
finding that the protein may not be secreted by the classical pathway in macrophages.  It 
remains possible that ADAMDEC1 is cytosolic and/or secreted by an alternate pathway. 
Cytosolic proteins are degraded by autophagy, a process by which proteins are taken up into 
a double membrane autophagosome which fuses with a lysosome or late endosomes, or by 
ubiquitination and proteasomal degradation.  
The protein expression of ADAMDEC1 in stimulated MDM was increased by addition of 
Bafilomycin A, an inhibitor of maturation of autophagocytic vacuoles, which acts by preventing 
fusion between the autophagosome and lysosomes by inhibiting vacuolar H+ ATPase (Figure 
4.17-4.18).  ADAMDEC1 is also increased by 3-methyladenine (3MA) (Figure 4.18), inhibits 
autophagy by blocking autophagosome formation via the inhibition of type III 
Phosphatidylinositol 3-kinases (PI-3K). These results suggest that following activation of MDM 
with HkEc ADAMDEC1 is transported from the cytosol to the autophagosome. 
Interestingly monensin, a proton ionophore, which inhibits acidification of the lysosome, did 
not increase the protein expression of ADAMDEC1 (Figure 4.17-4.18), suggesting 
degradation of ADAMDEC1 does not appear to occur in the lysosome. 
However, intracellular protein levels of ADAMDEC1 were increased by adding MG132, an 
inhibitor of proteasomal degradation (Figure 4.18).  This suggests that the ubiquitination-
proteasomal pathway plays a role in degradation of ADAMDEC1.  Either it is degraded directly 
by the proteasome or an inhibitor of ADAMDEC1 is degraded by proteosomal degradation. 
 
Figure 4.17: The protein expression of ADAMDEC1 is upregulated in MDM by 
Bafilomycin A but not HkEc, Brefeldin or Monensin. Following sterile culture of human 
peripheral blood MDM in FCS for seven days, cells were either unstimulated (US) or 
stimulated for 24 hours with HkEc. Inhibitors of vesicle trafficking were then added for an 
additional four hours before lysing. Western blot was performed, cell lysates were probed with 
an antibody which detected the proform of ADAMDEC1 (53KDa). Actin was used as a control. 
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Figure 4.18:  ADAMDEC1 is upregulated in human MDM by inhibitors of the 
autophagosome and proteosomal degradation. Human MDM were stimulated for 24 hour 
with HkEc prior to four hours stimulation with vesicle trafficking molecules before lysing. 
Western blot was performed, cell lysates were probed with an antibody which detected the 
proform of ADAMDEC1 (53KDa). ADAMDEC1 was upregulated by 3MA, Bafilomycin A (BafA) 
and MG132. No change in protein expression was seen with Brefeldin A (BrefA) or monensin 
(Mon).  Actin was used as a control. 
 
 
4.2.13 Subcellular Fractionation of Differentiated THP1 Cell 
By fractionation of THP1 cells, stimulated for 24 hours with HkEc, over a sucrose gradient, we 
were able to ascertain the location of ADAMDEC1 within the cell.  By probing the cell fractions 
with antibodies directed towards either the C terminus or prodomain (N terminus) of 
ADAMDEC1 the distribution of the pro-form (53KDa) and the cleaved (‘activated’) subunits 
were visualised separately.  The N terminus antibody detects both the full length ADAMDEC1 
(53KDa) and activated form (37KDa) whilst the C terminus antibody detects the full length and 
prodomain (26KDa). Using markers for each different location within the cell it was possible to 
infer where the full length ADAMDEC1 and cleaved subunits may reside (Figure 4.19).  
The results support that ADAMDEC1 is not membrane bound. The proform of ADAMDEC1 
was present within the cytosolic compartment. Following cleavage, the 26KDa prodomain was 
seen within the Golgi fractions, furin cleavage of full length ADAMs has previously been 
described in the Golgi [256](12514095). A band was also seen at 37KDa subunit (consistent 
with the mature form of ADAMDEC1) in the vesicle fractions associated with the late 
endosome and phagosomes.  
The distribution of the mature form of ADAMDEC1 mirrored that of LC3 (a marker of the 
autophagosome formation) within the cell fractions (figure 4.19). LC3, a mammalian 
homologue of yeast Atg8, is the classic marker of autophagosome formation. It is a cytosolic 
protein (LC3I; 18KDa) which is taken up on to the autophagosome membrane (LC3II; 16KDa). 
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As it is bound to both sides of the autophagosome membrane, LC3 on the internal membrane 
is degraded by lysosomal degradation within the autophagolysosome and as such is used a 
marker of autophagy [420]. 
The ADAMDEC1 c-terminus antibody also revealed a smaller ≈35KDa molecule in the 
cytosolic fractions (Figure 4.19) which was not present in the vesicle fractions.  This 
observation suggests that ADAMDEC1 may undergo a form of post translational modification 
i.e. glycosylation or perhaps even mono-ubiquination following cleavage of the prodomain.  
Mature ADAMDEC1 has a number of predicted glycosylation sites and is reported to have 
been modified with at least one N-linked glycan [265].  Using site directed mutagenesis the 
Aspartate at position 237 (N237) has recently been shown to be an active glycosylation site 
in ADAMDEC1.  When mutated, and replaced by a glutamate, N237Q exhibits increased 
electrophoretic mobility consistent with a molecule of a lower molecular weight (≈30KDa 
compared with 33KDa).  It is possible that once cleaved, mature ADAMDEC1 is glycosylated 
either within the vesicles or in order to be transported to the vesicles.  
One of the SNPs, located in the truncated disintegrin-like domain, identified in our 
ADAMDEC1low outlier patients, resulted in an amino acid change from Aspartate to Serine, 
N444S.  In order to predict whether this Aspartate is a glycosylation site, and if so whether this 
amino acid change could potentially result in reduced glycosylation, the amino acid sequence 
was analysed using the Hirst group GPP predictor server (Nottingham university) [421].  This 
program claims to predict Aspartate-glycosylation sites with an accuracy of 92%.  Using this 
technology N444 was not predicted to be a glycosylation site however the Serine at this site 
(S444) is predicted to be glycosylated (accuracy of 92%).  The implication of this potential 
altered glycosylation state has yet to be determined but one may envisage that it would affect 
protein folding, transport within the cell perhaps even substrate interaction. 
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Figure 4.19:  Subcellular fractionation of HkEc stimulated THP1 cells, over a sucrose 
gradient. THP1 cells were stimulated for 24 hours with HkEc. Cells were fractionated and the 
post-nuclear supernatant was layered over a sucrose gradient, the percentage of which was 
measured by a refractometer.  Each fraction was probed with antibodies for the C terminus 
and prodomain of human ADAMDEC1 and organelle markers. The proform of ADAMDEC1 
was present in the cytosolic compartment (fractions 1-4), the prodomain was seen in the Golgi 
compartment (fractions 4-5) and the mature form was seen predominantly in the vesicle 
compartment (fractions 6-7).  
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4.3 Discussion 
The tissue distribution of ADAMDEC1 is striking. In health ADAMDEC1 is almost exclusively 
expressed in the GI tract, predominately in the ileum and colon, with the highest expression 
found in the small bowel.  This expression profile correlates with the sites at which CD 
pathology are found.  Interestingly it is the only ADAM protein to date which has been reported 
as solely expressed within the gut and it is the most highly expressed ADAM in the GI tract.  
Within the intestinal wall ADAMDEC1 is not seen in the epithelial layer, it is present within 
mononuclear phagocytes in the LP.  Historically the ability to distinguish the mononuclear 
phagocyte subsets unambiguously in the intestine had been complicated by the fact that many 
of the surface markers used to identify DCs and macrophages are expressed, at different 
levels, by multiple cell types in the intestine.  In recent years, multi-coloured FACS analysis 
has been employed by a number of groups to differentiate these cell populations using a 
combination of surface expression markers [407].  By interrogating gene expression profile 
data sets of multi-coloured FACS sorted murine intestinal cells, published online, we identified 
that ADAMDEC1 was expressed in CD11b+ CD11c+/- F480+ Ly6clo CD103- CX3CR1Hi 
intestinal CD45+ populations in the steady state.  Classically these cells have been described 
as resident intestinal macrophages which are reported as functionally phagocytic, bactericidal, 
non-migratory and derived from Ly6hi PBMC.  In comparison to MDM recruited to the intestine 
during inflammation, these resident intestinal macrophages are tolerant to TLR stimulation 
and produce constitutive IL10 (see section 1.1.2). 
Functional analysis of this cell population is limited by the isolation process from intestinal 
tissue.  The lengthy ex vivo preparation, which requires collagenase digestion and FACS or 
MACS sorting of live cells, inevitably alters the state of differentiation and activation of the 
cells, and potentially compromises their viability and function.  As we found ADAMDEC1 
expression in CD11b+ cells isolated by MACS was significantly reduced 24 hours after plating 
in sterile culture conditions.  Whether this was secondary to reduced cell viability or change in 
the cellular environment is unknown but it does pose the question whether results obtained 
from in vitro studies of LP cells isolated in this manner actually reflect what is happening in 
vivo.  Due to the challenges of working with isolated intestinal LP macrophages, and carrying 
out meaningful functional assays on these cells, subsequent studies were carried out using 
peripheral blood MDM and activated THP1 cells cultured in sterile conditions. Ideally further 
studies should be carried out using LP macrophages, which could be isolated by laser capture 
dissection thereby minimising the effects of the digestion process [121]. 
As discussed in Chapter Three, ADAMDEC1 has been reported to be significantly up 
regulated at extra-intestinal sites of tissue inflammation (see section 3.12), suggesting it may 
139 
play a role in the acute inflammatory response.  We and other investigators have 
demonstrated a rapid and robust induction of ADAMDEC1, in monocytes and MDM, in 
response to bacterial antigens, in particular LPS [403], supporting a role as a bacterial 
response gene. iMNPs which express ADAMDEC1 are ideally positioned in the LP, beneath 
a monolayer of epithelial cells, to respond to bacteria invading the intestinal wall, they are the 
sentinels of the intestinal barrier and are professional phagocytes, experts in bacterial 
identification and clearance.  Although the action of ADAMDEC1 remains unknown, based on 
the host cell characteristics, tissue expression profile and response to bacterial antigens, it is 
probable that ADAMDEC1 plays a role in bacterial clearance by intestinal macrophages and 
contributes to gut homeostasis.  
Although present at extra-intestinal sites during inflammation, ADAMDEC1 is primarily 
restricted to the gut mononuclear phagocytes in health.  A number of studies and online data 
sets demonstrate ADAMDEC1 is not detectable in mature macrophage populations resident 
in extra-intestinal tissue such as the peritoneum, lung, liver and adipose and is only moderately 
expressed in mature splenic macrophages relative to colonic macrophages [409], [410].  As a 
consequence it has been proposed that the tissue expression of ADAMDEC1, in the GI tract, 
is a consequence of background exposure to, or ‘priming’ by, LPS [263].  This supposition is 
challenged however by the finding that ADAMDEC1 is present in the GI tracts of germ free 
mice and in the un-colonised sterile prenatal embryological bowel. Furthermore we, and other 
investigators, have demonstrated that ADAMDEC1 is significantly up-regulated during 
monocyte to macrophage differentiation in sterile culture in the absence of bacterial ligands.  
These findings suggest therefore that exposure to bacterial antigens is not a prerequisite for 
ADAMDEC1 expression in the MDM or gut.  
An alternate explanation for the tissue and cellular expression of ADAMDEC1 may be found 
in the origin of resident tissue macrophages.  Historically, all tissue resident macrophages 
were believed to be part of a linear mononuclear phagocytic system (MPS) and originate from 
circulating blood monocytes, similar to inflammatory macrophages.  However, in recent years, 
fate mapping studies in mice [422]–[424] have challenged this view and provoked re-
emergence of the concept that resident macrophages from the skin (Langerhan cells) [425], 
brain (microglial cells) [426], lung [427], kidney and liver (Kupffer cells) are laid down early in 
development, arise from embryologic progenitors in the yolk sac, and or foetal liver and 
undergo clonal expansion in situ with little or no contribution from circulating monocytes in 
adult life. 
This does not appear to be the case in the gut however.  A number of studies using animal 
models have demonstrated that the intestinal resident macrophage population requires 
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continuous replenishment from circulating blood monocytes and in adulthood is derived from 
haemopoietic stem cells.  Stephan Jung and colleagues were first to demonstrate that 
inflammatory Ly6Chi monocytes enter the gut mucosa to replenish the macrophage 
compartment, albeit following repeated diphtheria-toxin-mediated depletion of resident 
macrophages [24].  This group proceeded to demonstrate that green fluorescent 
protein- (GFP) tagged monocytes injected into the circulation of naïve mice migrate to the gut 
and differentiate into macrophages where they develop the expression profile of resident gut 
macrophages in the steady state [408].  Alan Mowat’s group extended this work further and 
demonstrated that bone marrow derived Ly6Chi monocytes constitutively enter, un-
manipulated, the steady state colonic mucosa and differentiate locally through short-lived 
CX3CR1int intermediaries to give rise to CX3CR1hi macrophages, a process which involves 
down-regulation of Ly6C, and up-regulation of F4/80, CD11c, and CX3CR1 and is dependent 
on the chemokine CC ligand (CCL)2 CCR2 [28].  Recently, Alan Mowat and Frederick 
Geissman’s groups published the results of a collaboration in which they employed a 
combination of fate mapping models and monocytopenic mice, together with bone marrow 
chimeric and parabiotic models in order to elucidate the origins of the intestinal resident 
macrophage.  Their results suggest that whilst embryonic precursors seed the intestinal 
mucosa and proliferate in situ in the neonatal period, these cells do not persist in adult intestine.  
Instead, they are replaced around the time of weaning by an influx of circulating Ly6Chi 
monocytes that differentiated locally into mature, anti-inflammatory macrophages [43].  This 
process of continuous renewal by circulating monocytes is believed to continue throughout 
adult life to maintain a normal intestinal macrophage pool. 
 
It is probable therefore that the reason ADAMDEC1 is selectively expressed in the bowel is 
because it is the only tissue in which resident macrophages are monocyte derived in the naïve 
non inflamed state.  It follows that ADAMDEC1 may be observed at extra-intestinal sites during 
inflammation as circulating PBMC are recruited to tissues during inflammation and 
differentiate locally into inflammatory MDM.  Up-regulation of ADAMDEC1 in these infiltrating 
monocytes is likely to account for the observed increase in tissue expression at extra-intestinal 
sites of inflammation rather than up-regulation of ADAMDEC1 in mature resident cells.  In 
support of this theory a study by Stephan Jung and colleagues compared expression profiles 
of isolated resident intestinal macrophages pre and during an experimental colitis [408]. 
Extraction of ADAMDEC1 levels from the GEO data set, GSE42101, demonstrate very little 
change in ADAMDEC1 expression in the resident macrophage population during inflammation 
but a significant up-regulation in recruited monocytes differentiating into macrophages in the 
inflamed tissue (Figure 4.20). 
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Figure 4.20: Comparison of expression profiles of isolated resident intestinal 
macrophages pre and during an experimental colitis. Extrapolation of Adamdec1 levels 
from the online data set (GSE42101) [408] demonstrated very little change in Adamdec1 
expression in the resident macrophage population during a chemical (Day 3 DSS) induced 
colitis but a significant up-regulation in Ly6CHi monocytes recruited to the inflamed tissue. 
 
 
Following activation conflicting evidence exists as to whether ADAMDEC1 is secreted or not. 
The data presented here suggests ADAMDEC1 is not secreted from MDM via the classical 
ER-Golgi secretion pathway (Figure 4.21). It may interact with the autophagocytic pathway 
perhaps in a similar manner to the ATG proteins. This will be discussed further in Chapter 7 
however the studies to date remain preliminary and require further study. 
 
 
142 
 
 
Figure 4.10: Secretion pathways from MDM. Classically proteins are transported from the 
endoplasmic reticulum (ER) to the Golgi, packaged into vesicles and secreted by exocytosis 
at the cell membrane. Proteins not secreted are degraded within the lysosome. The 
autophagosome removes cytosolic proteins. Fusion of the autophagosome with a lysosome 
allows lysosomal degradation of the autophagosome contents. Brefeldin A (Bref A) inhibits ER 
to Golgi transport, Bafilomycin A (Baf A) inhibits autophagosome-lysosome fusion and 
Monensin inhibits lysosomal acidification and degradation of contents. Diagram adapted from 
http://www.tutorvista.com/biology/function-of-lysosomes. 
 
 
4.4 Conclusion 
ADAMDEC1 is up-regulated in monocyte to macrophage differentiation and in response to 
bacterial antigens; this finding suggests ADAMDEC1 is a bacterial response gene with a role 
in the acute inflammatory response, albeit exposure to bacterial antigens is not a prerequisite 
to ADAMDEC1 expression in the gut.  The restricted expression profile of ADAMDEC1 in the 
steady state, in macrophages in the intestinal LP macrophages, indicates that it may play a 
central role in gut homeostasis in healthy individuals. Studies exploiting vesicle trafficking and 
protein degradation inhibitors, and subcellular fractionation of macrophages, suggest that 
ADAMDEC1 is not secreted from macrophages via the classical ER-Golgi secretion pathway, 
but, instead, may be a cytosolic molecule which interacts with the autophagocytic pathway.  
Further studies are required to establish the mode and site of action of this molecule.  
  
Monensin 
Baf A 
Bref A 
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5. Investigation of ADAMDEC1 in GI Tract using a Chemical Induced Mouse 
Model of Colitis, DSS, and Characterisation of the Adamdec1-/- Mouse 
 
5.1 Introduction 
Over the last three decades a significant number of animal models have been developed to 
investigate bowel inflammation [428], [429].  Genetically modified animals; gene knockout (i.e.: 
IL10-/-  [430]) and inbred strains which develop a spontaneous colitis (ie: the SAMP mouse 
[431]), adoptive transfer [432] and chemical [433] and bacterial [434] inducible models of colitis 
have all been extensively used.  Whilst these models cannot replicate the complex pathology 
of IBD they are an excellent way to investigate the intestinal immune response and function 
of individual molecules.   
Mice are frequently used to investigate bowel inflammation and were chosen as the preferred 
animal model to study the role of ADAMDEC1 in the intestinal tract for a number of biological 
and practical reasons.  Genetically humans and mice are very similar; 99% of mouse genes 
have a homolog in the human genome [435].  Many of the immunological processes are 
shared between mouse and human, although differences have been reported [436], [437].  
Furthermore the mouse immune system is well characterised.  Both humans and mice are 
mammals, they breast feed their young prior to weaning, and have a prenatal sterile gut which 
is colonised with commensal bacteria during and following birth.  They require comparable 
conditions to survive and are susceptible to similar environmental insults such as infectious 
pathogens and toxins.  From a practical point of view mice are relatively small, have a short 
gestation period, tend to have large, numerous litters and are relatively cheap to house. 
Since the techniques for gene targeting in mice were established in the 1980s, by the 2007 
Nobel Laureates Mario Capecchi, Oliver Smithies and Martin Evans, the use of gene specific 
knockout animal models has allowed us to selectively examine the action of individual 
molecules in vivo.  To date a number of ADAMs and MMPs have been knocked out in mice 
and recent publications have reported the functional consequence of loss of individual 
metalloproteases in the intestine [21], [438], [439], [440], [441], [442], [443], [444], [445], [446], 
[447], [398], [272], [448], [449] (Table 5.1). 
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Table 5.1: Target deletion of specific metalloproteases in murine colitis models. The 
susceptibility of individual metalloproteinase gene knockout mice to an acute experimentally 
induced colitis, reported on Pubmed. DSS (dextran sodium sulphate), TNBS (2,4,6-
trinitrobenzenesulfonic acid). 
 
 
Target deletion of specific molecules in mice has enabled substrate identification and 
highlighted vital roles of specific metalloproteases in modulating the inflammatory response 
by influencing leukocyte recruitment and altering the function and activity of cytokines and 
proteases in addition to degrading and remodelling the ECM.  
In order to further examine the role of ADAMDEC1 in vivo and assess its function in gut 
homeostasis and inflammation we purchased three Adamdec1+/- (heterozygote knock out) 
mice from Deltagen which were backcrossed onto C57BL/6 mice (Charles Rivers) for at least 
6 generations. Adamdec1-/- (homozygous knock out) and Adamdec1+/+ (homozygous wild 
type) mice were then exposed to an experimental model of colitis.  
The chemical toxin DSS is a widely used and published method to induce colitis in mice [433], 
[450].  DSS is administered orally; it is usually added to drinking water for 3-7 days.  At an 
appropriate dose it produces an acute colitis within days of the challenge with diarrhoea, 
weight loss and rectal bleeding.  Depending on the prescribed dose, the colitis usually resolves 
following cessation of treatment [451].  A chronic colitis can be induced by recurrent 
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challenges of DSS [452], [453].  The mode of action by which DSS induces colitis is not 
completely understood.  Oral administration of DSS has been shown to render the inner 
colonic mucus layer penetrable to bacteria which allows direct contact between the lumen 
bacteria and the underlying IEC [454].  DSS is also reported as directly toxic to colonic 
epithelial cells, it strips the epithelial layer and results in a breakdown of epithelial integrity 
exposing the underlying LP to the luminal contents and bacteria [455].  Exposure of C57BL/6 
wild type mice to DSS has been described extensively in the literature, the animals challenged 
with this colitogenic agent develop a predominately neutrophilic infiltrate with a continuous 
colitis which resembles UC in humans [452].   
 
 
Hypothesis for Chapter Five 
1. ADAMDEC1 is important in the inflammatory response to colitis 
2. ADAMDEC1 deficiency results in an increased susceptibility to colitis 
 
 
Aims for Chapter Five 
In chapter 4 the tissue expression of Adamdec1 in wild type C57BL/6 mice was illustrated and 
shown to be identical to humans, predominately in the small and large bowel.  Similar to 
humans, murine Adamdec1 is expressed within the LP cells of the intestine within macrophage 
populations.  
The aims of this chapter: 
1. To compare the amino acid sequence for ADAMDEC1 in human and mouse and 
determine whether the protein domains, and potentially functional sites, are conserved 
across the two species.   
2. To document the change in colonic expression of Adamdec1, throughout the course 
of an acute experimentally induced colitis, in mice.   
3. To characterise the Adamdec1 knock out mouse  
4. To study the phenotype of the Adamdec1 knock out mouse following exposure to acute 
and chronic DSS. 
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5.2 Results 
 
5.2.1 Comparison of Human and Mouse ADAMDEC1 Amino Acid Sequences 
Amino acid sequences for human and mouse ADAMDEC1 were retrieved from Ensembl.  As 
illustrated in Chapter 3, human ADAMDEC1 has four transcripts, of which only two are protein 
coding: transcript 001 contains 13 exons but transcript 002 is missing the first two exons. In 
comparison murine Adamdec1 only has one known transcript and contains 14 exons (Figure 
5.1). The amino acid sequence for human ADAMDEC1 transcript 001 was aligned to the 
mouse amino acid sequence for Adamdec1 in SDSC biology work bench [456]. 
 
 
Figure 5.1: Mouse transcript for ADAMDEC1 contains 14 exons. 
 
The human protein is three amino acids longer than mouse (470 amino acids in human 
compared with 467 in the mouse). Alignment analysis demonstrated that the amino acid 
sequence for ADAMDEC1 is highly conserved between human and mouse with 68% 
homology (Figure 5.2).  The prodomain, predicted prodomain cleavage site, metalloprotease 
domain and truncated disintegrin domain are all present in both species.  There is 
conservation of the zinc binding site in the mouse including the unique aspartate residue 
(D362) in ADAMDEC1 which replaces the histidine (H) present in all other ADAMs. 
Furthermore the amino acid N444 which is changed to Serine (S444) in our ADAMDEC1low 
outlier patients, and the surrounding amino acids in this region are conserved.  
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Figure 5.2: ADAMDEC1 is well conserved throughout species with 68% homology 
between human and mouse.  The mouse (top) and human (below) ADAMDEC1 amino acid 
sequences from Ensemble were aligned in SDSC biology work bench. The human protein is 
467 amino acids compared with 470 in the mouse. ↓ indicates the predicted prodomain 
cleavage site. ADAMs have a zinc binding motif which is conserved (boxed in blue). The 
disintegrin domain, the beginning of which is identified by the blue arrow, is truncated in both 
species. The SNP rs3765124, associated with ADAMDEC1low expressors, which results in an 
amino acid change in the disintegrin domain, is conserved in both species and represented 
by the red circle. * Single fully conserved residue : Conservation of strong groups. 
Disintegrin Domain
↓
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5.2.2 Murine DSS Colitis 
5.2.3 DSS dose response in Wild Type C57BL/6 Mice 
In order to choose an appropriate dose of DSS to induce an experimental colitis in our animal 
model, an initial dose response study was performed. 25 wild type C57BL/6 male mice, 8-10 
weeks old, were divided into 5 cages of equal numbers.  Their drinking water was replaced 
with different concentrations of DSS (1%, 2%, 3%, 5%) dissolved in drinking water for 7 days.  
One group of mice did not have DSS added to the water and acted as the control group.  After 
7 days the DSS was replaced by normal drinking water. Weights were measured and stool 
samples collected daily.  Mice that survived the DSS challenge were culled at D15. 
 
Figure 5.3: DSS results in a dose dependent weight loss in C57BL/6 mice.  DSS was 
dissolved in drinking water for 7 days at different percentages. Mice were weighed daily and 
plotted as a percentage of their original weight, error bars represent S.E.M. Dotted red line 
denotes 15% weight loss. Mice were litter mates, age, weight and sex matched, n=5 per group. 
 
The clinical scores; weight loss (Figure 5.3) and change in bowel habit, were similar in each 
group.  Mice exposed to 3-5% DSS developed a rapid and severe response to the treatment; 
they experienced bloody diarrhoea by day 5, lost >15% of their body weight by day 7 and all 
had to be culled by day 10.  In contrast mice exposed to 1% DSS lost very little weight and 
had minimal diarrhoea or PR bleeding. 2% was deemed the ideal concentration of DSS to use 
for further experiments as mice lost <15% of their original weight which was maximal by day 
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10, but all had regained their baseline weight and normal stool consistency by the end of the 
experiment on day 15. 
C57BL/6 mice were exposed to 7 days of 2% DSS.  Mice were sacrificed at each time point 
on days 0, 3, 7, 10, 14.  At each time point, stool samples were examined for consistency and 
blood.  Cardiac puncture was performed and serum saved post mortem.  Colons were 
resected, measured, 5mm snips were taken from distal colon for qPCR and the remainder of 
the colon was sent for histology or digested for FACS analysis. 
 
 
5.2.4 Colonic Expression of Adamdec1 Expression after Exposure to 2% DSS 
Tissue was prepared as described in the Methods Section to isolate RNA and qPCR was 
carried out for Adamdec1.  Gene expression was normalised to the housekeeping gene Ppia, 
which has been shown to be a suitable reference gene for mouse intestine [457], [458].  
Relative transcript levels were determined by the 2−ΔΔCt [459].  
 
Figure 5.4: Adamdec1 is up-regulated in the intestine during DSS induced colitis.  
Wild type mice were exposed to seven days of 2% DSS. a. Quantitative PCR of Adamdec1 
relative to house-keeping gene Ppia in the colon of wild type mice culled at set time points 
during and after the DSS challenge (n=3-4 at each time point). Data represented as mean ± 
SEM. Two tailed unpaired t-test p<0.05*, p<0.001***. 
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Adamdec1 expression in the distal colon of mice exposed to DSS, mirrored the weight loss 
(Figure 5.3) over time. Adamdec1 mRNA levels were progressively and significantly up-
regulated over the first 10 days during which time the mice displayed clinical signs of colitis 
with diarrhoea, PR bleeding and weight loss.  The colonic expression of Adamdec1 returned 
to baseline following cessation of DSS and resolution of clinical signs.  The mRNA levels also 
mirrored the local and systemic inflammatory response as reflected by the immune cell 
recruitment to the bowel and serum cytokine response (Figure 5.12). 
 
5.2.5 Adamdec1 Knock Out Mouse 
As previously demonstrated, ADAMDEC1 is highly and almost exclusively expressed in the 
bowel in the naïve state and is significantly up-regulated in murine bowel during an acute 
experimental colitis, and in MDM in response to enteric bacterial antigens. As such it was 
hypothesised that ADAMDEC1 is an active member of the acute inflammatory response in the 
gut, which responds acutely to tissue injury and subsequent bacterial invasion, either in a pro- 
or anti- inflammatory capacity. In order to ascertain the importance of ADAMDEC1 in the 
intestinal tract, and the consequence of its loss, Adamdec1 knock out mice were employed.  
The Adamdec1 knock out mouse was originally re-derived from a mutated 129/Ola embryonic 
stem cell line with a neomycin resistant cassette inserted into exon 11 of the Adamdec1 
sequence (Figure 5.5).  The mutated embryonic stem cells were injected into C57BL/6 
embryos. The chimera offspring was back crossed at least six generations onto C57BL/6.   
We purchased three female Adamdec1 heterozygote mice from Deltagen and back crossed 
these further onto C57BL/6 mice (Charles Rivers).  Genotyping was performed by PCR of 
genomic DNA isolated from ear clips amplified with recommended Adamdec1 gene specific 
primers for Adamdec1+/+ mice: AGCTTGAGCGCAAACCCAATGCTTC and 
CCTCAGGTACTGATTCATCACACAG, expected size 322bp, and Adamdec1-/- mice: 
GACGAGTTCTTCTGAGGGGATCGATC and CCTCAGGTACTGATTCATCACACAG, 
expected size 600bp (Figure 5.7). 
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Figure 5.5: Generation of the Adamdec1
-/- 
mouse.   A) Schematic diagram of the mouse 
coding isoform of Adamdec1 gene which contains 14 exons.  B) Lac Z neomycin resistant 
cassette was inserted into exon 11 (indicated by red arrow) of the mouse Adamdec1 
sequence.  Deleted endogenous sequence highlighted in green box and flanking vector 
targets highlighted in red box.  Targeting vector arm lengths (represented by a full black line): 
5’: 1.5kb, 3’: 4kb. (Endogenous locus represented by broken black line). 
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Figure 5.6: Genotyping Adamdec1
-/- 
and Adamdec1
+/+
 mice.  (A) Schematic diagram of 
primers used for genotyping and (B) expected results. A combination of gene specific (GS) 
primers target the endogenous Adamdec1 gene and produce a 332bp amplicon on PCR. 
Primers targeting the vector region containing the neomycin (Neo) cassette produce a larger 
600bp amplicon. gDNA from heterozygotes produce both the 332bp and 600bp amplicons.  
(C) Genotyping was performed by PCR of gDNA isolated from mouse ear clips. The parent 
ES lines (negative controls) showed bands representing the endogenous (wild-type) 
Gene #1227 allele.  In contrast, the recombinant embryonic stem cell line 3928 (ES#3928) 
showed an additional band representing the targeted allele from the expected homologous 
recombination event.    
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5.2.6 Verification of Absence of Adamdec1 mRNA in Adamdec1-/- Mouse 
In order to confirm that Adamdec1 mRNA was not expressed in Adamdec1-/- mice qPCR 
(Figure 5.7A) and in situ hybridisation (Figure 5.7B) for Adamdec1 were performed on the 
colon and small bowel of Adamdec1-/- and Adamdec1++ mice.  Adamdec1 was expressed in 
the small and large bowel of wild type mice using both methods. Adamdec1 expression in the 
small intestine was significantly higher than in the colon of wild type mice (p<0.05) similar to 
human tissue. In situ hybridization confirmed Adamdec1 expression was restricted to the 
intestinal LP of wild type mice.  No Adamdec1 expression was detectable in Adamdec1-/- mice 
using either method. 
 
 
5.2.7 Verification of Absence of Protein ADAMDEC1 in Adamdec1-/- Mouse 
In order to verify that ADAMDEC1 protein was not translated in the knock out mouse western 
blot was performed using a rabbit polyclonal antibody, raised against the catalytic site of 
mouse ADAMDEC1, on whole tissue lysate from the small bowel of Adamdec1-/- and wild type 
mice (Figure 5.7C).  Full length recombinant ADAMDEC1 mouse protein, expressed in a 
eukaryotic HEK293 cell line, was used as a positive control and produced a single band at 
~42KDa.  This band was also present in the ADAMDEC1 wild type colon lysate, along with a 
second band at ~35KDa.  Both bands were absent in the tissue lysate from the Adamdec1 
knock out bowel.  The antibody targeted the catalytic domain and as such the bands at 
~42KDa and ~35KDa are likely to represent the full and activated forms of ADAMDEC1 in 
mouse.  Actin was used as a loading control and confirmed equal amounts of protein were 
present.  Immunohistochemical staining of Adamdec1 knock out and wild type mouse bowel, 
using the same antibody confirmed the presence of ADAMDEC1 within the LP cells in wild 
type mice but not in the Adamdec1 knock out mouse (Figure 5.7D). 
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Figure 5.7: Adamdec1 expression is absent in the GI tract of Adamdec1
-/- 
mice.  (A) 
qPCR demonstrates that Adamdec1 expression is higher in the small intestine that the colon 
of wild type (+/+) mice relative to house-keeping gene Ppia. No Adamdec1 expression was 
detectable in Adamdec1
-/- 
mice (-/-).  (B) In situ hybridization was performed on large (LB) and 
small (SB) bowel tissue from wild type and Adamdec1
-/- 
mice in order to ascertain the location 
of the mRNA expression. Adamdec1
 
expressing cells were restricted to the lamina propria 
(Blue stain, yellow arrow) in the SB and LB. Adamdec1 was not detected in the epithelium 
(red arrow). No specific staining was seen in the intestine tissue from Adamdec1
-/- 
mice.  (C) 
Western blot analysis of mouse colonic tissue demonstrated the presence of two bands at ~40 
and 35KDa in the wild type mouse which were absent in the knock out mouse. Actin was used 
as a loading control and recombinant mouse ADAMDEC1 (Control) was run to confirm the 
specificity of the antibody.  (D) Immunohistochemistry revealed that the ADAMDEC1 protein 
was highly expressed (brown stain) in cells located in the lamina propria (yellow arrows) in 
mouse small bowel. Knockout tissue demonstrated no specific staining.   
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5.2.8 Clinical characterisation of the Adamdec1-/- Mouse 
No significant differences were detected during breeding or on physical examination and 
necropsy between naive Adamdec1-/- and Adamdec1+/+ mice.  Both are black mice with no 
characteristic markings.  
Fertility: No problems were noted with fertility.  The number and size of litters were 
comparable between knockout and wild type mice and the pups were born in expected 
Mendelian ratios (male:female ratio 1:1.1, n=179, p=0.5).  
Growth curve: Loss of Adamdec1 had no obvious impact on the health of mice maintained 
in SPF conditions.  No difference in weight was seen between naive age and sex matched 
Adamdec1-/- and Adamdec1+/+ mice (Figure 5.8). 
 
 
Figure 5.8 Adamdec1
-/- 
mice do not exhibit impaired growth.  Growth curves for A) 
male and B) female Adamdec1
-/- 
and Adamdec1
+/+
 mice. No significant difference in weight for 
age and sex matched wild type and Adamdec1
-/- 
mice between the age of 7 to 14 weeks  (n=25 
mice for each sex and genotype). Results at each point expressed as mean ± SEM. 
 
 
Clinically there was no evidence of spontaneous colitis in the knock out mice: Stool 
consistency was the same for each genotype.  Fresh stool samples retrieved from naïve 
Adamdec1-/- were fully formed stool with no evidence of PR bleeding. Knock out mice were 
maintained in SPF conditions for up to one year without the development of spontaneous 
colitis or any other adverse phenotype. 
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5.2.9 Baseline investigations to characterise the Adamdec1-/- Mouse 
Stool cultures were performed by Deltagen and have been checked subsequently on 
numerous occasions by the vets at UCL animal services.  There was no evidence of 
opportunistic infection in either strain. In particular there was no evidence of Helicobacter 
species which may influence the susceptibility of mice to colitis [460]. 
Routine blood tests: A number of routine blood tests were carried out by Deltagen. No 
differences were reported between wild type C57BL/6 and Adamdec1-/- mice:  
 Full blood count: including haemoglobin, white cell counts, platelets; kidney function: 
Urea and creatinine, liver function, bone including calcium and phosphate were tested 
and no differences were noted between genotypes.  
 Markers of systemic inflammation: CRP and ESR were not raised in the knock out 
mice. 
FACS analysis of cells from blood, spleen, bone marrow, peritoneal cavity/lavage and 
intestinal colonic LP cells did not demonstrate a difference in baseline populations between 
knock out and wild type mice in the naïve state.  
Baseline serum cytokines were not raised in either strain as measured by MSD® Mouse Pro-
Inflammatory 7-Plex Ultra-Sensitive Kit (TNF, IFNγ, IL1β, IL6, IL12p70, KC (IL8), IL10) (Figure 
5.12) 
Histology: Both macroscopic and microscopic examination of organs post mortem revealed 
no discrepancies.  These results, in particular those of the small and large bowels, were 
verified in our Adamdec1-/- and Adamdec1+/+ mice.  Large and small bowels were similar in 
weight and length (Figure 5.9A).  Histological examination of the GI tract (Figure 5.9) No 
evidence of intestinal inflammation in the naïve Adamdec1-/- mice.   
Intestinal permeability: Loss of ADAMDEC1 had no significant effect on intestinal 
permeability in the naïve, non-inflamed state (Figure 5.9B).  
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Figure 5.9: Baseline investigations reveal no histological or permeability 
abnormalities in the intestinal tract of naïve Adamdec1
-/- 
mouse. (A) Histology 
examination of the naïve Adamdec1
-/- 
mouse GI tract reveals no obvious morphological 
abnormalities or evidence of inflammation on Hematoxylin & Eosin staining, magnification: 
40x. (B) Intestinal permeability measured by determining the concentration of FITC-Dextran 
(µg/ml) in the serum of Adamdec1+/+ (WT) and Adamdec1-/- (KO) mice. Data are expressed as 
mean ± SEM (n = 3 per genotype), n.s. non-significant. 
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5.2.10 2% DSS Induced Colitis in Adamdec1 Knock Out Mouse 
Adamdec1-/- and Adamdec1+/+ mice were cohoused in UCL animal facility.  Mice were age, 
weight and sex matched.  Diet, ambient temperature, light and living conditions were identical 
for the two groups.  Prior to experimentation mice were rested in the animal facility for at least 
7 days to acclimatize. 2% DSS was added to the drinking water on D0 for seven days and 
then this was replaced with normal drinking water.  Mice were assessed for weighed daily, 
stool samples were collected.  Blood was obtained from tail bleeds and cardiac puncture for 
serum and bowels were resected post mortem for qPCR, FACS and histology.  
 
Clinical Signs 
On examination both strains of mice became clinically unwell and developed a colitis during 
the seven day exposure to 2% DSS. Clinical signs of diarrhoea, rectal bleeding and weight 
loss peaked at D10 in both strains.  
Adamdec1-/- mice were found to be more susceptible to a 2% DSS induced colitis than litter 
mate Adamdec1+/+ mice.  This was evident clinically by an increased and more rapid weight 
loss (p<0.001) (Figure 5.10A) and clinical signs of a more severe and earlier onset colitis with 
bloody diarrhoea.   
In addition to morbidity, mortality (as defined by >15% weight loss) was increased significantly 
(p<0.001) with only 20% survival of Adamdec1-/- mice compared with 80% of wild type at D10 
(Figure 5.10B).  In the surviving mice clinical improvement was seen in both strains from D11 
onwards; mice regained their original weights and stool consistency returned to normal (Figure 
5.10A). 
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Figure 5.10: Loss of Adamdec1 results in an increased systemic response to the 
chemical colitogenic agent; DSS.  Adamdec1
-/-
 (-/-) and wild type Adamdec1
+/+
 (+/+) mice 
were exposed to seven days of 2% DSS. A) The change in original body weight and B) survival 
curves show Adamdec1
-/-
 mice experience significantly greater weight loss and a higher rate 
of mortality, as defined as loss of >15% of body weight, than wild type mice following exposure 
to DSS (combination of 4 experiments, n=25 mice per genotype). Results shown are mean ± 
SEM. p<0.05*, p<0.01** and p<0.001***; two-tailed, unpaired t-test).  
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Mice that are heterozygous for Adamdec1 demonstrated a response which was between that 
of the homozygous knockout and wild type mice (Figure 5.11).  
 
 
Figure 5.11: DSS in Adamdec1+/- mice. Mice that are heterozygous for Adamdec1 
demonstrated a response which was between that of the homozygous knockout and wild type 
mice following exposure to seven days of 2% DSS. Results shown are mean ± SEM 
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Serum Cytokines 
During the course of the experiment tail bleeds, or cardiac puncture, were performed on days 
0, 3, 7, 10, 14, 21.  No significance difference in serum cytokines was seen at baseline (D0) 
(Figure 12) and both strains displayed an increase in proinflammatory cytokines through the 
course of the experiment (Figure 5.12).  However IL1β (p<0.01) was found to be significantly 
elevated in the Adamdec1-/- compared with the wild type mice on day 10 and both IL1β and 
IL6 remained raised and significantly higher in Adamdec1-/- even after the colitis had resolved 
clinically by D14 (p<0.05).  TNFα, IFNγ and KC (IL8) were not found to be significantly 
different.  The anti-inflammatory cytokine IL10 was significantly lower in Adamdec1-/- 
compared with the wild type mice on Day 7 (p<0.05).  
 
 
Figure 5.12: Adamdec1
+/+
 mice display increased serum levels of IL1β and IL6 
compared with wild type mice following exposure to DSS.  Serum IL6, IL1β, TNF, INFγ, 
KC (IL8), IL10 were measured in naïve mice, day 7, 10 and 14 days after DSS, in tail bleed 
and cardiac puncture serum (n=5 mice per group, these results have been verified in a second 
cohort, data not shown). A significant increase in the serum cytokines IL1β and IL6 are seen 
by day 10 and 14, whereas IL10 was lower on day 14, in Adamdec1
-/-
 (black box) compared 
with Adamdec1
+/+
 mice (clear box).  Results shown are mean ± SEM (p<0.05*, p<0.01** and 
p<0.001***; two-tailed, unpaired t-test). 
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Histology 
Mice were culled on Day 5, 9 and 21 to determine histological evidence of colitis.  At each 
time point comparison was made with naïve bowel (Figure 5.13).  As previously discussed 
(section 5.29) no macroscopic or microscopic differences were observed in the colon of 
Adamdec1-/- naïve mice compared with Adamdec1+/+ naïve mice.  By  D9 both strains had 
developed shorter colons, as previously described in association with DSS colitis in C57BL/6 
mice [461], however a significant difference in length was also observed between the knock 
out and wild type mouse at this time point; the Adamdec1-/- colons were found to be 
significantly shorter (p<0.01) (Figure 5.13A-B). 
Consistent with clinical signs, both strains developed evidence of a microscopic colitis with 
increased cell infiltration, crypt elongation, distortion and ulceration, maximal at D9.  This 
inflammation was continuous throughout the length of the colon.  The Adamdec1-/- mice 
developed more severe histological signs of inflammation which preceded the wild type by 
days as can be seen on the H&E stained slides, on D5 and D9 (Figure 5.13C),. 
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Figure 5.13: Loss of Adamdec1 results in an increased susceptibility to DSS induced 
colitis.  (A) Representative photographs of colons resected post mortem from Adamdec1
-/- 
(-
/-) and wild type (+/+) mice on day 9 post DSS. The colons from Adamdec1
-/-
 mice contained 
bloody stools, seen here in the shrunken caecum, and were significantly shorter than those 
from wild type mice.  (B) Colon lengths on day 9 (n=7 per genotype). Data represented as 
mean ± SEM, unpaired, two tailed t-test, **p<0.01   (C) Representative image of haematoxylin 
and eosin (H&E) stained large bowel tissue (20× magnification, scale bar: 200 µm) on days 5, 
9 and 21 after the DSS challenge demonstrate a more severe colitis in the Adamdec1
-/- 
mice 
with increased cellular infiltration, crypt distortion on day 5 and 9 and ulceration on day 9 in 
the -/- mice.  On day 21 the colons of the surviving Adamdec1
-/-
 and wild type mice showed 
resolution of inflammation with normal tissue architecture and similar histological appearances 
on H&E staining. 
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Cellular Recruitment Determined by FACS 
As discussed earlier (Figure 5.14) no difference was seen in the number of cells or cellular 
composition within the colonic LP in naive Adamdec1-/- mice compared with wild type.  
Following the introduction of oral DSS, Adamdec1-/- mice developed an early and robust 
increase in cell numbers by day 3 compared with base line (P>0.001).  By D7 the total cell 
numbers within the colonic LP was significantly greater in Adamdec1-/- mice than wild type 
(p<0.01) (Figure 5.14). 
 
Figure 5.14: Adamdec1
-/- 
mice have an early robust cellular infiltration into the colon 
following exposure to DSS. The total number of colonic lamina propria cells were counted 
following EDTA removal of epithelial layer and collagenase digestion of the large bowel, 
excluding the caecum. (5 mice per genotype at each time point). Open boxes represent wild 
type mice and black boxes represent knock out mice. Results expressed as mean ± SEM, 
two tailed, unpaired t-test p<0.01**, p<0,001***. 
 
 
FACS analysis of the colonic LP cell populations at each time point following exposure to DSS 
was performed for each genotype: An early increase in the proportion (Figure 5.15A) and 
number (Figure 5.15B) of neutrophils (Cd11b+ Gr1+ F480-) recruited to the colon by day 3 were 
observed in Adamdec1-/- mice (p<0.001).  In comparison Adamdec1+/+ mice showed a 
significantly less neutrophilic infiltration at this early stage (p<0.01).  By D7 a robust 
inflammatory response was seen in both strains with an increase in the recruitment of 
mononuclear cells: CD11b+ GR1low F480Hi MDMs. The proportion of these iMNPs did not differ 
between genotype, in particular no cell population was missing or grossly over represented. 
165 
The total number of recruited cells remained significantly greater in Adamdec1-/- mice on D7 
(p<0.01) representing the exuberant inflammatory response to DSS in this knockout genotype. 
 
Figure 5.15: Adamdec1
-/- 
mice have an early robust neutrophilic infiltration into the 
colon following exposure to DSS.  (A) Representative FACS plots of isolated colonic LP 
cells in naïve mice (D0) and 3 days post DSS (D3) in Adamdec1 knock out (-/-) and wild type 
(+/+).  The proportion of neutrophils (CD11b
+
/Gr-1
+
, red box) and macrophages (CD11b
+
/Gr-
1
-
, black box) were determined using FACS analysis. (B) Graphs illustrating the number of (i) 
neutrophils (CD11b
+
/Gr-1
+
) and (ii) macrophages (CD11b
+
/Gr-1
-
), adjusted for cells numbers 
were plotted.  In naive wild type and Adamdec1
-/- 
mice (day 0) levels of tissue resident 
macrophages and neutrophils are similar.  A significant increase in neutrophils, corrected for 
cell numbers, was observed in the colonic LP of knockout mice exposed to DSS for three days 
(p<0.001).  Wild type animals did not demonstrate a significant increase in neutrophil numbers 
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by day three.  The number of tissue macrophages, corrected for cell numbers, did not 
significantly change after three days of DSS exposure in either genotype.  Results are 
expressed as the mean ± SEM *p<0.05, **p<0.01 (5 mice per genotype, at each time point).  
 
qPCR 
The increased expression of neutrophil marker, lactoferrin, in the Adamdec1+/+ mice support 
the histological findings and FACS analysis, of an exaggerated neutrophilic infiltrate in early 
stages following exposure to DSS in the knock out mouse (Figure 5.16).  
 
 
Figure 5.16: Expression of neutrophil marker, lactoferrin, in the Adamdec1-/- and 
Adamdec1+/+ mice following exposure to DSS. The expression of lactoferrin, relative to 
base line on day 0 and house-keeping gene, Ppia (3 mice per genotype at each time point) 
Open boxes represent wild type mice, black boxes represent knock out mice. Results 
presented as mean ± SEM 
 
 
5.2.11 Chronic DSS 
Studies in which mice have been exposed to recurrent challenges with DSS have been 
published and report development of a chronic colitis.  Male Adamdec1-/- and Adamdec1+/+ 
mice were exposed to three consecutive 7 day challenges of 2% DSS.  After each challenge 
a period of recovery was permitted; between the first and second challenge 14 days recovery 
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was permitted, after the second challenge the recovery was extended to 28 days before the 
final 7 days of DSS.  The mice were monitored for 12 weeks in total. 
Adamdec1 knock out mice demonstrated a failure to thrive following the third challenge of 
DSS, illustrated by significantly reduction in body weight at the end of the experiment on day 
84 (p<0.001) (Figure 5.17).  Despite 3 weeks of recovery following the final DSS challenge the 
knock out mice failed to regain weight, unlike the wild type mice which regained weight and 
continued to thrive.  
 
 
Figure 5.17: Adamdec1
-/-
 mice were more susceptible to a model of chronic colitis.  
Male mice were exposed to three 7 day challenges of DSS; starting on days 0, 21 and 56 
(n=16 per genotype). Adamdec1 knock out mice demonstrated a failure to thrive following the 
third challenge of DSS, illustrated here by significantly reduction in body weight by day 84 at 
the end of the experiment (p<0.001, unpaired, two tailed, t-test). Results presented as mean 
± SEM. 
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5.3 Discussion 
In Chapter 4 the similarity between tissue and cellular distribution of ADAMDEC1 in mice and 
humans was demonstrated. In this chapter, ADAMDEC1 was shown to be highly conserved 
at the amino acid level. The domains and features which make ADAMDEC1 a unique ADAM 
protein in humans, are conserved in the mouse.  As such it is probable that the function of 
ADAMDEC1 and its substrate interactions are comparable in mouse and human.  Mice were 
thereby deemed a suitable animal model in which to study this molecule and in vivo studies 
were performed on this animal species to further investigate the role of ADAMDEC1 in the 
intestinal inflammatory response.  
C57BL/6 mice were exposed to 2% DSS colitis.  In response to this colitogenic agent 
Adamdec1 was up-regulated in the large bowel.  Exposure of wild type mice to this dose of 
DSS induced a self-limiting colitis, the intestinal expression of Adamdec1 mirrored the local 
and systemic clinical response, peaking at the height of inflammation and returning to baseline 
as the colitis resolved.  The dynamic changes in expression of Adamdec1 in response to 
intestinal inflammation would suggest that the molecule has a role in the acute inflammatory 
response in the gut.  
Whether the observed increase in tissue expression of Adamdec1, in response to DSS colitis, 
is due to up-regulated expression within local resident cells or recruitment of Adamdec1 
expressing immune cells to the site of injury remains to be determined.  Evidence from the 
publically available dataset (GSE42101) would suggest the latter. This study, which was 
discussed in Chapter 5 (Figure 4.19), examined transcript profiles of resident and recruited 
MDM in the intestine pre and during a DSS colitis.  Although highly expressed on resident 
intestinal macrophages, Adamdec1 was not significantly up-regulated in these cells following 
exposure to DSS. Adamdec1 was however up-regulated on maturing MDM recruited to the 
inflamed bowel where they developed a transcript profile similar to the resident intestinal 
macrophages [408].  In our study the tissue expression of Adamdec1 does mirror the 
recruitment of cells to the inflamed bowel which would support this result. 
The finding that colonic Adamdec1 was increased in response to a murine experimental colitis 
suggests that the reduced expression of ADAMDEC1 in the bowel of patients with IBD, 
reported by a number of independent sources, is not secondary to intestinal inflammation per 
se.  One could argue however that patients with IBD experience chronic intestinal inflammation 
and as such the colonic expression of murine Adamdec1 should have been measured 
following the induction of chronic DSS.  Indeed, further studies are required to assess both 
the colonic expression of Adamdec1 and change in cellular composition throughout the course 
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of a chronic colitis induced by recurrent challenges of DSS.  It is also plausible that the 
response of Adamdec1 to inflammation may differ in mice and humans.  This is unlikely, 
particularly as ADAMDEC1 is up-regulated at extra-intestinal sites of chronic inflammation in 
humans [331], [334], and in human MDM in response to bacterial stimulation. Another 
possibility is that the low levels of ADAMDEC1 observed in patients with CD may actually 
predispose to intestinal inflammation.  
The Adamdec1 knock out mouse was employed to investigate the effect of Adamdec1 
deficiency in an animal model of colitis.  The Adamdec1 knock out mouse does not display 
evidence of spontaneous colitis or systemic inflammation in the naïve state but, when 
challenged, was found to have an increased susceptibility to acute and chronic chemical 
induced colitis: In the absence of Adamdec1 a more severe colitis and increased mortality 
were observed in response to DSS with an exaggerated neutrophil recruitment to the bowel 
in the early stages of inflammation, raised serum IL-1β and IL-6 and reduction of the anti-
inflammatory cytokine IL-10. Although Il-10 was raised in the knock out mice on day 14 this 
result did not meet statistical significance and on repeat experiment IL-10 was not raised in 
the knockout mice, this discrepancy would suggest that the initial cytokine experiment alone 
was as underpowered.  Chronic exposure to DSS, in the absence of Adamdec1 resulted in a 
failure to thrive. Together these findings provide an in vivo role for Adamdec1 in the mouse 
and the first piece of evidence linking ADAMDEC1 to a regulatory function in bowel immunity.  
Furthermore they support the possibility that ADAMDEC1 deficiency in humans may 
predispose to intestinal inflammation. 
ADAMDEC1 is not the only metalloprotease to play a role in the acute inflammatory response 
in the intestine to DSS.  Similar to Adamdec1 a number of metalloproteases have been 
reported as up-regulated in the colon of mice and rats following DSS exposure [21]. Target 
deletion of ADAM17 [449], MMP2 and MMP10 have shown to result in an increased 
susceptibility to DSS induced colitis, whereas deletion of MMP7 or MMP9 provide protection 
against chemical colitis (Table 5.1), reviewed by O’Shea and Smith, 2015 [21].  ADAMDEC1 
is, however, the only member of the metalloprotease family, expressed in the LP of the gut, to 
be reported as under-expressed in patients with CD to date, which suggests it may be 
associated with disease pathogenesis.  
The pathophysiology of DSS colitis in mice is not fully understood.  It is widely accepted that 
DSS is toxic to epithelial cells and causes defects in the epithelial barrier integrity, including 
break down in the tight junction complex with a loss of tight junction proteins [462], a local 
increase in pro-inflammatory cytokines and epithelial apoptosis [463] within the first 24 hours 
of DSS exposure.  Over the ensuing days an increased intestinal permeability is seen with 
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histological changes and an increased inflammatory cell infiltration.  Although T and B cells 
are recruited during the course of a DSS colitis, the onset of inflammation is dependent on the 
innate immunity and is induced in the absence of T and B cells (in immune-deficient, SCID 
mice) [464].  Break down in the epithelial wall allows infiltration of the DSS, bacteria and faecal 
contents into the intestinal wall which is believed to further exacerbate the inflammatory 
response.  Evidence to implicate the microflora in the pathogenesis of DSS induced colitis 
comes from studies of antibiotic treated [465], and germ free [464], [466], mice which are found 
to develop a less severe colitis following exposure to DSS.  The finding of a low grade colitis 
in the absence of microbiota however demonstrates that the presence of bacteria is not a 
prerequisite for DSS to induce colitis, and DSS alone may cause colonic inflammation.  At 
which stage in this process ADAMDEC1 influences the effect of DSS and protects against 
intestinal inflammation is unknown.  As a member of the metalloprotease family it may support 
epithelial integrity by acting on the ECM, or minimise the direct damage caused by DSS.  It 
may however play a role in handling bacteria following a breach in the intestinal wall.  In order 
to investigate this further the next chapter looks at the response of Adamdec1 deficient mice 
to GI infection with enteric pathogens. 
 
 
5.4 Conclusion 
ADAMDEC1 is highly conserved across mammalian species and as such mice are a useful 
model to study the role of this molecule in the intestine.  Adamdec1 is up-regulated in the 
intestinal tract in response to DSS induced colitis implicating it in the acute inflammatory 
response in the gut. In mice deficient in Adamdec1 there is an increased sensitivity to this 
chemical induced colitis, associated with an early robust neutrophilic infiltrate, raised IL1β and 
IL6 and an increased mortality demonstrating that ADAMDEC1 has a protective role in the 
intestine against inflammation.  Although DSS colitis resembles the microscopic features of 
IBD, in particular UC, it does not truly reflect the pathophysiology of human IBD. A further 
limitation of this study was that the intestinal expression of Adamdec1 was not assessed 
following exposure to chronic DSS induced colitis. This omission restricts the extent to which 
this expression data can be extrapolated to patients with IBD, a chronic inflammatory condition. 
These results do, however, indicate that ADAMDEC1 has a role in mucosal immunity and, 
when deficient, the host is at risk of developing colitis.  The following chapter investigates the 
response of Adamdec1-/- mice to bacteria-induced colitis. 
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6. Investigation of ADAMDEC1 in Intestinal Tract using Bacterial Infection 
Mouse Models to Induce Colitis 
 
6.1 Introduction 
In humans, the onset or flare of IBD is frequently reported following an episode of 
gastroenteritis.  Numerous publications have identified infectious agents (in particular enteric 
pathogens; campylobacter, shigella, salmonella, pathogenic E.coli or clostridium difficile) 
present in the intestine or stool cultures at the time of diagnosis, in the preceding years, or 
during an exacerbation [467], [468], [469],[470]. As such it was deemed relevant to investigate 
the role of ADAMDEC1 in the inflammatory response to a bacterial infection within the gut, the 
study of which is akin to what may occur naturally in the clinical setting. 
Surprisingly few bacterial colitis models are available for investigating the host defence 
mechanisms and immune response in the murine intestinal tract.  Although the enteral route 
is effective for infecting mice with many enteric pathogens, it rarely leads to significant 
microbial colonisation or intestinal inflammation in the wild type mouse.  Fortunately, two 
intestinal infection models, employing C. rodentium in naive mice and S. typhimurium in 
antibiotic-pretreated mice, exist which are well characterised and produce a robust 
reproducible response with significant intestinal inflammation in wild type mice [434], [471], 
[472]. 
 
6.1.1 C. Rodentium 
In the 1960s-70s a number of outbreaks of spontaneous colitis were reported in mouse 
colonies in the USA [473]–[475] and Japan [476].  A range of clinical manifestations were 
reported and mortality rates varied, however diarrhoea was a predominent feature, colonic 
hyperplasia was a common finding at post mortem and co-housing of infected and uninfected 
mice resulted in spread of the infection within days.  Culture of faecal and intestine samples 
from the infected mice revealed an atypical C. freundii strain and DNA analysis confirmed 
theses strains were related and were assigned to a common species, C. rodentium [477], 
[478]. A number of the strains are now currently available (DBS100, ICC168, ATCC 51459) 
and stem from the original stocks.  ICC169, which was kindly gifted to us by G. Frankel, is a 
spontaneous nalidixic acid resistant derivative of ICC168 [479], the genome of which has been 
sequenced by the Sanger [480].  
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C. rodentium is now well recognized as a murine enteric pathogen.  Although readily isolated 
from human faeces it has not been reported to cause pathology in a human host.  It is related 
to the human pathogens enteropathogenic E.coli (EPEC) and enterohaemorrhagic E.coli 
(EHEC) and which utilise attaching and effacing lesions to colonise the host GI tract [481]. 
These lesions are characterised by local destruction of the brush border microvilli and 
attachment of the bacteria to the apical surface of the host epithelial membrane in the caecum 
and colon forming a pedestal like structure with the cell [482]. In general these bacteria do not 
tend to penetrate the deep mucosal layers or cause systemic infection and essentially act as 
mucosal pathogens. 
The majority of mouse strains including C57BL/6 are rapidly colonised with C .rodentium within 
days following oral challenge.  Visualisation of C. rodentium using bioluminescence imaging 
indicates that the caecum is colonised within 24 hours, following oral gavage with 108-109 
organisms.  Bacteria are observed in the distal colon at 2-3 days and colonic levels peak 
between 7-14 days post infection.  Colonic hyperplasia and a patchy colitis is observed during 
the course of the infection.  The clinical response is mild and mortality rare in otherwise healthy 
adult mice.  In the majority of strains the infection is self-limiting and bacterial clearance occurs 
within 21-28 days.  Following initial infection and eradication mice develop resistance to a 
second bacterial challenge [483].   
 
6.1.2 S. Typhimurium 
Salmonella are gram-negative rod shaped enterobacteria which, dependent on the strain and 
host, cause a range of diseases from self-limiting intestinal infection to life threatening 
systemic infection, such as typhoid fever. In humans, and cattle, ingestion of S. typhimurium 
typically results in a non-systemic enterocolitis whereas C56BL/6 mice are intrinsically 
resistant to intestinal colonisation with S. typhimurium and demonstrate minimal intestinal 
inflammation [484].  In mice, S. typhimurium leads to a systemic infection of the liver and 
spleen which resembles typhoid and mice succumb to sepsis within days of ingesting the 
bacteria [485]. 
Pre-treatment of C57BL/6 wild type mice with antibiotics renders them susceptible to S. 
typhimurium intestinal colonisation and colitis following oral infection [486].  This method is 
now commonly used to induce an experimental colitis in mice which is similar to that observed 
in humans and bovine models [484].  Crypt hyperplasia, loss of goblet cells, ulceration of the 
epithelial layer, submucosal oedema and significant leukocyte infiltration into the submucosa, 
LP, and epithelial layer are recognised features.  Despite the similarities, differences do exist 
[487]. Diarrhoea with considerable luminal secretions is common in humans. In contrast 
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antibiotic-pre-treated mice infected with S. typhimurium have a mild secretory response 
restricted to softening of the stool.  Furthermore, the distribution of intestinal inflammation 
differs between affected hosts; in cattle, both the ileum and the colon are affected, whereas in 
antibiotic pre-treated mice the inflammation is limited to the colon following S. typhimurium 
oral infection.  In humans, anecdotal evidence suggests that the colon is predominately 
affected following S. typhimurium infection [488], [489].   
A range of different antibiotics have been used to predispose mice to a S. typhimurium induced 
colitis including streptomycin [486], [490], metronidazole [161] and vancomycin [491].  The 
antibiotics alter the normal intestinal microbiota [161], reducing the resistance to colitis and 
allowing the orally inoculated S. typhimurium to colonise the lumen of the caecum and colon 
more effectively than without antibiotic pre-conditioning.  As a consequence, S. typhimurium 
are able to grow to a high density in the caecum and colon within 24 hours, accompanied by 
significant intestinal inflammation over the same time period.  This model is especially useful 
for examining the early (4–72 h) intestinal events that occur following oral S. typhimurium 
infection.  It is less suitable for monitoring the long term immune response as antibiotic pre-
treated wild type mice typically succumb to a lethal systemic disease within 5 –7 days of oral 
S. typhimurium inoculation.  A similar picture to antibiotic pre-treated mice is seen following 
infection of germ-free mice with S. typhimurium, underlining the importance of the normal 
microbiota in limiting S. typhimurium-induced intestinal inflammation in mice [485]. 
 
Hypothesis of Chapter Six 
1. Adamdec1 knockout mice have an increased susceptibility to bacterial induced colitis 
2. Bacterial clearance is impaired in Adamdec1 knockout mice exposed to bacterial 
induced colitis. 
 
Aims of Chapter Six 
1. To assess the local and systemic inflammatory response, of Adamdec1 knockout mice, 
following oral inoculation with a murine enteric pathogen, C. rodentium. 
2. To determine whether bacterial clearance is impaired in the Adamdec1 knock out mice 
following exposure to C. rodentium.  
3. To assess the systemic response of Adamdec1 knockout mice, pre-treated with 
antibiotics, to S. typhimurium, an intracellular pathogen.  
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6.2 Results 
 
6.2.1 C. Rodentium Colitis in Adamdec1-/- Mice 
A nalixidic acid resistant C. rodentium strain ICC169 was kindly donated by G. Frankel.  The 
oral inoculation dose of C. rodentium reportedly used by investigators varies between 108- 
1010 bacteria.  A number of work up experiments were performed to ascertain an appropriate 
dose to use and a reliable method for approximating the number of bacteria to gavage for 
each experiment. 
 
To Calculate the Concentration of C. Rodentium using Optical Density (OD) Measurement: 
Bacteria were grown overnight, for 16 hours, in LB medium (at 1:1000 dilution from glycerol 
stock), supplemented with nalixidic acid 50ng/ml, centrifuged at 4000 × g, and washed once 
in sterile PBS.  Following a second centrifugation step, bacterial cultures were resuspended 
in PBS, serial dilutions were made.  These dilutions were then measured using the OD600 to 
provide an OD to approximate the number of bacteria. 
To determine the exact corresponding number of viable bacteria the serial dilutions of the 
bacterial solutions were plated on MacConkey II agar plates (Becton Dickinson and Co., 
Sparks, Md.), incubated at 37°C overnight, and enumerated the following day.  C. rodentium 
colonies displayed characteristic pink centres surrounded by a white rim. Using this method 
approximately 1010 - 1011 bacteria were grown per ml. 
For each dilution the OD values were plotted against the number of bacterial colonies 
observed after 24 hours.  A best fit line was drawn using excel and the following equation was 
calculated: 
No of C. rodentium/ml, y=x1.053 x 109.053 
(Where x is OD600 is between 0.031-1.254) 
This equation, based on an OD measurement, was subsequently used to approximate the 
number of C. rodentium bacteria to gavage prior to each experiment.  
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Dose Response of C. Rodentium in Wild Type C57BL/6 Mice: 
Wild type C57BL/6 mice were infected with 200μl of PBS containing either ~108 or 109 CFU 
bacterial by oral gavage; control mice received PBS only. 
Mice used in this study were weighed prior to infection to determine mean baseline weights 
and every day thereafter.  Weight change was expressed as a percentage of the original 
baseline weight.  Stools were collected from each mouse on alternate days and cultured on 
nalidixic acid plates.  Serum was obtained from tail bleeds during the experiment.  Mice were 
culled at set time points.  Post mortem caecal weights were weighed, spleens cultured, serum 
obtained from cardiac puncture and large bowel was resected for qPCR or digested for FACs 
analysis. 
At both the lower and higher doses of C .rodentium inoculation wild type C57BL/6 mice 
displayed few clinical signs apart from slightly softened stools during the height of the infection, 
there was no evidence of PR bleeding.  Weight loss was minimal and no mice succumbed to 
infection. Bacterial clearance was achieved by day 16 at both doses.  Translocation of bacteria 
to the spleen was not seen during in mice infected with ~108 C. rodentium and only 
approximately 10% of mice exposed to the higher dose ~109 had positive splenic cultures.  No 
significant difference was seen in either the splenic or caecal weights.  Histological 
examination of the bowel revealed a patchy superficial colitis; proximal > distal at both doses.  
 
C. Rodentium Induced Colitis in Adamdec1-/- Mice 
To investigate the antibacterial role of ADAMDEC1 in the bowel, Adamdec1-/- and 
Adamdec1+/+ mice were inoculated with ~109 C. rodentium and the systemic and bowel 
response was monitored.  Similar to the DSS model, Adamdec1-/- mice demonstrated an 
increased systemic susceptibility to C. rodentium inoculation compared with Adamdec1+/+ 
mice, as evident by significantly greater weight loss (p<0.001) (Figure 6.1A) and increased 
mortality (p<0.01) (Figure 6.1B).  
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Figure 6.1: Adamdec1 deficiency results in an increased susceptibility to C. 
rodentium.  (A) Adamdec1
-/-
 mice demonstrate a significant reduction in total body weight 
after C. rodentium inoculation (~10
9
) compared with wild type animals (n=15 per genotype, 
results replicated in 4 further experiments, data not shown). (B) An increased level of mortality 
was evident in Adamdec1
-/-
 mice compared with wild type animals. Results shown are mean 
± SEM, two tailed unpaired t-test p<0.01**, p<0.001***. 
 
 
The response to oral C. rodentium was dose dependent in the knock out mice; Adamdec1-/- 
mice gavaged with ~108 bacteria, experienced a less severe clinical picture; they lost less 
weight and suffered no mortalities.  However there remained a significant difference in weight 
lost between the wild type and knock out mice (p<0.001) (Figure 6.2). 
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Figure 6.2: Low dose C. rodentium infection of Adamdec1
-/-
 and wild type mice. The 
increased susceptibility of Adamdec1 deficient animals is evident at 10
8
 C. rodentium but 
Adamdec1
-/- 
mice loose less weight following inoculation with 10
8
 C. rodentium compared with 
the higher dose of 10
9 
bacteria. Adamdec1 deficient animals do not succumb to C. rodentium 
infection at the lower dose of 10
8
. n=10 per genotype. Results shown are mean ± SEM two 
tailed unpaired t-test p<0.05*, p<0.01**, p<0.001*** 
 
 
 
The observed increase in susceptibility in the Adamdec1 deficient mice was not due to a 
difference in intraluminal C. rodentium levels, as demonstrated by the number of colony 
forming units of C. rodentium per gram of stool in faecal samples (Figure 6.3).  Furthermore 
the clearance of bacteria from the stools was not delayed in the knock out mice compared 
with the wild type controls, clearance was achieved by day 16 in both genotypes. 
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Figure 6.3: Increased susceptibility of Adamdec1
-/-
 mice to C. rodentium is not 
associated with impaired intraluminal bacterial clearance.  No significant difference was 
seen in the number of C. rodentium  CFU cultured per mg of  faeces at day 6 and 12, following 
oral gavage of ~10
9
 C. rodentium, between knock out an wild type mice. (n=4 per genotype, 
replicated in second experiment, data not shown). Results are expressed as the mean ± SEM 
n.s. non- significant; two tailed unpaired t test. 
 
 
Following C. rodentium inoculation with 109 bacteria, increased levels of pro-inflammatory 
cytokines were measured in the serum of both the Adamdec1-/- and Adamdec1+/+ mice 
compared with naïve mice.  The serum levels mirrored the onset and severity of inflammation 
within the bowel in both strain of animals.  The serum levels of both IL1β and IL6 were 
significantly higher in the Adamdec1 deficient mice as compared with naïve animals by day 
13, similar to the response observed in the DSS colitis (Figure 6.4). IL10 TNF, IL12p40 and 
KC serum levels were similar in both wild type and knockout animals. 
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Figure 6.4: Increased susceptibility of Adamdec1
-/-
 mice to C. rodentium is 
associated with a raised serum levels of IL1β and IL6 compared with wild type mice.  
(A) IL1β and (B) IL6 are significantly elevated in serum from Adamdec1
-/-
 mice on day 13 post 
infection compared with wild type mice on day 13 and naïve mice (day 0), irrespective of their 
genotype.  (C) No significant difference is seen in serum IL10 between Adamdec1
-/-
 and wild 
type mice (n=4 per genotype, replicated in second experiment, data not shown). Results are 
expressed as the mean ± SEM, p<0.05*, p<0.01** & p<0.001***. 
 
 
On initial examination the caecum of Adamdec1-/- mice looked shrunken and contained less 
stool on day 13, similarly the colon of Adamdec1-/- mice contained less well formed stool 
pellets.  On dissection of the caecum however, the walls were thickened and oedematous and 
the caecal weights were significantly higher in Adamdec1-/- compared with Adamdec1+/+ mice 
by day 13 (p<0.001) (Figure 6.5A).  The initial observation regarding the difference in size 
reflected the reduced faecal matter in the lumen most likely secondary to an increased 
secretion of luminal contents in the knock out mice. In order to ascertain whether the increased 
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caecal weight in the Adamdec1-/- mice represented an increased inflammatory infiltrate into 
the intestinal walls, colonic LP cell numbers were counted following collagenase digestion of 
bowel.  A significant increase in cell numbers were seen in both genotypes by day 13. However 
Adamdec1-/- mice demonstrated a significantly greater number of colonic LP cells compared 
to wild type mice on day 13 (p<0.01) (Figure 6.5B). 
 
 
Figure 6.5: Increased susceptibility of Adamdec1
-/-
 mice to C. rodentium is 
associated with an elevation in tissue inflammation.  (A) Change in caecal weight post C. 
rodentium infection. Adamdec1
-/-
 mice demonstrate an increase in total caecal weight 13 days 
post infection. No alteration in caecal weight is evident in the wild type mice.  (B) Total cell 
numbers from isolated colonic lamina propria post C. rodentium infection.  A significant 
increase in the number of colonic LP  cells  is seen at day 13 post C. rodentium in knock out 
and wild type mice. This cellular infiltration is significantly greater in knock out mice compared 
with wild type.  Results are expressed as the mean ± SEM, p<0.05*, p<0.01***, p<0.001***. 
 
 
To investigate the cellular composition of the inflammatory milieu and recruitment to the bowel 
during inflammation, we performed flow cytometry of cells recovered from whole colonic 
tissue.  Naïve tissue contained equivalent numbers of CD11b+ CD11c- F4/80+  and CD11b+ 
CD11c+ F4/80+  macrophages and CD11b- CD11c+ F4/80- DCs, CD19+ B cells, CD3+ T cells 
and CD11b+ Gr1+ neutrophils in both Adamdec1-/- and Adamdec1+/+ mice as in previous 
experiments.  Although a significant increase in the total cells numbers was seen in the knock 
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out mice, no significant difference was detected within the cellular populations throughout the 
course of infection.  
The results from qPCR of the bowel were disappointing; due to the patchy nature of the colitis 
the 5mm sections resected from the distal colon were not a true representation of the 
inflammatory state of the whole colon.  As a consequence error bars were wide and results 
insignificant.  Retrospectively either the whole bowel, or a proximal section such as the 
caecum, should have been homogenized for qPCR, particularly as the infection starts 
proximally and extends distally with time [492].  
 
Adamdec1-/- Mice develop a bacteraemia following exposure to C. rodentium 
In contrast to the wild type mice, Adamdec1-/- mice became systemically unwell. Weight loss 
and increased mortality were associated with a significant increase in splenic weight 
(p<0.01**) and positive C. rodentium splenic cultures (p<0.05*), consistent with bacterial 
translocation and impaired containment of the bacteria in the knock out mice (Figure 6.6).  
 
It has been reported that clearance of C. rodentium from the gut is dependent on B cells and 
IgG secretion (Infect Immun. 2004 Jun; 72(6): 3315–3324.). Adamdec1-/- mice do produce 
antibodies against C. rodentium (Figure 6.7). These results demonstrate that ADAMDEC1 
deficiency does not influence the development of a B cell mediated adaptive immune response 
to C. rodentium infection. 
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Figure 6.6: Increased susceptibility of Adamdec1
-/-
 mice to C. rodentium is 
associated with an elevation in systemic infection.  (A) Change in splenic weight post C. 
rodentium infection. Adamdec1
-/-
 mice demonstrate an increase in splenic weight 13 days post 
infection. No alteration in splenic weight is evident in the wild type mice.  (B) Percentage of 
mice with live C. rodentium in their spleens 13 days post infection. Adamdec1
-/-
 mice were 
found to have live C. rodentium in their spleens more frequently than wild type animals.  (C) A 
higher concentration of C. rodentium (colony forming units, CFU) was found in spleens from 
Adamdec1
-/-
 mice compared to wild type animals. Results are expressed as the mean ± SEM, 
p<0.05*, p<0.01**, p<0.001***. 
 
 
 
 
183 
 
Figure 6.7: Adamdec1 deficient mice are capable of mounting an antibody response 
to C. rodentium infection.  Antibodies against a C. rodentium protein lysate were detectable 
by day 13 in the serum from Adamdec1
+/+
 and Adamdec1
-/- 
mice (highlighted by black arrows).   
 
 
6.2.2 S. Typhimurium Induced Colitis in Adamdec1-/- Mice 
S. enterica serovar Typhimurium (JT11) was kindly provided by Dr Elizabeth de Pinna, Public 
Health England, UK. Mice were pre-treated with metronidazole for 5 days.  As in previous 
publications the antibiotic was dissolved in the drinking water at 750mg/litre [493]. This 
antibiotic was chosen as stocks were available for use in the laboratory. After 5 days the 
normal drinking water was replaced for 20 hours and then mice were fasted for 4 hours prior 
to oral gavage with ~108 S. typhimurium, a dose commonly used in publications [486]. 
Following inoculation, the systemic and bowel response was monitored over 48 hours. 
Unpaired t-tests, comparing mean (± SEM) weight loss of wild type and knock out mice, at 24 
and 48 hours, were not significant due to the wide variability in weight loss. As such, paired t-
tests were employed to analyse this data, to minimise the effect of experimental variability 
within each group. The change in weight between two set time points; 24 and 48 hours post 
inoculation, were compared for each genotype. Similar to the DSS and C. rodentium models, 
Adamdec1-/- mice lost a greater proportion of their body weight after S. typhimurium infection 
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compared to wild type animals (Figure 6.8A) and at 48 hours post infection 55% of the 
knockout mice compared to only 11% of the wild type animals had succumbed to the infection 
(Figure 6.8B). These results suggest that ADAMDEC1 provides some protection to the host 
during the early phase of S. typhimurium infection. 
 
Figure 6.8: Increased susceptibility of Adamdec1
-/-
 mice to Salmonella infection.  (A) 
Percentage change in original body weight between 24 and 48 hours post oral infection of 
Salmonella.  (B) Percentage of animals surviving after 48 hours infection with Salmonella. 
Paired t test p<0.001***, ns = non-significant. 
 
 
6.3 Discussion 
In chapter 5, intestinal expression of Adamdec1 was shown to be up-regulated in response to 
an experimental colitis in C57BL/6 wild type mice.  Mice deficient in Adamdec1 were found to 
have an increased susceptibility to a chemical induced colitis.  In this chapter two bacterial 
models of colitis, C. rodentium and S. typhimurium, were employed to investigate the role of 
Adamdec1 in the host’s response to enteric pathogens in vivo.  
In wild type mice, oral inoculation with C. rodentium resulted in a mild self-limiting colitis with 
minimal systemic sequel. In contrast, mice deficient in Adamdec1 developed a more severe 
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colitis, became systemically unwell and succumbed to the infection. Adamdec1 deficiency had 
no effect on faecal bacteria clearance, but was associated with a significant increase in the 
risk of bacterial translocation to the spleen and lethal systemic infection. 
Similar to infection with C. rodentium, Adamdec1 knock out mice, pre-treated with antibiotic, 
displayed an increased susceptibility and mortality within the first 48 hours after inoculation 
with oral S. typhimurium compared with wild type mice.  
Together these results provide the first in vivo role for ADAMDEC1 in response to enteric 
pathogens and support the findings in chapter 5 that ADAMDEC1 has a possible protective 
role in the gut, in the innate immune defence of the intestinal barrier. The exact mechanism 
by which ADAMDEC1 may exert this ‘protective effect’ against colitis is yet to be determined.  
ADAMDEC1 has evolved from a superfamily of zinc dependent proteolytic enzymes, which 
are well recognised to activate, degrade and bind a variety of targets including chemokines, 
cytokines, growth factors, ECM proteins and integrins [21], [256].  Through these substrate 
interactions they manipulate the function and recruitment of inflammatory cells, regulate tissue 
maintenance and repair and shape the innate and adaptive immune response.  The proteolytic 
targets of ADAMDEC1, however, remain elusive.  A recent study has identified three potential 
substrates (α2-macroglobulin, carboxymethylated transferrin and casein) as well as 
demonstrating the lack of responsiveness to the classical ADAMs inhibitors TIMP1-3 [265], 
[394].  It is unclear if any of the substrates identified so far are the true biological targets of 
ADAMDEC1, but it is plausible that ADAMDEC1 has evolved to escape inhibition by 
endogenous metalloprotease inhibitors.  
In chapter 5 and 6, Adamdec1-/- mice displayed an exaggerated level of serum IL1β, and the 
down-stream cytokine IL6, during both a chemical and bacterial induced colitis.  A number of 
metalloproteases have been reported to cleave, activate, and in some cases degrade IL1β 
[275], [276], [494]: This pro-inflammatory cytokine, proteolytically activated in vivo by IL1β 
convertase (caspase-1), can also be cleaved by MMP2, -3, and -9.  The mature form of IL1β 
is degraded by MMP3, and to a lesser extent MMP1, 2, and 9.  MMP7 activated cryptdins 
have also been reported to reduce cellular release of IL1β in DSS colitis.  The finding of 
significantly elevated circulating levels of IL1β in Adamdec1-/- mice compared with wild type 
mice, in two different models of colitis, therefore raises the possibility that ADAMDEC1 may 
play a role in secretion and/or degradation of IL1β during the acute inflammatory response.  
Further work is needed to identify the biologically relevant ligands for ADAMDEC1 and 
investigate the relationship between ADAMDEC1 and IL1β. 
186 
In this chapter, mice deficient in Adamdec1 were shown to develop a systemic bacteraemia 
following ingestion of C. rodentium.  In wild type mice this potentially fatal sequela is rarely 
seen and C. rodentium is contained by the intestinal barrier.  Faecal bacterial load and 
intraluminal clearance were similar in both genotypes and preliminary studies demonstrate no 
difference in intestinal wall permeability at baseline.  The results suggest that containment 
and/or clearance of viable bacteria within the tissue may be impaired in Adamdec1-/- mice.  
MMP2 [438], MMP3 [440] and MMP7 [441] knock out mice display impaired bacterial 
clearance within the intestinal wall and an increased susceptibility to bacterial induced colitis 
following ingestion of C. rodentium and/or S. typhimurium.  
It is well recognised that metalloproteases influence leuckocyte recruitment, and thereby 
bacterial clearance, through their substrate interaction with chemokines, cytokines, integrins 
and ECM proteins.  Indeed, C. rodentium infection in MMP3-/- mice is associated with a 
reduced recruitment of leukocytes to the gut.  Adamdec1-/- mice do not, however, display 
evidence of delayed neutrophil recruitment or attenuated cytokine secretion in response to 
chemical or bacterial colitogenic agents implicating another mechanism of action for 
ADAMDEC1.  
The adaptive immune response is believed to play a role in intraluminal bacterial clearance of 
C. rodentium as mice lacking CD4 T and/or B cells fail to clear the bacteria and succumb to 
infection [495], [496].  No difference was seen, however, in intraluminal bacterial clearance in 
Adamdec1-/- mice suggesting that they are able to mount an adequate adaptive response and 
lending further support to the role of ADAMDEC1 in the innate immune response in the gut. 
Wild type mice that recover from C. rodentium infection are immune to rechallenge.  Transfer 
of serum IgG from mice who have recovered from C. rodentium infection into a) naïve mice 
has been reported to lower the number of colonic C. rodentium [497] and into b) CD4 T cell 
deficient mice protects them against overwhelming infection and death [498].  Adamdec1-/- 
mice produce similar levels of IgG in response to C rodentium infection as Adamdec1+/+ mice 
supporting normal antigen presenting and B cell responses in the absence of Adamdec1.  
ADAMDEC1 is highly expressed in intestinal tissue macrophages renowned to be both 
phagocytic and bactericidal. It is therefore possible that ADAMDEC1 may be directly involved 
in bacterial handling through auto/phagocytic or bactericidal mechanisms.  A couple of MMPs 
have been described as directly or indirectly bactericidal. MMP12 is the only known MMP 
currently to be directly bactericidal. It is predominantly expressed in mature tissue 
macrophages and is secreted both extracellular and intracellular into the phagolysosome [418].  
The MMP12 knockout mouse has been shown to have reduced survival to both intraperitoneal 
and transtracheal Staphlococcus aureus and E.coli with impaired bacterial clearance in vitro.  
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Recombinant human MMP12 inhibits S.aureus in a dose-dependent manner. MMP7 is the 
only other MMP known to be involved in bacterial killing, but does so indirectly by cleaving and 
activating proalpha defensins (cryptdins), a family of antimicrobial peptides, within Paneth 
cells before their secretion into the gut [499], [500].  The MMP7 knock out mouse has been 
shown to have an impaired ability to handle enteric pathogens and is hypersensitive to 
bacterial infections.  It would be interesting to ascertain whether ADAMDEC1 has bactericidal 
properties.  
 
 
6.4 Conclusion 
The results of this chapter demonstrate that Adamdec1 knockout mice have an increased 
susceptibility to oral inoculation with two different murine enteric pathogens. Following 
exposure to these infection-colitis models, mice deficient in Adamdec1 develop an augmented 
local and systemic inflammatory response, associated with an increased bacteriaemia and 
mortality. Further study is now needed to identify the biologically relevant ligands for 
ADAMDEC1 and mechanisms by which ADAMDEC1 protects against colitis, bacterial 
translocation and systemic infection.  Current evidence suggests that ADAMDEC1 may have 
an anti-inflammatory role in the gut either by a direct effect on bacterial clearance and/or 
containment or by manipulation of the immune response to enable effective clearance of the 
bacteria and prevent an aggressive inflammatory response which would be deleterious for the 
host. Intraluminal clearance of bacteria is not impaired and antibodies are produced against 
bacteria in the absence of Adamdec1 implicating an innate immune defect. The next step 
would be to ascertain whether intestinal macrophages from Adamdec1 knock out mice contain 
an increased bacterial burden which would support the hypothesis of impaired bacterial 
clearance from macrophages, potential options for extending these studies are discussed in 
Chapter 7. 
  
188 
7. General Discussion 
 
7.1 Summary of Findings 
 Transcriptomic analysis performed on cultured human MDM found ADAMDEC1 to be 
grossly under-expressed in ~10% of patients with quiescent CD, in two independent 
experiments 
 CD patients identified with attenuated MDM expression of ADAMDEC1 share a 
haplotype of SNPs which were found to be eQTL (rs12674766, rs4872231, rs2291577, 
rs3765124) 
 rs3765124 results in a potentially damaging amino acid change from Asparagine (N) 
to Serine (S) (N444S) within the disintegrin domain of ADAMDEC1 which is highly 
conserved across mammalian species 
 In the steady state, ADAMDEC1 is almost exclusively expressed within LP 
mononuclear phagocytes in the GI tract, predominantly in the small intestine 
 The tissue and cellular expression of ADAMDEC1 is highly conserved across 
mammalian species 
 ADAMDEC1 is under-expressed in the intestinal tract of patients with IBD and GI 
tumours 
 ADAMDEC1 is up-regulated at extra-intestinal sites of inflammation 
 ADAMDEC1 is up-regulated during MDM differentiation over 5-7 days 
 A rapid and robust increase in ADAMDEC1 expression is seen in monocytes 
stimulated with bacterial antigens via TLR4 and to a lesser extent TLR2, over 24 hours 
 Exposure to bacterial components is not a prerequisite for ADAMDEC1 expression in 
the GI tract 
 Although recombinant ADAMDEC1 is secreted from transfected HEK293 cells 
endogenous ADAMDEC1 was not found to be secreted from MDM or LP macrophages 
 Subcellular fractionation studies of THP1 cells located full length ADAMDEC1 in the 
cytosol and activated subunit in the vesicle fractions associated with the late endosome 
and phagosomes 
 Preliminary studies using inhibitors of vesicle trafficking implicate ADAMDEC1 in the 
formation of the autophagosome  
 The amino acid sequence of ADAMDEC1 is highly conserved between human and 
mouse with 68% homology.  
 Colonic expression of Adamdec1 is up-regulated in C57BL/6 mice in response to an 
acute experimental colitis 
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 Adamdec1-/- mice are not developmentally challenged and do not develop 
spontaneous colitis 
 Adamdec1-/- mice exposed to oral DSS display an increased susceptibility to colitis 
with an early neutrophilic infiltration, raised serum IL1β and IL6 and increased mortality, 
compared with wild type mice. 
 Adamdec1-/- mice infected with oral C. rodentium develop a dose dependent increased 
susceptibility to colitis, associated with increased cellular infiltration and raised serum 
IL1β and IL6, compared with wild type mice. 
 Adamdec1-/- mice infected with oral C. rodentium have an increased risk of bacterial 
translocation, systemic infection and mortality, compared with wild type mice. 
 Infection of metronidazole pre-treated Adamdec1-/- mice with oral S. typhimurium is 
associated with an increased morbidity and mortality, compared with wild type mice. 
 
 
7.2 Discussion of Findings, Implications and Study Limitations 
 
7.2.1 CD is Associated with Intrinsic Defects in Macrophage Function and Impaired 
Bacterial Clearance 
CD is a chronic relapsing IBD predominately of the small and large bowel, characterised by 
patchy, transmural inflammation and granulomas.  Extra-intestinal manifestations in the joints, 
skin and eyes are a recognised feature, highlighting the systemic nature of the disease.   
The aetiology is complex and multifactorial. In recent years, a convergence of findings from 
different fields of investigation has led to the concept that CD is a form of immunodeficiency 
[234], [291], [132], [501], [292]. An increasing body of evidence now supports underlying 
defects in the innate immune response to invading gut bacteria as central to the disease 
pathogenesis [502] [199], [241], [243], [290], [293], [502], [503]. 
Impaired bacteria clearance is a recognised feature of CD. Granulomas are pathognomonic, 
increased bacterial aggregates are found in intestinal macrophages [121] and prolonged 
survival of E.coli in MDM has been demonstrated [120], [122] in CD. Delayed neutrophil 
recruitment to sites of inflammation and a dose dependent failure to clear bacteria from tissues 
has been reported as a common phenotype trait, in patients with CD [241], [243] 
Macrophages are pivotal in bacterial clearance and intrinsic defects in macrophage function 
have been strongly implicated in the pathogenesis of CD: 
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 Attenuated secretion of pro-inflammatory cytokines are observed from CD 
macrophages following activation of TLRs with bacterial antigens and E.coli [243], 
[244], [122] and linked to inherent defects of vesicle trafficking [243], [246].  
 GWAS have identified numerous CD susceptibility genes associated with bacterial 
recognition (NOD2, TLR4), autophagy (ATG16L1, IRGM) and bacterial killing (NCF4) 
in macrophages [199].  Animal models in which these candidate genes have been 
knocked out have demonstrated impaired bacterial clearance and an increased 
susceptibility to colitis. 
 Variants of the IL23R gene have also been linked to Crohn’s [198], [504]. IL23R is 
expressed by activated DCs and macrophages, and IL23 can induce production of 
inflammatory cytokines by macrophages [505] These results suggest that an important 
function of IL23 may be to drive an autocrine loop within the innate immune system.  
IL23 induces production of pro-inflammatory cytokines, in particular IL17 from innate 
lymphoid cells [506], monocytes and macrophages [507], epithelial and stromal cells 
[507] and Th17 cells [508]. IL17 has been reported to mediate mucosal immunity the 
early stages of inflammation by regulating the recruitment of neutrophils and activation 
of AMP [509].  
 
In order to further identify molecules responsible for the impaired bacterial clearance and 
subsequent increased susceptibility to intestinal inflammation observed in CD, transcriptomic 
analysis of MDM was performed [245]. 
The two most common genes detected as grossly under-expressed in patients with quiescent 
Crohn’s were OPTINEURIN and ADAMDEC1 (12% and 8.6% of the CD patients tested, 
respectively).  OPTINEURIN is a vesicle trafficking molecule and an autophagy receptor [312], 
[314], [315], [510]–[513]. A recent publication from our laboratory demonstrated that deficiency 
in OPTINEURIN resulted in reduced TNF and IL6 production, impaired neutrophil recruitment 
to sites of inflammation and an increased susceptibility to intestinal infection with C. rodentium 
[246]. 
 
7.2.2 ADAMDEC1 Deficiency is found in a Subset of CD Patients and is Associated 
with an Increased Susceptibility to Colitis 
ADAM-like, decysin-1 (ADAMDEC1) was the second most common under-expressed gene in 
MDM from patients with CD [245].  This result was verified in a second independent cohort. 
ADAMDEC1low CD patients were not found to share a clinical phenotype but did share a 
haplotype of SNPs which were in linkage disequilibrium with known expression quantitative 
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loci.  One of these SNPs, rs3765124, results in a potentially damaging amino acid change 
from Asparagine (N) to Serine (S) (N444S) within the disintegrin domain of ADAMDEC1, a 
region highly conserved across mammalian species 
Identification of ADAMDEC1 as a potential CD related gene was an intriguing finding. 
ADAMDEC1 is a relatively unknown molecule but it belongs to a family of metalloproteases 
which in recent years have become recognised as central to inflammation, leukocyte 
recruitment and bacterial clearance from tissues and would healing.  One of the most notorious 
members of this family, ADAM17, cleaves and activates TNF.  An ADAM17 mutation was 
reported in a family with skin and bowel inflammation whilst we were investigating ADAMDEC1 
[269]. 
A striking features of ADAMDEC1 is the tissue expression which is restricted to the intestinal 
tract in the steady state, with the greatest expression observed in the small bowel.  A low 
expression is seen in secondary lymphoid tissues.  The expression pattern correlates well with 
the sites at which CD pathology commonly occur.  
A recent publication reported attenuated expression of ADAMDEC1 in the TI of CD patients 
both in active and quiescent disease [268] and our data, along with a number of online 
transcriptomic data sets, support the finding of low levels of ADAMDEC1 in the intestine of 
patients with IBD.  In humans ADAMDEC1 is reported as up-regulated at extra intestinal sites 
of inflammation and in a mouse model of colitis we demonstrated that murine ADAMDEC1 is 
up-regulated in the inflamed colon.  These findings suggest that the attenuated expression of 
ADAMDEC1 observed in the intestine of CD patients is not secondary to acute or chronic 
inflammation per se and as such we hypothesised that ADAMDEC1 deficiency may 
predispose to inflammation. 
At a cellular level ADAMDEC1 is highly selective to MDM and iMNPs. Intestinal macrophages 
are the only resident tissue macrophages known to be monocyte derived which is likely to 
explain the distinct tissue distribution of ADAMDEC1 [43]. Undetectable in monocytes, 
ADAMDEC1 is up-regulated in vitro during MDM differentiation. A more rapid and robust 
increase in expression occurs in response to stimulation of monocytes with bacterial antigens, 
in particular LPS, supporting the role of ADAMDEC1 as a bacterial response gene and a 
mediator of the acute inflammatory response. Exposure to bacterial antigens is not however 
a prerequisite for intestinal expression of ADAMDEC1 as expression of Adamdec1 was 
demonstrated in the GIT of adult germ free mice and mice embryos. Up-regulation of 
ADAMDEC1 expression at sites of inflammation is likely to be secondary to the recruitment of 
MDM to sites of tissue injury.  
192 
In order to test the hypothesis a number of well recognised mouse colitis models were used, 
the results clearly demonstrated that deficiency of ADAMDEC1 significantly 
 increases the risk of colitis,  
 predisposes to increased bacterial translocation and systemic infection, 
 increases mortality, following exposure to a colitogenic agent. 
Both DSS and C. rodentium colitis models exhibit raised serum IL1β and IL6 in the Adamdec1-
/- compared with Adamdec1+/+ mice. IL1β is a known substrate of a number of MMPs [275], 
[494] and as such may be a target of ADAMDEC1. IL1β is secreted from macrophages by a 
non-classical, autophagosome type, pathway. Pro IL1β is cleaved by caspase-1, which in turn 
is induced by ‘danger signals’ and inflammasome activation [514]–[516]. IL6 is a known 
downstream signal of IL1β, consistently raised in serum of patients with NLRP3 
inflammasome-mediated conditions, however it has no direct role in inflammasome driven 
disease [517]. Both IL1β and IL6 are crucial for neutrophil recruitment to sites of infection and 
play a central role in modulating adaptive effector T-cell responses by preferentially inducing 
Th1 and Th17 differentiation [516]. In humans, CD4+ T cells require IL1β and IL6 to 
differentiate into Th17 cells [518].  
Evidence to suggest ADAMDEC1 is associated with an autophagocytic, non-classical 
secretion pathway arises from preliminary studies described in chapter 4.  Protein expression 
of ADAMDEC1 in, unstimulated and heat killed E.coli stimulated, macrophages was not 
increased by Brefeldin, an inhibitor of the conventional secretion pathway (ER to Golgi) by 
which TNF is secreted. It was however induced by Bafilomycin A, an inhibitor of 
autophagolysosome formation.  Furthermore an association between ADAMDEC1 and 
autophagocytic machinery was found in the subcellular fractionation study of stimulated 
MDMs: The distribution of ADAMDEC1 within subcellular fractions was found to mirror the 
classic autophagy marker LC3 (Microtubule-associated protein light chain 3).  Full length 
ADAMDEC1 and LC3 (LC3I) were found in the cytosolic fractions whereas the activated form 
of LC3 (LC3II), which is recruited to the autophagosome, and remains attached during 
autophagolysosome formation, was visible in the membrane fractions along with the activated 
form of ADAMDEC1.  During autophagosome formation LC3 aids elongation of the 
autophagosome and resides on both sides of the double membrane autophagosome [519].  
The internalized LC3 undergoes lysosomal degradation, whereas LC3 on the outer surface is 
cleaved and dissociates [520], [521].  Monensin a proton ionophore, does not affect protein 
MDM expression of ADAMDEC1, suggesting that ADAMDEC1 may reside on the outer 
surface of the autophagolysosome and therefore not undergo lysosomal degradation. MG132, 
an inhibitor of proteasomal degradation, increases the expression of the activated 
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ADAMDEC1 suggesting the activated form of ADAMDEC1 may undergo proteosomal 
degradation within the cytosol, potentially following dissociation from the autophagolysosome.  
It is plausible, based on these findings that ADAMDEC1 may participate in the formation of 
the autophagolysosome and thereby regulate IL1β secretion. Indeed ADAMDEC1 expression 
is switched on in monocytes by starvation of nutrients, which is a trigger for autophagy.  
ADAMDEC1 deficiency may impair autophagocytic degradation of IL1β and ‘tip the balance’ 
in preference of IL1β secretion via the endosome pathway.  Although this suggestion is 
speculative the findings from these preliminary studies indicate this line of inquiry 
warrants/merits further investigation. 
 
7.2.3 Extrapolating Findings from Mice to Men 
Adamdec1 is up-regulated at a tissue level in the intestine of mice in response to inflammatory 
insults.  Mouse models deficient in Adamdec1 clearly demonstrate that deficiency of this 
molecule increases the host’s susceptibility to colitis and potentially lethal systemic infection.  
The function of ADAMDEC1 is highly likely to be conserved in mouse and human; the tissue 
and cellular distribution of ADAMDEC1 are highly conserved across mammalian species and 
the protein is similar down to the amino acid level.  Based on these findings it is plausible that 
ADAMDEC1 may play an important role in human intestinal immunity, similar to mice, and 
protect against the development of overwhelming infection and chronic inflammation. 
Individuals with grossly attenuated expression levels may therefore be at an increased risk of 
developing CD as a consequence of an impaired ability to handle enteric bacterial pathogens. 
This assumption may be criticised for a number of reasons: 
i. Animal models are not representative of CD: 
The use of animal models in this context was not intended to replicate CD.  CD is a 
heterogeneous, multifaceted disorder in which a complex interplay of environmental, 
microbial and genetic factors determine the onset and severity of disease in individuals. 
It is not possible to reproduce all the pathological features of human CD in a single 
mouse model.  For example relatively few models demonstrate features such as 
granuloma formation, discontinuous transmural inflammation, stricturing disease, 
fistulae, and extra intestinal manifestations all of which are classic of CD, albeit not 
pathognomonic of, or specific to, the disease itself.  The models chosen where simple 
reproducible models of intestinal inflammation in which a single variable was altered 
and the response to an insult was observed; the DSS model produces a continuous 
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colitis with similarities to UC whereas the bacterial infection models produce a patchy 
colitis, which demonstrate similarities to CD.  
The rationale for using these mouse models was not to reproduce CD but was to 
investigate whether ADAMDEC1 has a significant role in the immune response in the 
gut.  The use of mouse colitis models enabled us to clearly demonstrate that 
ADAMDEC1 deficiency has pathological consequences, namely an increased 
susceptibility to colitis and mortality.  These results strongly suggest that the molecule 
has a protective effect in the gut and plays a significant role in the intestinal acute 
inflammatory response.  At present the direct applicability of these results to human 
CD remains unclear.  However the results do provide compelling evidence to support 
the possibility that significantly attenuated levels of ADAMDEC1 may predispose 
humans to enterocolitis and potentially the clinical manifestations of CD. 
ii. Differences exist between mouse and human immunology: 
In evolutionary terms, mice and humans diverged between 65 and 75 million years 
ago, and over the millennia, have exploited different habitats and as such differ in their 
exposure to antigens, potential pathogens and environmental stressors.  It is not 
surprising therefore that differences exist between the mouse and human immunology 
and these have been reviewed in the literature [436], [437], [522]. The most striking 
difference is in the balance of lymphocytes and neutrophils. Human blood is neutrophil 
rich (50–70% neutrophils, 30–50% lymphocytes) whereas mouse blood has a strong 
preponderance of lymphocytes (75–90% lymphocytes, 10–25% neutrophils).  The 
functional consequence is unknown. Other reported differences include absence of 
some cell surface markers and chemokines, a variation in the number of PRR and the 
abundance and distribution of defensins. 
As a number of differences have been identified between mice and human immunology, 
and the response to some bacterial pathogens vary between species, caution must be 
employed in directly extrapolating the results of mouse studies to human conditions.  
With these caveats in mind, mice immunology is very similar to human and it is the 
functional similarity between these two mammalian physiologies which has enabled 
mouse models of human diseases to yield important insights into human disease 
pathogenesis and has greatly aided the development of novel treatment approaches 
for many human disorders.  Whilst we should heed Robert Koch’s warning “Gentlemen, 
never forget that mice are not humans”, mice remain an invaluable model to investigate 
the function of new molecules and consequence of their loss.  
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7.3 Conclusion 
Using transcriptomic analysis of macrophages from CD patients we have identified a molecule, 
ADAMDEC1, highly selective to iMNPs and MDM, which is involved in mucosal immunity in 
the intestinal tract.  Deficiency of ADAMDEC1 in mice increases the host susceptibility to 
intestinal inflammation, bacterial translocation and systemic infection. Individuals with grossly 
attenuated expression levels may be at an increased risk of developing CD as a consequence 
of an impaired ability to handle enteric bacterial pathogens.  Further work is now required to 
ascertain the mechanism by which ADAMDEC1 protects against inflammation in the gut.  
 
 
7.4 Future Work 
Further work is now required to elucidate the precise role of ADAMDEC1 in the immune 
response, the mechanism by which it protects against intestinal inflammation and the 
substrate(s) it acts upon.  
 
7.4.1 Proposed Studies 
i. To study the role of ADAMDEC1 in bacterial handling and clearance (phagocytosis, 
digestion, killing, autophagy) by macrophages 
ii. To assess whether ADAMDEC1 plays a direct role in IL1β secretion from LP 
macrophages  
iii. To assess whether dysbiosis in Adamdec1-/- mice could be contributing to their 
phenotype: Adamdec1+/+ and Adamdec1-/- mice could be co housed and their 
microbiota could be sequenced using next generation sequencing 
iv. To determine whether ADAMDEC1 acts on the intestinal ECM and if so how does that 
influence gut permeability, wound healing, leukocyte recruitment directly and/or 
release of an ECM degradation product such as collagen-derived fragment, proline–
glycine–proline (PGP), which has been shown to have a chemotactic effects on 
neutrophils.  
v. To produce an ADAMDEC1 protein for in vitro functional studies. 
vi. To identify ADAMDEC1 substrates using a degradative proteomic approach 
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vii. Candidate substrates could be tested in vitro initially using purified protein, then 
potential substrates could be functionally tested in vivo using our Adamdec1-/- mouse 
model. Identification of ADAMDEC1’s natural substrate is crucial for understanding its 
function and to allow design of specific inhibitors. 
 
7.4.2 Human Studies 
Once the immunological consequences of ADAMDEC1 deficiency in mice have been 
established using mouse models, testing could be extrapolated to humans. Human MDMs 
(and potentially isolated LP macrophages from endoscopic pinch biopsies) could be examined 
to ascertain whether patients with low levels of ADAMDEC1 have a similar functional defect 
to our knock-out mice. 
 
Providing a mechanistic link between ADAMDEC1 and CD would be of immense clinical value, 
not only would it enhance our knowledge of gut physiology but it would greatly increase our 
understanding of this complex and heterogeneous disease.  Based on the transcriptomic data 
approximately 10% of CD patients could have low levels of ADAMDEC1 and potentially a 
common functional abnormality which may form the basis of a therapeutic target and 
individualised treatment option in the future. 
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Appendices 
 
Appendix 1 Primers for qRT-PCR 
 
Gene Primer pair Primer Sequence (5’ – 3’) 
Adamdec1 (mouse) 
 
ADAMDEC1 (human) 
 
Ppia (mouse) 
 
PPIA (human) 
 
Forward 
Reverse 
Forward 
Reverse 
Forward 
Reverse  
Forward 
Reverse 
GTAATTGAGGCTAAAAAAAAGAATAATGTG 
GCGTGGCCCAACTCATG 
CGTGTAAACTGAAGCCTGGA 
TTCACAAGATTCCTGGGACAG 
GGGCCGCGTCTCCTTT 
ATCCTTTCTCTCCAGTGCTCAGA 
CCCACCGTGTTCTTCGACATT 
GGACCCGTATGCTTTAGGATGA 
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Appendix 2 Primer Sets Used for Amplification of human ADAMDEC1 Gene 
 
Exon and 
promotor regions 
Oligo pair Oligo Sequence (5’ – 3’) Size (bp) 
Promotor I 
 
Promotor ii 
 
Promotor iii 
 
1 
PiF: Forward 
PiR: Forward 
PiiF: Forward 
PiiR: Forward 
PiiiF: Forward 
PiiiR: Forward 
AF: Forward 
CCAAATGCCCATCATTCAA 
TCTTATCAGTGCCCTACCCTTT 
GCAAAGAAGGTGGTACACATGA 
GCTGGCCTTAACCGAACTAT 
TGAAAATCTACCATATTTGTCAGAGA 
TGGCTGTGGTTATAGCTCATTG 
CGTAATGGTCCAGTTTGGTG  
698 
 
1000 
 
567 
 
536 
 AR: Reverse CCAAAATGCAAATGGTAATGG  
2 BF: Forward GCATTCACAATCTCCTTTACTCTG 418 
 BR: Reverse AAAAATGGAGACATTGGGTCA  
3 CF: Forward TAGTGGGAGGGAGAGCAAAA 468 
 CR: Reverse TCCTGAACAAAGGGGAGTTG  
4 DF: Forward GGGCAAATGAGAAGTCCCTA 384 
 DR: Reverse TGCTCCCCAATTTCATAACC  
5 EF: Forward CATCCTGAGTGGTCCATGC 205 
 ER: Reverse TTGAGCCCTTTGGAGATCTTA  
6 FF: Forward TCACATACACACACACACACACA 371 
 FR: Reverse CATCAAGGTCCAGAGTGTAGCA  
7 GF: Forward GGGCAGACATCAATCCATTC 582 
 GR: Reverse GAGGGCCGTGTGTTTCATAC  
8 HF: Forward TGAAATCTTGTATGCCATCAGC 709 
 HR: Reverse TGGAAATCCCTGCTAAGGAA  
9 IF: Forward GCGAGGCAATTCGTTAATGT 226 
 IR: Reverse TGCTGGCCTTCATAGAGGAT  
10 JF: Forward CCCAACCACTTTAAATGCTCTT 321 
 JR: Reverse TCTCTCCTTTTAGGATGACAAGG  
11 KF: Forward GCAGAAGGCACCACACTGTA 270 
 KR: Reverse GCATAATTCTTCTGCCCCAAT  
12 IF: Forward TGTTGAACCCACCTTTTTCC 466 
 IR: Reverse GAGCTCATCAACTGAGGCTGT  
13 MF: Forward AACCCTGGCTTCCAAATTTTA 839 
 MR: Reverse TGATGTGAGCTTCAGCACCT  
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